ID   CAC1S_HUMAN             Reviewed;        1873 AA.
AC   Q13698; A4IF51; B1ALM2; Q12896; Q13934;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 4.
DT   15-FEB-2017, entry version 178.
DE   RecName: Full=Voltage-dependent L-type calcium channel subunit alpha-1S;
DE   AltName: Full=Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav1.1;
GN   Name=CACNA1S; Synonyms=CACH1, CACN1, CACNL1A3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS HIS-458 AND ASP-1840.
RC   TISSUE=Skeletal muscle;
RX   PubMed=7713519; DOI=10.1006/geno.1994.1677;
RA   Hogan K., Powers P.A., Gregg R.G.;
RT   "Cloning of the human skeletal muscle alpha 1 subunit of the
RT   dihydropyridine-sensitive L-type calcium channel (CACNL1A3).";
RL   Genomics 24:608-609(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASP-1840.
RX   PubMed=8838325; DOI=10.1006/geno.1996.0066;
RA   Hogan K., Gregg R.G., Powers P.A.;
RT   "The structure of the gene encoding the human skeletal muscle alpha 1
RT   subunit of the dihydropyridine-sensitive L-type calcium channel
RT   (CACNL1A3).";
RL   Genomics 31:392-394(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-1800.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 788-830; 1019-1085 AND 1293-1318.
RX   PubMed=7916735; DOI=10.1006/geno.1993.1017;
RA   Gregg R.G., Couch F., Hogan K., Powers P.A.;
RT   "Assignment of the human gene for the alpha-1 subunit of the skeletal
RT   muscle DHP-sensitive calcium channel (CACNL1A3) to chromosome 1q31-
RT   q32.";
RL   Genomics 15:107-112(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1200-1300, AND VARIANTS HOKPP1 GLY-1239
RP   AND HIS-1239.
RX   PubMed=8004673; DOI=10.1016/0092-8674(94)90135-X;
RA   Ptacek L.J., Tawil R., Griggs R.C., Engel A.G., Layzer R.B.,
RA   Kwiecinski H., McManis P.G., Santiago L., Moore M., Fouad G.,
RA   Bradley P., Leppert M.F.;
RT   "Dihydropyridine receptor mutations cause hypokalemic periodic
RT   paralysis.";
RL   Cell 77:863-868(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1223-1413.
RA   Soldatov N.M.;
RT   "Human skeletal muscle L-type Ca2+ channel alpha 1S subunit gene shows
RT   splicing patterns similar to alpha 1C and alpha 1D genes in the region
RT   involved in hereditary disorders.";
RL   Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO TTPP1.
RX   PubMed=15001631; DOI=10.1210/jc.2003-030924;
RA   Kung A.W., Lau K.S., Fong G.C., Chan V.;
RT   "Association of novel single nucleotide polymorphisms in the calcium
RT   channel alpha 1 subunit gene (Ca(v)1.1) and thyrotoxic periodic
RT   paralysis.";
RL   J. Clin. Endocrinol. Metab. 89:1340-1345(2004).
RN   [9]
RP   VARIANT HOKPP1 HIS-528.
RX   PubMed=7987325; DOI=10.1093/hmg/3.8.1415;
RA   Jurkatt-Rott K., Lehmann-Horn F., Elbaz A., Heine R., Gregg R.G.,
RA   Hogan K., Powers P.A., Lapie P., Vale-Santos J.E., Weissenbach J.,
RA   Fontaine B.;
RT   "A calcium channel mutation causing hypokalemic periodic paralysis.";
RL   Hum. Mol. Genet. 3:1415-1419(1994).
RN   [10]
RP   SEQUENCE REVISION, VARIANT MHS5 HIS-1086, AND VARIANTS HIS-458 AND
RP   CYS-1539.
RX   PubMed=9199552; DOI=10.1086/515454;
RA   Monnier N., Procaccio V., Stieglitz P., Lunardi J.;
RT   "Malignant-hyperthermia susceptibility is associated with a mutation
RT   of the alpha-1-subunit of the human dihydropyridine-sensitive L-type
RT   voltage-dependent calcium-channel receptor in skeletal muscle.";
RL   Am. J. Hum. Genet. 60:1316-1325(1997).
RN   [11]
RP   VARIANTS HOKPP1 HIS-528; HIS-1239 AND GLY-1239.
RX   PubMed=18162704; DOI=10.3346/jkms.2007.22.6.946;
RA   Kim J.-B., Kim M.-H., Lee S.J., Kim D.-J., Lee B.C.;
RT   "The genotype and clinical phenotype of Korean patients with familial
RT   hypokalemic periodic paralysis.";
RL   J. Korean Med. Sci. 22:946-951(2007).
RN   [12]
RP   VARIANT HOKPP1 HIS-1239.
RX   PubMed=17418573; DOI=10.1016/j.nmd.2007.01.020;
RA   Houinato D., Laleye A., Adjien C., Adjagba M., Sternberg D.,
RA   Hilbert P., Vallat J.M., Darboux R.B., Funalot B., Avode D.G.;
RT   "Hypokalaemic periodic paralysis due to the CACNA1S R1239H mutation in
RT   a large African family.";
RL   Neuromuscul. Disord. 17:419-422(2007).
RN   [13]
RP   VARIANTS HOKPP1 GLY-528; HIS-528; SER-900; GLY-1239 AND HIS-1239.
RX   PubMed=19118277; DOI=10.1212/01.wnl.0000342387.65477.46;
RA   Matthews E., Labrum R., Sweeney M.G., Sud R., Haworth A.,
RA   Chinnery P.F., Meola G., Schorge S., Kullmann D.M., Davis M.B.,
RA   Hanna M.G.;
RT   "Voltage sensor charge loss accounts for most cases of hypokalemic
RT   periodic paralysis.";
RL   Neurology 72:1544-1547(2009).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1S
CC       gives rise to L-type calcium currents. Long-lasting (L-type)
CC       calcium channels belong to the 'high-voltage activated' (HVA)
CC       group. They are blocked by dihydropyridines (DHP),
CC       phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA
CC       (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-
CC       GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).
CC       Calcium channels containing the alpha-1S subunit play an important
CC       role in excitation-contraction coupling in skeletal muscle.
CC   -!- SUBUNIT: Multisubunit complex consisting of alpha-1, alpha-2, beta
CC       and delta subunits in a 1:1:1:1 ratio. The channel activity is
CC       directed by the pore-forming and voltage-sensitive alpha-1
CC       subunit. In many cases, this subunit is sufficient to generate
CC       voltage-sensitive calcium channel activity. The auxiliary subunits
CC       beta and alpha-2/delta linked by a disulfide bridge regulate the
CC       channel activity. An additional gamma subunit is present only in
CC       skeletal muscle L-type channel. Interacts with DYSF and JSRP1.
CC       Interacts with RYR1 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q86UT5:PDZD3; NbExp=3; IntAct=EBI-5329490, EBI-8744528;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Skeletal muscle specific.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- DOMAIN: The loop between repeats II and III interacts with the
CC       ryanodine receptor, and is therefore important for calcium release
CC       from the endoplasmic reticulum necessary for muscle contraction.
CC   -!- PTM: Phosphorylation by PKA activates the calcium channel.
CC       {ECO:0000250}.
CC   -!- DISEASE: Periodic paralysis hypokalemic 1 (HOKPP1) [MIM:170400]:
CC       An autosomal dominant disorder manifested by episodic flaccid
CC       generalized muscle weakness associated with falls of serum
CC       potassium levels. {ECO:0000269|PubMed:17418573,
CC       ECO:0000269|PubMed:18162704, ECO:0000269|PubMed:19118277,
CC       ECO:0000269|PubMed:7987325, ECO:0000269|PubMed:8004673}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Malignant hyperthermia 5 (MHS5) [MIM:601887]: Autosomal
CC       dominant disorder that is potentially lethal in susceptible
CC       individuals on exposure to commonly used inhalational anesthetics
CC       and depolarizing muscle relaxants. {ECO:0000269|PubMed:9199552}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Thyrotoxic periodic paralysis 1 (TTPP1) [MIM:188580]: A
CC       sporadic muscular disorder characterized by episodic weakness and
CC       hypokalemia during a thyrotoxic state. It is clinically similar to
CC       hereditary hypokalemic periodic paralysis, except for the fact
CC       that hyperthyroidism is an absolute requirement for disease
CC       manifestation. The disease presents with recurrent episodes of
CC       acute muscular weakness of the four extremities that vary in
CC       severity from paresis to complete paralysis. Attacks are triggered
CC       by ingestion of a high carbohydrate load or strenuous physical
CC       activity followed by a period of rest. Thyrotoxic periodic
CC       paralysis can occur in association with any cause of
CC       hyperthyroidism, but is most commonly associated with Graves
CC       disease. {ECO:0000269|PubMed:15001631}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1S subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L33798; AAA51902.1; -; mRNA.
DR   EMBL; U30707; AAB37235.1; -; Genomic_DNA.
DR   EMBL; U30666; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30667; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30668; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30669; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30670; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30671; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30672; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30673; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30674; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30675; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30676; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30677; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30678; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30679; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30680; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30681; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30682; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30683; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30684; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30685; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30686; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30687; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30688; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30689; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30690; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30691; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30692; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30693; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30694; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30695; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30696; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30697; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30698; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30699; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30700; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30701; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30702; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30703; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30704; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30705; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; U30706; AAB37235.1; JOINED; Genomic_DNA.
DR   EMBL; AL358473; CAI12386.1; -; Genomic_DNA.
DR   EMBL; AL139159; CAI12386.1; JOINED; Genomic_DNA.
DR   EMBL; AL139159; CAI23207.1; -; Genomic_DNA.
DR   EMBL; AL358473; CAI23207.1; JOINED; Genomic_DNA.
DR   EMBL; BC133671; AAI33672.1; -; mRNA.
DR   EMBL; M87486; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M87487; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M87488; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U09784; AAA20531.1; -; mRNA.
DR   EMBL; Z50091; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z50092; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z50093; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS1407.1; -.
DR   PIR; A55645; A55645.
DR   PIR; I38611; I38611.
DR   RefSeq; NP_000060.2; NM_000069.2.
DR   UniGene; Hs.1294; -.
DR   PDB; 2VAY; X-ray; 1.94 A; B=1522-1542.
DR   PDBsum; 2VAY; -.
DR   DisProt; DP01103; -.
DR   ProteinModelPortal; Q13698; -.
DR   SMR; Q13698; -.
DR   BioGrid; 107233; 4.
DR   IntAct; Q13698; 6.
DR   MINT; MINT-7899448; -.
DR   STRING; 9606.ENSP00000355192; -.
DR   BindingDB; Q13698; -.
DR   ChEMBL; CHEMBL3805; -.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB04920; Clevidipine.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB01023; Felodipine.
DR   DrugBank; DB00270; Isradipine.
DR   DrugBank; DB00653; Magnesium Sulfate.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB06712; Nilvadipine.
DR   DrugBank; DB00393; Nimodipine.
DR   DrugBank; DB00401; Nisoldipine.
DR   DrugBank; DB01054; Nitrendipine.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00661; Verapamil.
DR   GuidetoPHARMACOLOGY; 528; -.
DR   iPTMnet; Q13698; -.
DR   PhosphoSitePlus; Q13698; -.
DR   BioMuta; CACNA1S; -.
DR   DMDM; 209572767; -.
DR   PaxDb; Q13698; -.
DR   PeptideAtlas; Q13698; -.
DR   PRIDE; Q13698; -.
DR   Ensembl; ENST00000362061; ENSP00000355192; ENSG00000081248.
DR   GeneID; 779; -.
DR   KEGG; hsa:779; -.
DR   UCSC; uc001gvv.4; human.
DR   CTD; 779; -.
DR   DisGeNET; 779; -.
DR   GeneCards; CACNA1S; -.
DR   GeneReviews; CACNA1S; -.
DR   H-InvDB; HIX0028855; -.
DR   HGNC; HGNC:1397; CACNA1S.
DR   HPA; CAB009507; -.
DR   HPA; HPA048892; -.
DR   HPA; HPA056815; -.
DR   MalaCards; CACNA1S; -.
DR   MIM; 114208; gene.
DR   MIM; 170400; phenotype.
DR   MIM; 188580; phenotype.
DR   MIM; 601887; phenotype.
DR   neXtProt; NX_Q13698; -.
DR   OpenTargets; ENSG00000081248; -.
DR   Orphanet; 681; Hypokalemic periodic paralysis.
DR   Orphanet; 423; Malignant hyperthermia.
DR   Orphanet; 397755; Periodic paralysis with transient compartment-like syndrome.
DR   Orphanet; 79102; Thyrotoxic periodic paralysis.
DR   PharmGKB; PA85; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128247; -.
DR   HOGENOM; HOG000231529; -.
DR   HOVERGEN; HBG050763; -.
DR   InParanoid; Q13698; -.
DR   KO; K04857; -.
DR   OMA; DFAYYYF; -.
DR   OrthoDB; EOG090301A2; -.
DR   PhylomeDB; Q13698; -.
DR   TreeFam; TF312805; -.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-5576893; Phase 2 - plateau phase.
DR   Reactome; R-HSA-5576894; Phase 1 - inactivation of fast Na+ channels.
DR   EvolutionaryTrace; Q13698; -.
DR   GeneWiki; Cav1.1; -.
DR   GenomeRNAi; 779; -.
DR   PRO; PR:Q13698; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000081248; -.
DR   CleanEx; HS_CACNA1S; -.
DR   ExpressionAtlas; Q13698; baseline and differential.
DR   Genevisible; Q13698; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031674; C:I band; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030315; C:T-tubule; IDA:UniProtKB.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IDA:UniProtKB.
DR   GO; GO:0008331; F:high voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0061337; P:cardiac conduction; TAS:Reactome.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0006936; P:muscle contraction; IMP:UniProtKB.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR031649; GPHH_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR014873; VDCC_a1su_IQ.
DR   InterPro; IPR005450; VDCC_L_a1ssu.
DR   InterPro; IPR005446; VDCC_L_a1su.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   PANTHER; PTHR10037:SF238; PTHR10037:SF238; 1.
DR   Pfam; PF08763; Ca_chan_IQ; 1.
DR   Pfam; PF16905; GPHH; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01630; LVDCCALPHA1.
DR   PRINTS; PR01634; LVDCCALPHA1S.
DR   SMART; SM01062; Ca_chan_IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Calcium channel; Calcium transport;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Ion channel; Ion transport; Membrane; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Transmembrane;
KW   Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN         1   1873       Voltage-dependent L-type calcium channel
FT                                subunit alpha-1S.
FT                                /FTId=PRO_0000053943.
FT   TOPO_DOM      1     51       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     52     70       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM     71     88       Extracellular. {ECO:0000255}.
FT   TRANSMEM     89    108       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    109    120       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    121    139       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    140    160       Extracellular. {ECO:0000255}.
FT   TRANSMEM    161    179       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    180    198       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    199    218       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    219    309       Extracellular. {ECO:0000255}.
FT   TRANSMEM    310    334       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    335    432       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    433    451       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    452    466       Extracellular. {ECO:0000255}.
FT   TRANSMEM    467    486       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    487    494       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    495    513       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    514    523       Extracellular. {ECO:0000255}.
FT   TRANSMEM    524    542       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    543    561       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    562    581       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    582    636       Extracellular. {ECO:0000255}.
FT   TRANSMEM    637    661       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    662    799       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    800    818       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    819    834       Extracellular. {ECO:0000255}.
FT   TRANSMEM    835    854       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    855    866       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    867    885       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    886    892       Extracellular. {ECO:0000255}.
FT   TRANSMEM    893    911       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    912    930       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    931    950       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    951   1040       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1041   1065       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1066   1118       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1119   1137       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1138   1152       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1153   1172       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1173   1180       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1181   1199       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1200   1231       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1232   1250       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1251   1269       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1270   1289       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1290   1356       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1357   1381       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1382   1873       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       38    337       I.
FT   REPEAT      418    664       II.
FT   REPEAT      786   1068       III.
FT   REPEAT     1105   1384       IV.
FT   CA_BIND    1410   1421       {ECO:0000250}.
FT   REGION      357    374       Binding to the beta subunit.
FT                                {ECO:0000250}.
FT   REGION      988   1077       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1337   1403       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1349   1392       Phenylalkylamine binding. {ECO:0000250}.
FT   COMPBIAS    562    568       Poly-Leu.
FT   SITE        292    292       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        614    614       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1014   1014       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1323   1323       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES     393    393       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02789}.
FT   MOD_RES     397    397       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02789}.
FT   MOD_RES     687    687       Phosphoserine; by PKA. {ECO:0000250}.
FT   MOD_RES    1392   1392       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES    1575   1575       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02485}.
FT   MOD_RES    1617   1617       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P07293}.
FT   CARBOHYD     79     79       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    257    257       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1141   1141       N-linked (GlcNAc...). {ECO:0000255}.
FT   VARIANT      69     69       A -> G (in dbSNP:rs12406479).
FT                                /FTId=VAR_046970.
FT   VARIANT     458    458       L -> H (in dbSNP:rs12742169).
FT                                {ECO:0000269|PubMed:7713519,
FT                                ECO:0000269|PubMed:9199552}.
FT                                /FTId=VAR_001498.
FT   VARIANT     528    528       R -> G (in HOKPP1; dbSNP:rs80338778).
FT                                {ECO:0000269|PubMed:19118277}.
FT                                /FTId=VAR_054953.
FT   VARIANT     528    528       R -> H (in HOKPP1; dbSNP:rs80338777).
FT                                {ECO:0000269|PubMed:18162704,
FT                                ECO:0000269|PubMed:19118277,
FT                                ECO:0000269|PubMed:7987325}.
FT                                /FTId=VAR_001499.
FT   VARIANT     900    900       R -> S (in HOKPP1).
FT                                {ECO:0000269|PubMed:19118277}.
FT                                /FTId=VAR_054954.
FT   VARIANT    1086   1086       R -> H (in MHS5; dbSNP:rs1800559).
FT                                {ECO:0000269|PubMed:9199552}.
FT                                /FTId=VAR_001500.
FT   VARIANT    1239   1239       R -> G (in HOKPP1; dbSNP:rs28930069).
FT                                {ECO:0000269|PubMed:18162704,
FT                                ECO:0000269|PubMed:19118277,
FT                                ECO:0000269|PubMed:8004673}.
FT                                /FTId=VAR_001501.
FT   VARIANT    1239   1239       R -> H (in HOKPP1; dbSNP:rs28930068).
FT                                {ECO:0000269|PubMed:17418573,
FT                                ECO:0000269|PubMed:18162704,
FT                                ECO:0000269|PubMed:19118277,
FT                                ECO:0000269|PubMed:8004673}.
FT                                /FTId=VAR_001502.
FT   VARIANT    1539   1539       R -> C (in dbSNP:rs3850625).
FT                                {ECO:0000269|PubMed:9199552}.
FT                                /FTId=VAR_001503.
FT   VARIANT    1658   1658       R -> H (in dbSNP:rs13374149).
FT                                /FTId=VAR_046971.
FT   VARIANT    1800   1800       L -> S (in dbSNP:rs12139527).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_046972.
FT   VARIANT    1840   1840       E -> D (in dbSNP:rs1042379).
FT                                {ECO:0000269|PubMed:7713519,
FT                                ECO:0000269|PubMed:8838325}.
FT                                /FTId=VAR_046973.
FT   CONFLICT     26     26       R -> S (in Ref. 2; AAB37235).
FT                                {ECO:0000305}.
FT   CONFLICT    265    265       W -> C (in Ref. 1; AAA51902 and 2;
FT                                AAB37235). {ECO:0000305}.
FT   CONFLICT    574    574       A -> R (in Ref. 1; AAA51902 and 2;
FT                                AAB37235). {ECO:0000305}.
FT   CONFLICT    627    628       YG -> SS (in Ref. 1; AAA51902).
FT                                {ECO:0000305}.
FT   CONFLICT    628    628       G -> R (in Ref. 2; AAB37235).
FT                                {ECO:0000305}.
FT   CONFLICT    916    919       Missing (in Ref. 2; AAB37235).
FT                                {ECO:0000305}.
FT   CONFLICT    918    919       VQ -> AR (in Ref. 1; AAA51902).
FT                                {ECO:0000305}.
FT   CONFLICT   1180   1180       D -> N (in Ref. 1; AAA51902 and 2;
FT                                AAB37235). {ECO:0000305}.
FT   CONFLICT   1294   1295       LV -> FE (in Ref. 6; AAA20531).
FT                                {ECO:0000305}.
FT   CONFLICT   1318   1318       R -> RHA (in Ref. 2; AAB37235).
FT                                {ECO:0000305}.
FT   CONFLICT   1472   1472       R -> G (in Ref. 2; AAB37235).
FT                                {ECO:0000305}.
FT   CONFLICT   1510   1510       I -> M (in Ref. 2; AAB37235).
FT                                {ECO:0000305}.
FT   CONFLICT   1532   1532       H -> D (in Ref. 2; AAB37235).
FT                                {ECO:0000305}.
FT   CONFLICT   1671   1671       G -> A (in Ref. 1; AAA51902 and 2;
FT                                AAB37235). {ECO:0000305}.
FT   CONFLICT   1710   1710       V -> S (in Ref. 1; AAA51902).
FT                                {ECO:0000305}.
FT   CONFLICT   1815   1815       A -> G (in Ref. 1; AAA51902 and 2;
FT                                AAB37235). {ECO:0000305}.
FT   HELIX      1523   1536       {ECO:0000244|PDB:2VAY}.
FT   HELIX      1538   1541       {ECO:0000244|PDB:2VAY}.
SQ   SEQUENCE   1873 AA;  212350 MW;  7B7446727E578913 CRC64;
     MEPSSPQDEG LRKKQPKKPV PEILPRPPRA LFCLTLENPL RKACISIVEW KPFETIILLT
     IFANCVALAV YLPMPEDDNN SLNLGLEKLE YFFLIVFSIE AAMKIIAYGF LFHQDAYLRS
     GWNVLDFTIV FLGVFTVILE QVNVIQSHTA PMSSKGAGLD VKALRAFRVL RPLRLVSGVP
     SLQVVLNSIF KAMLPLFHIA LLVLFMVIIY AIIGLELFKG KMHKTCYFIG TDIVATVENE
     EPSPCARTGS GRRCTINGSE CRGGWPGPNH GITHFDNFGF SMLTVYQCIT MEGWTDVLYW
     VNDAIGNEWP WIYFVTLILL GSFFILNLVL GVLSGEFTKE REKAKSRGTF QKLREKQQLD
     EDLRGYMSWI TQGEVMDVED FREGKLSLDE GGSDTESLYE IAGLNKIIQF IRHWRQWNRI
     FRWKCHDIVK SKVFYWLVIL IVALNTLSIA SEHHNQPLWL TRLQDIANRV LLSLFTTEML
     MKMYGLGLRQ YFMSIFNRFD CFVVCSGILE ILLVESGAMT PLGISVLRCI RLLRIFKITK
     YWTSLSNLVA SLLNSIRSIA SLLLLLFLFI VIFALLGMQL FGGRYDFEDT EVRRSNFDNF
     PQALISVFQV LTGEDWTSMM YNGIMAYGGP SYPGMLVCIY FIILFVCGNY ILLNVFLAIA
     VDNLAEAESL TSAQKAKAEE KKRRKMSKGL PDKSEEEKST MAKKLEQKPK GEGIPTTAKL
     KIDEFESNVN EVKDPYPSAD FPGDDEEDEP EIPLSPRPRP LAELQLKEKA VPIPEASSFF
     IFSPTNKIRV LCHRIVNATW FTNFILLFIL LSSAALAAED PIRADSMRNQ ILKHFDIGFT
     SVFTVEIVLK MTTYGAFLHK GSFCRNYFNM LDLLVVAVSL ISMGLESSAI SVVKILRVLR
     VLRPLRAINR AKGLKHVVQC MFVAISTIGN IVLVTTLLQF MFACIGVQLF KGKFFRCTDL
     SKMTEEECRG YYYVYKDGDP MQIELRHREW VHSDFHFDNV LSAMMSLFTV STFEGWPQLL
     YKAIDSNAED VGPIYNNRVE MAIFFIIYII LIAFFMMNIF VGFVIVTFQE QGETEYKNCE
     LDKNQRQCVQ YALKARPLRC YIPKNPYQYQ VWYIVTSSYF EYLMFALIML NTICLGMQHY
     NQSEQMNHIS DILNVAFTII FTLEMILKLM AFKARGYFGD PWNVFDFLIV IGSIIDVILS
     EIDTFLASSG GLYCLGGGCG NVDPDESARI SSAFFRLFRV MRLIKLLSRA EGVRTLLWTF
     IKSFQALPYV ALLIVMLFFI YAVIGMQMFG KIALVDGTQI NRNNNFQTFP QAVLLLFRCA
     TGEAWQEILL ACSYGKLCDP ESDYAPGEEY TCGTNFAYYY FISFYMLCAF LVINLFVAVI
     MDNFDYLTRD WSILGPHHLD EFKAIWAEYD PEAKGRIKHL DVVTLLRRIQ PPLGFGKFCP
     HRVACKRLVG MNMPLNSDGT VTFNATLFAL VRTALKIKTE GNFEQANEEL RAIIKKIWKR
     TSMKLLDQVI PPIGDDEVTV GKFYATFLIQ EHFRKFMKRQ EEYYGYRPKK DIVQIQAGLR
     TIEEEAAPEI CRTVSGDLAA EEELERAMVE AAMEEGIFRR TGGLFGQVDN FLERTNSLPP
     VMANQRPLQF AEIEMEEMES PVFLEDFPQD PRTNPLARAN TNNANANVAY GNSNHSNSHV
     FSSVHYEREF PEETETPATR GRALGQPCRV LGPHSKPCVE MLKGLLTQRA MPRGQAPPAP
     CQCPRVESSM PEDRKSSTPG SLHEETPHSR STRENTSRCS APATALLIQK ALVRGGLGTL
     AADANFIMAT GQALADACQM EPEEVEIMAT ELLKGREAPE GMASSLGCLN LGSSLGSLDQ
     HQGSQETLIP PRL
//
ID   CAC1C_HUMAN             Reviewed;        2221 AA.
AC   Q13936; B2RUT3; E9PDJ0; Q13917; Q13918; Q13919; Q13920; Q13921;
AC   Q13922; Q13923; Q13924; Q13925; Q13926; Q13927; Q13928; Q13929;
AC   Q13930; Q13932; Q13933; Q14743; Q14744; Q15877; Q4VMI7; Q4VMI8;
AC   Q4VMI9; Q6PKM7; Q8N6C0; Q99025; Q99241; Q99875;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 4.
DT   15-FEB-2017, entry version 198.
DE   RecName: Full=Voltage-dependent L-type calcium channel subunit alpha-1C;
DE   AltName: Full=Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav1.2;
GN   Name=CACNA1C; Synonyms=CACH2, CACN2, CACNL1A1, CCHL1A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1),
RP   AND VARIANTS VAL-1869 AND ARG-1893.
RC   TISSUE=Fetal fibroblast;
RX   PubMed=1316612; DOI=10.1073/pnas.89.10.4628;
RA   Soldatov N.M.;
RT   "Molecular diversity of L-type Ca2+ channel transcripts in human
RT   fibroblasts.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4628-4632(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 18 AND 28), NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 1822-1863, FUNCTION, TISSUE SPECIFICITY, AND VARIANT
RP   ARG-84.
RC   TISSUE=Heart;
RX   PubMed=8392192; DOI=10.1073/pnas.90.13.6228;
RA   Schultz D., Mikala G., Yatani A., Engle D.B., Iles D.E., Segers B.,
RA   Sinke R.J., Weghuis D.O., Kloeckner U., Wakamori M., Wang J.-J.,
RA   Melvin D., Varadi G., Schwartz A.;
RT   "Cloning, chromosomal localization, and functional expression of the
RT   alpha-1 subunit of the L-type voltage-dependent calcium channel from
RT   normal human heart.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:6228-6232(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1112-1803 (ISOFORMS 24/27), AND NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1364-1972 (ISOFORMS 11/12/19/20/21/22/23/30/31/32).
RC   TISSUE=Hippocampus, and Lung fibroblast;
RX   PubMed=7959794; DOI=10.1006/geno.1994.1347;
RA   Soldatov N.M.;
RT   "Genomic structure of human L-type Ca2+ channel.";
RL   Genomics 22:77-87(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 12; 19 AND 20), ALTERNATIVE
RP   SPLICING, FUNCTION, AND MUTAGENESIS OF GLY-954 AND TYR-958.
RC   TISSUE=Fibroblast;
RX   PubMed=7737988; DOI=10.1074/jbc.270.18.10540;
RA   Soldatov N.M., Bouron A., Reuter H.;
RT   "Different voltage-dependent inhibition by dihydropyridines of human
RT   Ca2+ channel splice variants.";
RL   J. Biol. Chem. 270:10540-10543(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 16 AND 17),
RP   ALTERNATIVE SPLICING, AND VARIANTS ARG-84; VAL-1869 AND ARG-1893.
RC   TISSUE=Heart;
RX   PubMed=9087614;
RA   Kloeckner U., Mikala G., Eisfeld J., Iles D.E., Strobeck M.,
RA   Mershon J.L., Schwartz A., Varadi G.;
RT   "Properties of three COOH-terminal splice variants of a human cardiac
RT   L-type Ca2+-channel alpha1-subunit.";
RL   Am. J. Physiol. 272:H1372-H1381(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 26 AND 27), ALTERNATIVE SPLICING
RP   (ISOFORMS 9 AND 10), AND FUNCTION.
RC   TISSUE=Hippocampus;
RX   PubMed=9013606; DOI=10.1074/jbc.272.6.3560;
RA   Soldatov N.M., Zuelke R.D., Bouron A., Reuter H.;
RT   "Molecular structures involved in L-type calcium channel inactivation.
RT   Role of the carboxyl-terminal region encoded by exons 40-42 in alpha1C
RT   subunit in the kinetics and Ca2+ dependence of inactivation.";
RL   J. Biol. Chem. 272:3560-3566(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 21; 22 AND 23), AND FUNCTION.
RX   PubMed=9607315; DOI=10.1016/S0014-5793(98)00425-6;
RA   Zuehlke R.D., Bouron A., Soldatov N.M., Reuter H.;
RT   "Ca2+ channel sensitivity towards the blocker isradipine is affected
RT   by alternative splicing of the human alpha1C subunit gene.";
RL   FEBS Lett. 427:220-224(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Intestinal smooth muscle;
RX   PubMed=12176756; DOI=10.1152/ajpcell.00140.2002;
RA   Lyford G.L., Strege P.R., Shepard A., Ou Y., Ermilov L., Miller S.M.,
RA   Gibbons S.J., Rae J.L., Szurszewski J.H., Farrugia G.;
RT   "Alpha(1C) (Ca(V)1.2) L-type calcium channel mediates mechanosensitive
RT   calcium regulation.";
RL   Am. J. Physiol. 283:C1001-C1008(2002).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 13; 14; 15; 24 AND 25), FUNCTION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=17071743; DOI=10.1073/pnas.0606539103;
RA   Tiwari S., Zhang Y., Heller J., Abernethy D.R., Soldatov N.M.;
RT   "Atherosclerosis-related molecular alteration of the human CaV1.2
RT   calcium channel alpha1C subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17024-17029(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 11; 28; 29; 30; 31; 32 AND 33),
RP   ALTERNATIVE SPLICING, AND VARIANTS ARG-84; VAL-1869 AND ARG-1893.
RA   Soldatov N.;
RT   "Functional expression of splice variants of human l-type calcium
RT   channel (isoform 1 gene).";
RL   Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 35).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-180 (ISOFORM 34).
RX   PubMed=11741969; DOI=10.1074/jbc.C100642200;
RA   Blumenstein Y., Kanevsky N., Sahar G., Barzilai R., Ivanina T.,
RA   Dascal N.;
RT   "A novel long N-terminal isoform of human L-type Ca2+ channel is up-
RT   regulated by protein kinase C.";
RL   J. Biol. Chem. 277:3419-3423(2002).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1182-1503 (ISOFORMS 6/12/20/23/24), AND
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1182-1503 (ISOFORMS
RP   7/13/16/17/18/21/22).
RC   TISSUE=Heart;
RX   PubMed=2173707;
RA   Perez-Reyes E., Wei X., Castellano A., Birnbaumer L.;
RT   "Molecular diversity of L-type calcium channels. Evidence for
RT   alternative splicing of the transcripts of three non-allelic genes.";
RL   J. Biol. Chem. 265:20430-20436(1990).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1140-1206.
RC   TISSUE=Heart;
RX   PubMed=1653763; DOI=10.1016/0888-7543(91)90471-P;
RA   Powers P.A., Gregg R.G., Lalley P.A., Liao M., Hogan K.;
RT   "Assignment of the human gene for the alpha 1 subunit of the cardiac
RT   DHP-sensitive Ca2+ channel (CCHL1A1) to chromosome 12p12-pter.";
RL   Genomics 10:835-839(1991).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1196-1421.
RC   TISSUE=Brain;
RX   PubMed=1335957; DOI=10.1016/S0888-7543(05)80135-1;
RA   Sun W., McPherson J.D., Hoang D.Q., Wasmuth J.J., Evans G.A.,
RA   Montal M.;
RT   "Mapping of a human brain voltage-gated calcium channel to human
RT   chromosome 12p13-pter.";
RL   Genomics 14:1092-1094(1992).
RN   [17]
RP   MUTAGENESIS, CALCIUM-BINDING, AND SITE.
RX   PubMed=8099908;
RA   Tang S., Mikala G., Bahinski A., Yatani A., Varadi G., Schwartz A.;
RT   "Molecular localization of ion selectivity sites within the pore of a
RT   human L-type cardiac calcium channel.";
RL   J. Biol. Chem. 268:13026-13029(1993).
RN   [18]
RP   INTERACTION WITH CACNA2D4.
RX   PubMed=12181424; DOI=10.1124/mol.62.3.485;
RA   Qin N., Yagel S., Momplaisir M.-L., Codd E.E., D'Andrea M.R.;
RT   "Molecular cloning and characterization of the human voltage-gated
RT   calcium channel alpha(2)delta-4 subunit.";
RL   Mol. Pharmacol. 62:485-496(2002).
RN   [19]
RP   INTERACTION WITH CABP1.
RX   PubMed=15140941; DOI=10.1523/JNEUROSCI.5523-03.2004;
RA   Zhou H., Kim S.-A., Kirk E.A., Tippens A.L., Sun H., Haeseleer F.,
RA   Lee A.;
RT   "Ca2+-binding protein-1 facilitates and forms a postsynaptic complex
RT   with Cav1.2 (L-type) Ca2+ channels.";
RL   J. Neurosci. 24:4698-4708(2004).
RN   [20]
RP   INTERACTION WITH CABP1.
RX   PubMed=15980432; DOI=10.1074/jbc.M504167200;
RA   Zhou H., Yu K., McCoy K.L., Lee A.;
RT   "Molecular mechanism for divergent regulation of Cav1.2 Ca2+ channels
RT   by calmodulin and Ca2+-binding protein-1.";
RL   J. Biol. Chem. 280:29612-29619(2005).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 428-445 IN COMPLEX WITH
RP   CACNB2.
RX   PubMed=15141227; DOI=10.1038/nature02588;
RA   Van Petegem F., Clark K.A., Chatelain F.C., Minor D.L. Jr.;
RT   "Structure of a complex between a voltage-gated calcium channel beta-
RT   subunit and an alpha-subunit domain.";
RL   Nature 429:671-675(2004).
RN   [22]
RP   VARIANT TS ARG-406, AND CHARACTERIZATION OF VARIANT TS ARG-406.
RX   PubMed=15454078; DOI=10.1016/j.cell.2004.09.011;
RA   Splawski I., Timothy K.W., Sharpe L.M., Decher N., Kumar P.,
RA   Bloise R., Napolitano C., Schwartz P.J., Joseph R.M., Condouris K.,
RA   Tager-Flusberg H., Priori S.G., Sanguinetti M.C., Keating M.T.;
RT   "Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder
RT   including arrhythmia and autism.";
RL   Cell 119:19-31(2004).
RN   [23]
RP   VARIANT TS SER-402.
RX   PubMed=15863612; DOI=10.1073/pnas.0502506102;
RA   Splawski I., Timothy K.W., Decher N., Kumar P., Sachse F.B.,
RA   Beggs A.H., Sanguinetti M.C., Keating M.T.;
RT   "Severe arrhythmia disorder caused by cardiac L-type calcium channel
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8089-8096(2005).
RN   [24]
RP   VARIANTS BRGDA3 VAL-39 AND ARG-490, AND CHARACTERIZATION OF VARIANTS
RP   BRGDA3 VAL-39 AND ARG-490.
RX   PubMed=17224476; DOI=10.1161/CIRCULATIONAHA.106.668392;
RA   Antzelevitch C., Pollevick G.D., Cordeiro J.M., Casis O.,
RA   Sanguinetti M.C., Aizawa Y., Guerchicoff A., Pfeiffer R., Oliva A.,
RA   Wollnik B., Gelber P., Bonaros E.P. Jr., Burashnikov E., Wu Y.,
RA   Sargent J.D., Schickel S., Oberheiden R., Bhatia A., Hsu L.F.,
RA   Haissaguerre M., Schimpf R., Borggrefe M., Wolpert C.;
RT   "Loss-of-function mutations in the cardiac calcium channel underlie a
RT   new clinical entity characterized by ST-segment elevation, short QT
RT   intervals, and sudden cardiac death.";
RL   Circulation 115:442-449(2007).
RN   [25]
RP   VARIANT ARG-878.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
RN   [26]
RP   VARIANTS TS SER-381; ILE-456; ASP-582; HIS-858 AND CYS-1831, AND
RP   CHARACTERIZATION OF VARIANTS TS SER-381; ILE-456; ASP-582; HIS-858 AND
RP   CYS-1831.
RX   PubMed=24728418; DOI=10.1093/europace/euu063;
RA   Fukuyama M., Wang Q., Kato K., Ohno S., Ding W.G., Toyoda F., Itoh H.,
RA   Kimura H., Makiyama T., Ito M., Matsuura H., Horie M.;
RT   "Long QT syndrome type 8: novel CACNA1C mutations causing QT
RT   prolongation and variant phenotypes.";
RL   Europace 16:1828-1837(2014).
RN   [27]
RP   VARIANTS TS CYS-518 AND HIS-518, AND CHARACTERIZATION OF VARIANTS TS
RP   CYS-518 AND HIS-518.
RX   PubMed=26253506; DOI=10.1161/CIRCEP.115.002745;
RA   Boczek N.J., Ye D., Jin F., Tester D.J., Huseby A., Bos J.M.,
RA   Johnson A.J., Kanter R., Ackerman M.J.;
RT   "Identification and functional characterization of a novel CACNA1C-
RT   mediated cardiac disorder characterized by prolonged QT intervals with
RT   hypertrophic cardiomyopathy, congenital heart defects, and sudden
RT   cardiac death.";
RL   Circ. Arrhythm. Electrophysiol. 8:1122-1132(2015).
RN   [28]
RP   VARIANT TS THR-1186, AND CHARACTERIZATION OF VARIANT TS THR-1186.
RX   PubMed=25260352; DOI=10.1016/j.hrthm.2014.09.051;
RA   Boczek N.J., Miller E.M., Ye D., Nesterenko V.V., Tester D.J.,
RA   Antzelevitch C., Czosek R.J., Ackerman M.J., Ware S.M.;
RT   "Novel Timothy syndrome mutation leading to increase in CACNA1C window
RT   current.";
RL   Heart Rhythm 12:211-219(2015).
RN   [29]
RP   VARIANTS TS THR-28; GLY-860; THR-1186; VAL-1186; MET-1523; LYS-1544;
RP   ILE-1800 MET-1953 AND ILE-2097, CHARACTERIZATION OF VARIANTS TS
RP   THR-28; GLY-860; THR-1186; VAL-1186; MET-1523 AND LYS-1544, AND
RP   VARIANTS ARG-37; THR-304; LYS-477; SER-817; THR-1365; ILE-1755;
RP   GLY-1765; ASN-1787; MET-1835; ALA-1843; LYS-1948; CYS-1972; GLN-2056;
RP   ASN-2081; GLY-2122 AND SER-2174.
RX   PubMed=25633834; DOI=10.1016/j.yjmcc.2015.01.002;
RA   Wemhoener K., Friedrich C., Stallmeyer B., Coffey A.J., Grace A.,
RA   Zumhagen S., Seebohm G., Ortiz-Bonnin B., Rinne S., Sachse F.B.,
RA   Schulze-Bahr E., Decher N.;
RT   "Gain-of-function mutations in the calcium channel CACNA1C (Cav1.2)
RT   cause non-syndromic long-QT but not Timothy syndrome.";
RL   J. Mol. Cell. Cardiol. 80:186-195(2015).
RN   [30]
RP   VARIANTS GLU-850 DEL AND SER-2091, AND CHARACTERIZATION OF VARIANTS
RP   GLU-850 DEL AND SER-2091.
RX   PubMed=27218670; DOI=10.1111/chd.12371;
RA   Sutphin B.S., Boczek N.J., Barajas-Martinez H., Hu D., Ye D.,
RA   Tester D.J., Antzelevitch C., Ackerman M.J.;
RT   "Molecular and functional characterization of rare CACNA1C variants in
RT   sudden unexplained death in the young.";
RL   Congenit. Heart Dis. 11:683-692(2016).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1C
CC       gives rise to L-type calcium currents. Long-lasting (L-type)
CC       calcium channels belong to the 'high-voltage activated' (HVA)
CC       group. They are blocked by dihydropyridines (DHP),
CC       phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA
CC       (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-
CC       GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).
CC       Calcium channels containing the alpha-1C subunit play an important
CC       role in excitation-contraction coupling in the heart. The various
CC       isoforms display marked differences in the sensitivity to DHP
CC       compounds. Binding of calmodulin or CABP1 at the same regulatory
CC       sites results in an opposit effects on the channel function.
CC       {ECO:0000269|PubMed:12176756, ECO:0000269|PubMed:17071743,
CC       ECO:0000269|PubMed:7737988, ECO:0000269|PubMed:8392192,
CC       ECO:0000269|PubMed:9013606, ECO:0000269|PubMed:9607315}.
CC   -!- SUBUNIT: Voltage-dependent calcium channels are multisubunit
CC       complexes, consisting of alpha-1, alpha-2, beta and delta subunits
CC       in a 1:1:1:1 ratio. The channel activity is directed by the pore-
CC       forming and voltage-sensitive alpha-1 subunit. In many cases, this
CC       subunit is sufficient to generate voltage-sensitive calcium
CC       channel activity. The auxiliary subunits beta and alpha-2/delta
CC       linked by a disulfide bridge regulate the channel activity.
CC       Interacts with CACNA2D4. Interacts (via the N-terminus and the C-
CC       terminal C and IQ motifs) with CABP1. The binding via the C motif
CC       is calcium independent whereas the binding via IQ requires the
CC       presence of calcium and is mutually exclusive with calmodulin
CC       binding. The binding to the cytoplasmic N-terminal domain is
CC       calcium independent but is essential for the channel modulation.
CC       Interacts (via C-terminal CDB motif) with CABP5; in a calcium-
CC       dependent manner (By similarity). Interacts with CIB1; the
CC       interaction increases upon cardiomyocytes hypertrophy (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:12181424,
CC       ECO:0000269|PubMed:15140941, ECO:0000269|PubMed:15141227,
CC       ECO:0000269|PubMed:15980432}.
CC   -!- INTERACTION:
CC       Q9NZU7:CABP1; NbExp=4; IntAct=EBI-1038838, EBI-907894;
CC       P62158:CALM3; NbExp=12; IntAct=EBI-1038838, EBI-397435;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250|UniProtKB:P15381};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:P15381}. Cell
CC       membrane {ECO:0000250|UniProtKB:P15381}. Note=The interaction
CC       between RRAD and CACNB2 regulates its trafficking to the cell
CC       membrane. {ECO:0000250|UniProtKB:P15381}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=37;
CC         Comment=Additional isoforms seem to exist. Exons 8A, 21, 22, 31,
CC         32, 33, 40B, 43A, 41A and 45 are alternatively spliced in a
CC         variety of combinations. Experimental confirmation may be
CC         lacking for some isoforms.;
CC       Name=1; Synonyms=HFCC, Fibroblast;
CC         IsoId=Q13936-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13936-2; Sequence=VSP_000894;
CC       Name=3;
CC         IsoId=Q13936-3; Sequence=VSP_000886;
CC         Note=Contains exon 8a.;
CC       Name=4;
CC         IsoId=Q13936-4; Sequence=VSP_000887;
CC         Note=Lacks exon 21.;
CC       Name=5;
CC         IsoId=Q13936-5; Sequence=VSP_000888;
CC         Note=Lacks exon 22.;
CC       Name=6;
CC         IsoId=Q13936-6; Sequence=VSP_000889;
CC         Note=Lacks exon 31.;
CC       Name=7;
CC         IsoId=Q13936-7; Sequence=VSP_000890;
CC         Note=Lacks exon 32.;
CC       Name=8;
CC         IsoId=Q13936-8; Sequence=VSP_000891;
CC         Note=Lacks exon 33.;
CC       Name=9;
CC         IsoId=Q13936-9; Sequence=VSP_000892;
CC         Note=Contains exon 40B and 43A.;
CC       Name=10;
CC         IsoId=Q13936-10; Sequence=VSP_000893;
CC         Note=Contains exon 41A.;
CC       Name=11; Synonyms=Alpha-1C.90;
CC         IsoId=Q13936-11; Sequence=VSP_000895;
CC         Note=Lacks exon 45.;
CC       Name=12; Synonyms=Alpha-1C.70;
CC         IsoId=Q13936-12; Sequence=VSP_000888, VSP_000889, VSP_000895;
CC       Name=13; Synonyms=Alpha-1C.127;
CC         IsoId=Q13936-13; Sequence=VSP_000888, VSP_000890, VSP_000893,
CC                                   VSP_000895;
CC       Name=14; Synonyms=Alpha-1C.126;
CC         IsoId=Q13936-14; Sequence=VSP_000888, VSP_000889, VSP_022504,
CC                                   VSP_000893, VSP_000895;
CC       Name=15; Synonyms=Alpha-1C.125;
CC         IsoId=Q13936-15; Sequence=VSP_000888, VSP_000889, VSP_022503,
CC                                   VSP_000893, VSP_000895;
CC       Name=16;
CC         IsoId=Q13936-16; Sequence=VSP_000885, VSP_000886, VSP_000888,
CC                                   VSP_000890;
CC       Name=17;
CC         IsoId=Q13936-17; Sequence=VSP_000885, VSP_000886, VSP_000888,
CC                                   VSP_000890, VSP_000895;
CC       Name=18; Synonyms=HHT-1;
CC         IsoId=Q13936-18; Sequence=VSP_000885, VSP_000886, VSP_000888,
CC                                   VSP_000890, VSP_000894;
CC       Name=19; Synonyms=Alpha-1C.76;
CC         IsoId=Q13936-19; Sequence=VSP_000887, VSP_000889, VSP_000891,
CC                                   VSP_000895;
CC       Name=20; Synonyms=Alpha-1C.77;
CC         IsoId=Q13936-20; Sequence=VSP_000887, VSP_000889, VSP_000895;
CC         Note=Predominant isoform in atherosclerotic vascular smooth
CC         muscle cells.;
CC       Name=21; Synonyms=Alpha-1C.69;
CC         IsoId=Q13936-21; Sequence=VSP_000887, VSP_000890, VSP_000895;
CC       Name=22; Synonyms=Alpha-1C.78;
CC         IsoId=Q13936-22; Sequence=VSP_000888, VSP_000890, VSP_000895;
CC       Name=23; Synonyms=Alpha-1C.105;
CC         IsoId=Q13936-23; Sequence=VSP_000886, VSP_000887, VSP_000889,
CC                                   VSP_000895;
CC       Name=24; Synonyms=Alpha-1C.71;
CC         IsoId=Q13936-24; Sequence=VSP_000888, VSP_000889, VSP_000893,
CC                                   VSP_000895;
CC       Name=25; Synonyms=Alpha-1C.73;
CC         IsoId=Q13936-25; Sequence=VSP_000888, VSP_000889, VSP_000891,
CC                                   VSP_000893, VSP_000895;
CC       Name=26; Synonyms=Alpha-1C.86;
CC         IsoId=Q13936-26; Sequence=VSP_000887, VSP_000889, VSP_000892,
CC                                   VSP_000895;
CC         Note=Not inhibited by calcium. Ref.3 (CAA84348) sequence is in
CC         conflict in position: 1573:A->T. {ECO:0000305};
CC       Name=27; Synonyms=Alpha-1C.72;
CC         IsoId=Q13936-27; Sequence=VSP_000887, VSP_000889, VSP_000893,
CC                                   VSP_000895;
CC       Name=28;
CC         IsoId=Q13936-28; Sequence=VSP_000885, VSP_000886, VSP_000888,
CC                                   VSP_000889, VSP_000891, VSP_000894;
CC       Name=29; Synonyms=Alpha-1C.74;
CC         IsoId=Q13936-29; Sequence=VSP_000887, VSP_000889, VSP_000891,
CC                                   VSP_000893, VSP_000895;
CC       Name=30; Synonyms=Alpha-1C.87;
CC         IsoId=Q13936-30; Sequence=VSP_000889, VSP_000895;
CC       Name=31; Synonyms=Alpha-1C.88;
CC         IsoId=Q13936-31; Sequence=VSP_000888, VSP_000895;
CC       Name=32; Synonyms=Alpha-1C.89;
CC         IsoId=Q13936-32; Sequence=VSP_000887, VSP_000891, VSP_000895;
CC       Name=33; Synonyms=Alpha-1C.85;
CC         IsoId=Q13936-33; Sequence=VSP_000887, VSP_000889;
CC       Name=34; Synonyms=Alpha-1C,long-NT;
CC         IsoId=Q13936-34; Sequence=VSP_035146;
CC         Note=Enhanced by PKC activator.;
CC       Name=35;
CC         IsoId=Q13936-35; Sequence=VSP_035877, VSP_000888, VSP_000890,
CC                                   VSP_000895;
CC       Name=36;
CC         IsoId=Q13936-36; Sequence=VSP_000886, VSP_000888, VSP_000890;
CC         Note=Gene prediction based on EST data.;
CC       Name=37;
CC         IsoId=Q13936-37; Sequence=VSP_000886, VSP_000888, VSP_000890,
CC                                   VSP_000895;
CC         Note=Gene prediction based on EST data.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, heart, jejunum, ovary,
CC       pancreatic beta-cells and vascular smooth muscle. Overall
CC       expression is reduced in atherosclerotic vascular smooth muscle.
CC       {ECO:0000269|PubMed:12176756, ECO:0000269|PubMed:17071743,
CC       ECO:0000269|PubMed:8392192}.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- DOMAIN: Binding of intracellular calcium through the EF-hand motif
CC       inhibits the opening of the channel.
CC       {ECO:0000250|UniProtKB:P15381}.
CC   -!- PTM: Phosphorylation by PKA activates the channel.
CC       {ECO:0000250|UniProtKB:P15381}.
CC   -!- DISEASE: Timothy syndrome (TS) [MIM:601005]: Disorder
CC       characterized by multiorgan dysfunction including lethal
CC       arrhythmias, webbing of fingers and toes, congenital heart
CC       disease, immune deficiency, intermittent hypoglycemia, cognitive
CC       abnormalities and autism. {ECO:0000269|PubMed:15454078,
CC       ECO:0000269|PubMed:15863612, ECO:0000269|PubMed:24728418,
CC       ECO:0000269|PubMed:25260352, ECO:0000269|PubMed:25633834,
CC       ECO:0000269|PubMed:26253506}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Brugada syndrome 3 (BRGDA3) [MIM:611875]: A heart disease
CC       characterized by the association of Brugada syndrome with
CC       shortened QT intervals. Brugada syndrome is a tachyarrhythmia
CC       characterized by right bundle branch block and ST segment
CC       elevation on an electrocardiogram (ECG). It can cause the
CC       ventricles to beat so fast that the blood is prevented from
CC       circulating efficiently in the body. When this situation occurs,
CC       the individual will faint and may die in a few minutes if the
CC       heart is not reset. {ECO:0000269|PubMed:17224476}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1C subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA02500.2; Type=Frameshift; Positions=1844; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M92269; AAA17030.1; -; Genomic_DNA.
DR   EMBL; M92270; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M92271; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M92272; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M92273; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M92274; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M92275; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L04568; AAA02500.2; ALT_FRAME; Genomic_DNA.
DR   EMBL; L04569; AAA02501.1; -; mRNA.
DR   EMBL; L29529; AAA51899.1; -; mRNA.
DR   EMBL; Z26256; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26257; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26258; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26259; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26260; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26261; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26263; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26264; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26265; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26266; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26268; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26269; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26271; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26272; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26273; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26274; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26275; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26276; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26277; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26278; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26279; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26280; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26281; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26282; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26283; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26286; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26287; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26288; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z26294; CAA81218.1; -; mRNA.
DR   EMBL; Z26295; CAA81219.1; -; mRNA.
DR   EMBL; Z26308; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z34809; CAA84340.1; -; mRNA.
DR   EMBL; Z34810; CAA84341.1; -; mRNA.
DR   EMBL; Z34811; CAA84342.1; -; mRNA.
DR   EMBL; Z34812; CAA84343.1; -; mRNA.
DR   EMBL; Z34813; CAA84344.1; -; mRNA.
DR   EMBL; Z34814; CAA84345.1; -; mRNA.
DR   EMBL; Z34815; CAA84346.1; -; mRNA.
DR   EMBL; Z34816; CAA84347.1; -; mRNA.
DR   EMBL; Z34817; CAA84348.1; -; mRNA.
DR   EMBL; Z34818; CAA84349.1; -; mRNA.
DR   EMBL; Z34819; CAA84350.1; -; mRNA.
DR   EMBL; Z34820; CAA84351.1; -; mRNA.
DR   EMBL; Z34821; CAA84352.1; -; mRNA.
DR   EMBL; Z34822; CAA84353.1; -; mRNA.
DR   EMBL; L29530; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L29531; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L29532; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L29533; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L29534; AAA51900.1; -; mRNA.
DR   EMBL; L29535; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L29536; AAA51901.1; -; mRNA.
DR   EMBL; L29537; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L29538; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L29539; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z74996; CAA99284.1; -; mRNA.
DR   EMBL; AJ224873; CAA12174.1; -; mRNA.
DR   EMBL; AF465484; AAM70049.1; -; mRNA.
DR   EMBL; AY830711; AAX37354.1; -; mRNA.
DR   EMBL; AY830712; AAX37355.1; -; mRNA.
DR   EMBL; AY830713; AAX37356.1; -; mRNA.
DR   EMBL; AC005293; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005342; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005344; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005414; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005866; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006051; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC007618; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC146846; AAI46847.1; -; mRNA.
DR   EMBL; AY604867; AAT02226.1; -; mRNA.
DR   EMBL; M57971; AAA62832.1; -; mRNA.
DR   EMBL; M57972; AAB59461.1; -; mRNA.
DR   EMBL; M61130; AAA58409.1; -; Genomic_DNA.
DR   EMBL; M91370; AAA74590.1; -; Genomic_DNA.
DR   CCDS; CCDS44787.1; -. [Q13936-23]
DR   CCDS; CCDS44788.1; -. [Q13936-11]
DR   CCDS; CCDS44789.1; -. [Q13936-30]
DR   CCDS; CCDS44790.1; -. [Q13936-31]
DR   CCDS; CCDS44791.1; -. [Q13936-22]
DR   CCDS; CCDS44792.1; -. [Q13936-14]
DR   CCDS; CCDS44793.1; -. [Q13936-24]
DR   CCDS; CCDS44794.1; -. [Q13936-12]
DR   CCDS; CCDS44795.1; -. [Q13936-25]
DR   CCDS; CCDS44796.1; -. [Q13936-15]
DR   CCDS; CCDS44797.1; -. [Q13936-32]
DR   CCDS; CCDS44798.1; -. [Q13936-21]
DR   CCDS; CCDS44799.1; -. [Q13936-27]
DR   CCDS; CCDS44800.1; -. [Q13936-20]
DR   CCDS; CCDS44801.1; -. [Q13936-29]
DR   CCDS; CCDS53733.1; -. [Q13936-36]
DR   CCDS; CCDS53734.1; -. [Q13936-37]
DR   CCDS; CCDS53735.1; -. [Q13936-13]
DR   CCDS; CCDS53736.1; -. [Q13936-33]
DR   PIR; A23660; A23660.
DR   PIR; A44363; A44363.
DR   PIR; A45290; A45290.
DR   PIR; B23660; B23660.
DR   PIR; C23660; C23660.
DR   PIR; I54168; I54168.
DR   RefSeq; NP_000710.5; NM_000719.6. [Q13936-12]
DR   RefSeq; NP_001123299.1; NM_001129827.1. [Q13936-11]
DR   RefSeq; NP_001123301.1; NM_001129829.1. [Q13936-14]
DR   RefSeq; NP_001123302.2; NM_001129830.2.
DR   RefSeq; NP_001123303.1; NM_001129831.1. [Q13936-31]
DR   RefSeq; NP_001123304.1; NM_001129832.1. [Q13936-30]
DR   RefSeq; NP_001123305.1; NM_001129833.1. [Q13936-13]
DR   RefSeq; NP_001123306.1; NM_001129834.1. [Q13936-24]
DR   RefSeq; NP_001123307.1; NM_001129835.1. [Q13936-27]
DR   RefSeq; NP_001123308.1; NM_001129836.1. [Q13936-32]
DR   RefSeq; NP_001123309.1; NM_001129837.1. [Q13936-25]
DR   RefSeq; NP_001123310.1; NM_001129838.1. [Q13936-29]
DR   RefSeq; NP_001123311.1; NM_001129839.1. [Q13936-15]
DR   RefSeq; NP_001123312.1; NM_001129840.1. [Q13936-23]
DR   RefSeq; NP_001123313.1; NM_001129841.1. [Q13936-21]
DR   RefSeq; NP_001123314.1; NM_001129842.1. [Q13936-22]
DR   RefSeq; NP_001123315.1; NM_001129843.1. [Q13936-20]
DR   RefSeq; NP_001123316.1; NM_001129844.1. [Q13936-35]
DR   RefSeq; NP_001123318.1; NM_001129846.1. [Q13936-19]
DR   RefSeq; NP_001161095.1; NM_001167623.1. [Q13936-37]
DR   RefSeq; NP_001161096.2; NM_001167624.2.
DR   RefSeq; NP_001161097.1; NM_001167625.1.
DR   RefSeq; NP_955630.3; NM_199460.3.
DR   UniGene; Hs.118262; -.
DR   UniGene; Hs.690010; -.
DR   PDB; 1T0J; X-ray; 2.00 A; C=428-445.
DR   PDB; 2BE6; X-ray; 2.00 A; D/E/F=1659-1692.
DR   PDB; 2F3Y; X-ray; 1.45 A; B=1665-1685.
DR   PDB; 2F3Z; X-ray; 1.60 A; B=1665-1685.
DR   PDB; 2LQC; NMR; -; B=47-68.
DR   PDB; 3G43; X-ray; 2.10 A; E/F=1609-1682.
DR   PDB; 3OXQ; X-ray; 2.55 A; E/F=1609-1685.
DR   PDBsum; 1T0J; -.
DR   PDBsum; 2BE6; -.
DR   PDBsum; 2F3Y; -.
DR   PDBsum; 2F3Z; -.
DR   PDBsum; 2LQC; -.
DR   PDBsum; 3G43; -.
DR   PDBsum; 3OXQ; -.
DR   ProteinModelPortal; Q13936; -.
DR   SMR; Q13936; -.
DR   BioGrid; 107229; 14.
DR   DIP; DIP-29589N; -.
DR   IntAct; Q13936; 4.
DR   STRING; 9606.ENSP00000266376; -.
DR   BindingDB; Q13936; -.
DR   ChEMBL; CHEMBL1940; -.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB04920; Clevidipine.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB06751; Drotaverine.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB01023; Felodipine.
DR   DrugBank; DB00308; Ibutilide.
DR   DrugBank; DB00270; Isradipine.
DR   DrugBank; DB00653; Magnesium Sulfate.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB06712; Nilvadipine.
DR   DrugBank; DB00393; Nimodipine.
DR   DrugBank; DB00401; Nisoldipine.
DR   DrugBank; DB01054; Nitrendipine.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00661; Verapamil.
DR   GuidetoPHARMACOLOGY; 529; -.
DR   TCDB; 1.A.1.11.4; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; Q13936; -.
DR   PhosphoSitePlus; Q13936; -.
DR   BioMuta; CACNA1C; -.
DR   DMDM; 308153651; -.
DR   PaxDb; Q13936; -.
DR   PeptideAtlas; Q13936; -.
DR   PRIDE; Q13936; -.
DR   Ensembl; ENST00000344100; ENSP00000341092; ENSG00000151067. [Q13936-14]
DR   Ensembl; ENST00000347598; ENSP00000266376; ENSG00000151067. [Q13936-11]
DR   Ensembl; ENST00000399591; ENSP00000382500; ENSG00000151067. [Q13936-29]
DR   Ensembl; ENST00000399595; ENSP00000382504; ENSG00000151067. [Q13936-25]
DR   Ensembl; ENST00000399597; ENSP00000382506; ENSG00000151067. [Q13936-22]
DR   Ensembl; ENST00000399601; ENSP00000382510; ENSG00000151067. [Q13936-20]
DR   Ensembl; ENST00000399603; ENSP00000382512; ENSG00000151067. [Q13936-37]
DR   Ensembl; ENST00000399606; ENSP00000382515; ENSG00000151067. [Q13936-30]
DR   Ensembl; ENST00000399621; ENSP00000382530; ENSG00000151067. [Q13936-24]
DR   Ensembl; ENST00000399629; ENSP00000382537; ENSG00000151067. [Q13936-32]
DR   Ensembl; ENST00000399637; ENSP00000382546; ENSG00000151067. [Q13936-27]
DR   Ensembl; ENST00000399638; ENSP00000382547; ENSG00000151067. [Q13936-31]
DR   Ensembl; ENST00000399641; ENSP00000382549; ENSG00000151067. [Q13936-23]
DR   Ensembl; ENST00000399644; ENSP00000382552; ENSG00000151067. [Q13936-21]
DR   Ensembl; ENST00000399649; ENSP00000382557; ENSG00000151067. [Q13936-15]
DR   Ensembl; ENST00000399655; ENSP00000382563; ENSG00000151067. [Q13936-12]
DR   Ensembl; ENST00000402845; ENSP00000385724; ENSG00000151067. [Q13936-13]
DR   GeneID; 775; -.
DR   KEGG; hsa:775; -.
DR   UCSC; uc001qjz.3; human. [Q13936-1]
DR   CTD; 775; -.
DR   DisGeNET; 775; -.
DR   GeneCards; CACNA1C; -.
DR   GeneReviews; CACNA1C; -.
DR   H-InvDB; HIX0010327; -.
DR   HGNC; HGNC:1390; CACNA1C.
DR   HPA; HPA039796; -.
DR   MalaCards; CACNA1C; -.
DR   MIM; 114205; gene.
DR   MIM; 601005; phenotype.
DR   MIM; 611875; phenotype.
DR   neXtProt; NX_Q13936; -.
DR   OpenTargets; ENSG00000151067; -.
DR   Orphanet; 130; Brugada syndrome.
DR   Orphanet; 65283; Timothy syndrome.
DR   PharmGKB; PA83; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128247; -.
DR   HOVERGEN; HBG050763; -.
DR   InParanoid; Q13936; -.
DR   KO; K04850; -.
DR   PhylomeDB; Q13936; -.
DR   TreeFam; TF312805; -.
DR   Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-5576893; Phase 2 - plateau phase.
DR   Reactome; R-HSA-5576894; Phase 1 - inactivation of fast Na+ channels.
DR   SIGNOR; Q13936; -.
DR   ChiTaRS; CACNA1C; human.
DR   EvolutionaryTrace; Q13936; -.
DR   GeneWiki; Cav1.2; -.
DR   GenomeRNAi; 775; -.
DR   PRO; PR:Q13936; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000151067; -.
DR   ExpressionAtlas; Q13936; baseline and differential.
DR   Genevisible; Q13936; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:1990454; C:L-type voltage-gated calcium channel complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IDA:UniProtKB.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IDA:UniProtKB.
DR   GO; GO:0030018; C:Z disc; ISS:BHF-UCL.
DR   GO; GO:0051393; F:alpha-actinin binding; IPI:BHF-UCL.
DR   GO; GO:0005516; F:calmodulin binding; IPI:UniProtKB.
DR   GO; GO:0008331; F:high voltage-gated calcium channel activity; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0086056; F:voltage-gated calcium channel activity involved in AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086007; F:voltage-gated calcium channel activity involved in cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IMP:UniProtKB.
DR   GO; GO:0061577; P:calcium ion transmembrane transport via high voltage-gated calcium channel; IDA:BHF-UCL.
DR   GO; GO:0060402; P:calcium ion transport into cytosol; TAS:BHF-UCL.
DR   GO; GO:0035585; P:calcium-mediated signaling using extracellular calcium source; TAS:BHF-UCL.
DR   GO; GO:0043010; P:camera-type eye development; IMP:BHF-UCL.
DR   GO; GO:0061337; P:cardiac conduction; IMP:UniProtKB.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; IMP:BHF-UCL.
DR   GO; GO:0086064; P:cell communication by electrical coupling involved in cardiac conduction; TAS:BHF-UCL.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0007507; P:heart development; IMP:BHF-UCL.
DR   GO; GO:0002520; P:immune system development; IMP:BHF-UCL.
DR   GO; GO:0098912; P:membrane depolarization during atrial cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086045; P:membrane depolarization during AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086012; P:membrane depolarization during cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; TAS:BHF-UCL.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0098911; P:regulation of ventricular cardiac muscle cell action potential; IMP:BHF-UCL.
DR   Gene3D; 1.20.120.350; -; 6.
DR   InterPro; IPR031688; CAC1F_C.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR031649; GPHH_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR014873; VDCC_a1su_IQ.
DR   InterPro; IPR005451; VDCC_L_a1csu.
DR   InterPro; IPR005446; VDCC_L_a1su.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   PANTHER; PTHR10037:SF240; PTHR10037:SF240; 1.
DR   Pfam; PF08763; Ca_chan_IQ; 1.
DR   Pfam; PF16885; CAC1F_C; 2.
DR   Pfam; PF16905; GPHH; 1.
DR   Pfam; PF00520; Ion_trans; 5.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01630; LVDCCALPHA1.
DR   PRINTS; PR01635; LVDCCALPHA1C.
DR   SMART; SM01062; Ca_chan_IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autism; Autism spectrum disorder;
KW   Brugada syndrome; Calcium; Calcium channel; Calcium transport;
KW   Cell membrane; Complete proteome; Disease mutation; Disulfide bond;
KW   Glycoprotein; Ion channel; Ion transport; Long QT syndrome; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1   2221       Voltage-dependent L-type calcium channel
FT                                subunit alpha-1C.
FT                                /FTId=PRO_0000053928.
FT   TOPO_DOM      1    124       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    125    143       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    144    160       Extracellular. {ECO:0000255}.
FT   TRANSMEM    161    181       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    182    193       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    194    212       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    213    232       Extracellular. {ECO:0000255}.
FT   TRANSMEM    233    251       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    252    270       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    271    290       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    291    380       Extracellular. {ECO:0000255}.
FT   TRANSMEM    381    405       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    406    524       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    525    543       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    544    558       Extracellular. {ECO:0000255}.
FT   TRANSMEM    559    578       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    579    586       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    587    605       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    606    615       Extracellular. {ECO:0000255}.
FT   TRANSMEM    616    634       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    635    653       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    654    673       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    674    728       Extracellular. {ECO:0000255}.
FT   TRANSMEM    729    753       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    754    900       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    901    919       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    920    935       Extracellular. {ECO:0000255}.
FT   TRANSMEM    936    955       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    956    987       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    988   1006       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1007   1013       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1014   1032       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1033   1051       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1052   1071       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1072   1161       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1162   1186       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1187   1239       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1240   1258       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1259   1273       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1274   1293       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1294   1301       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1302   1320       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1321   1372       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1373   1391       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1392   1410       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1411   1430       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1431   1499       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1500   1524       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1525   2221       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      111    408       I.
FT   REPEAT      510    756       II.
FT   REPEAT      887   1189       III.
FT   REPEAT     1226   1527       IV.
FT   CA_BIND    1553   1564       {ECO:0000250}.
FT   REGION      428    445       AID/alpha-interaction domain; mediates
FT                                interaction with the beta subunit.
FT                                {ECO:0000250|UniProtKB:P22002}.
FT   REGION     1109   1199       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1478   1546       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1492   1535       Phenylalkylamine binding. {ECO:0000250}.
FT   COMPBIAS    654    660       Poly-Leu.
FT   COMPBIAS    768    774       Poly-Glu.
FT   COMPBIAS   1167   1173       Poly-Ile.
FT   COMPBIAS   2084   2087       Poly-Gly.
FT   SITE        363    363       Calcium ion selectivity and permeability.
FT                                {ECO:0000269|PubMed:8099908}.
FT   SITE        706    706       Calcium ion selectivity and permeability.
FT                                {ECO:0000250|UniProtKB:P15381}.
FT   SITE       1135   1135       Calcium ion selectivity and permeability.
FT                                {ECO:0000269|PubMed:8099908}.
FT   SITE       1464   1464       Calcium ion selectivity and permeability.
FT                                {ECO:0000269|PubMed:8099908}.
FT   MOD_RES     469    469       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01815}.
FT   MOD_RES     476    476       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q01815}.
FT   MOD_RES     808    808       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01815}.
FT   MOD_RES     815    815       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01815}.
FT   MOD_RES    1535   1535       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES    1718   1718       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01815}.
FT   MOD_RES    1739   1739       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01815}.
FT   MOD_RES    1973   1973       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES    1981   1981       Phosphoserine; by PKA. {ECO:0000255}.
FT   CARBOHYD    153    153       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    328    328       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1436   1436       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1487   1487       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ       1     29       Missing (in isoform 16, isoform 17,
FT                                isoform 18 and isoform 28).
FT                                {ECO:0000303|PubMed:8392192,
FT                                ECO:0000303|PubMed:9087614,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000885.
FT   VAR_SEQ       1     16       MVNENTRMYIPEENHQ -> MLRAFVQPGTPAYQPLPSHLS
FT                                ANTEVKFKGTLVHEAQLNYFYISPG (in isoform
FT                                34). {ECO:0000303|PubMed:11741969}.
FT                                /FTId=VSP_035146.
FT   VAR_SEQ     306    308       Missing (in isoform 35).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035877.
FT   VAR_SEQ     372    391       VNDAVGRDWPWIYFVTLIII -> MQDAMGYELPWVYFVSL
FT                                VIF (in isoform 3, isoform 16, isoform
FT                                17, isoform 18, isoform 23, isoform 28,
FT                                isoform 36 and isoform 37).
FT                                {ECO:0000303|PubMed:8392192,
FT                                ECO:0000303|PubMed:9087614,
FT                                ECO:0000303|PubMed:9607315,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000886.
FT   VAR_SEQ     932    951       Missing (in isoform 4, isoform 19,
FT                                isoform 20, isoform 21, isoform 23,
FT                                isoform 26, isoform 27, isoform 29,
FT                                isoform 32 and isoform 33).
FT                                {ECO:0000303|PubMed:7737988,
FT                                ECO:0000303|PubMed:9013606,
FT                                ECO:0000303|PubMed:9607315,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000887.
FT   VAR_SEQ     952    971       Missing (in isoform 5, isoform 12,
FT                                isoform 13, isoform 14, isoform 15,
FT                                isoform 16, isoform 17, isoform 18,
FT                                isoform 22, isoform 24, isoform 25,
FT                                isoform 28, isoform 31, isoform 35,
FT                                isoform 36 and isoform 37).
FT                                {ECO:0000303|PubMed:12176756,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17071743,
FT                                ECO:0000303|PubMed:7737988,
FT                                ECO:0000303|PubMed:8392192,
FT                                ECO:0000303|PubMed:9087614,
FT                                ECO:0000303|PubMed:9607315,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000888.
FT   VAR_SEQ    1297   1324       Missing (in isoform 6, isoform 12,
FT                                isoform 14, isoform 15, isoform 19,
FT                                isoform 20, isoform 23, isoform 24,
FT                                isoform 25, isoform 26, isoform 27,
FT                                isoform 28, isoform 29, isoform 30 and
FT                                isoform 33).
FT                                {ECO:0000303|PubMed:12176756,
FT                                ECO:0000303|PubMed:17071743,
FT                                ECO:0000303|PubMed:7737988,
FT                                ECO:0000303|PubMed:8392192,
FT                                ECO:0000303|PubMed:9013606,
FT                                ECO:0000303|PubMed:9607315,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000889.
FT   VAR_SEQ    1325   1352       Missing (in isoform 7, isoform 13,
FT                                isoform 16, isoform 17, isoform 18,
FT                                isoform 21, isoform 22, isoform 35,
FT                                isoform 36 and isoform 37).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17071743,
FT                                ECO:0000303|PubMed:8392192,
FT                                ECO:0000303|PubMed:9087614,
FT                                ECO:0000303|PubMed:9607315}.
FT                                /FTId=VSP_000890.
FT   VAR_SEQ    1351   1363       Missing (in isoform 15).
FT                                {ECO:0000303|PubMed:17071743}.
FT                                /FTId=VSP_022503.
FT   VAR_SEQ    1353   1363       Missing (in isoform 8, isoform 19,
FT                                isoform 25, isoform 28, isoform 29 and
FT                                isoform 32).
FT                                {ECO:0000303|PubMed:17071743,
FT                                ECO:0000303|PubMed:7737988,
FT                                ECO:0000303|PubMed:8392192,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000891.
FT   VAR_SEQ    1363   1363       M -> MGPSCSHPPLAVLTAPPVADGFQ (in isoform
FT                                14). {ECO:0000303|PubMed:17071743}.
FT                                /FTId=VSP_022504.
FT   VAR_SEQ    1618   1699       LRIKTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGD
FT                                DEVTVGKFYATFLIQEYFRKFKKRKEQGLVGKPSQRNALSL
FT                                -> LREAELSSQVQYQAKEASLLERRRKSSHPKSSTKPNKL
FT                                LSSGGSTGWVEDARALEGQVLARGCGWLGSLEERERGPHHP
FT                                PLGF (in isoform 9 and isoform 26).
FT                                {ECO:0000303|PubMed:9013606}.
FT                                /FTId=VSP_000892.
FT   VAR_SEQ    1623   1623       E -> EEGPSPSEAHQGAEDPFRPA (in isoform 10,
FT                                isoform 13, isoform 14, isoform 15,
FT                                isoform 24, isoform 25, isoform 27 and
FT                                isoform 29).
FT                                {ECO:0000303|PubMed:17071743,
FT                                ECO:0000303|PubMed:9013606,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000893.
FT   VAR_SEQ    1864   1898       Missing (in isoform 11, isoform 12,
FT                                isoform 13, isoform 14, isoform 15,
FT                                isoform 17, isoform 19, isoform 20,
FT                                isoform 21, isoform 22, isoform 23,
FT                                isoform 24, isoform 25, isoform 26,
FT                                isoform 27, isoform 29, isoform 30,
FT                                isoform 31, isoform 32, isoform 35 and
FT                                isoform 37).
FT                                {ECO:0000303|PubMed:12176756,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17071743,
FT                                ECO:0000303|PubMed:7737988,
FT                                ECO:0000303|PubMed:9013606,
FT                                ECO:0000303|PubMed:9087614,
FT                                ECO:0000303|PubMed:9607315,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000895.
FT   VAR_SEQ    1864   1897       ERHVPMCEDLELRRDSGSAGTQAHCLLLRKANPS -> MHC
FT                                CDMLDGGTFPPALGPRRAPPCLHQQLQGSLAGLREDTPCIV
FT                                PGHASLCCSSRVGEWLPAGCTAPQHA (in isoform 2,
FT                                isoform 18 and isoform 28).
FT                                {ECO:0000303|PubMed:8392192,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_000894.
FT   VARIANT      28     28       A -> T (in TS; only with cardiac
FT                                manifestation; unknown pathological
FT                                significance; increased channel
FT                                activity). {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075148.
FT   VARIANT      37     37       G -> R (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075149.
FT   VARIANT      39     39       A -> V (in BRGDA3; loss of function).
FT                                {ECO:0000269|PubMed:17224476}.
FT                                /FTId=VAR_044039.
FT   VARIANT      84     84       Q -> R (in dbSNP:rs1051345).
FT                                {ECO:0000269|PubMed:8392192,
FT                                ECO:0000269|PubMed:9087614,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_045987.
FT   VARIANT     304    304       I -> T (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075150.
FT   VARIANT     381    381       P -> S (in TS; only with cardiac
FT                                manifestation; unknown pathological
FT                                significance; no effect on channel
FT                                activity). {ECO:0000269|PubMed:24728418}.
FT                                /FTId=VAR_075151.
FT   VARIANT     391    391       I -> L (in dbSNP:rs1051356).
FT                                /FTId=VAR_045988.
FT   VARIANT     402    402       G -> S (in TS).
FT                                {ECO:0000269|PubMed:15863612}.
FT                                /FTId=VAR_026741.
FT   VARIANT     406    406       G -> R (in TS; causes a nearly complete
FT                                loss of voltage-dependent channel
FT                                inactivation).
FT                                {ECO:0000269|PubMed:15454078}.
FT                                /FTId=VAR_026742.
FT   VARIANT     456    456       M -> I (in TS; only with cardiac
FT                                manifestation; unknown pathological
FT                                significance; no effect on channel
FT                                activity). {ECO:0000269|PubMed:24728418}.
FT                                /FTId=VAR_075152.
FT   VARIANT     477    477       E -> K (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075153.
FT   VARIANT     490    490       G -> R (in BRGDA3; loss of function).
FT                                {ECO:0000269|PubMed:17224476}.
FT                                /FTId=VAR_044040.
FT   VARIANT     518    518       R -> C (in TS; only with cardiac
FT                                manifestation; decreased current density;
FT                                associated with slower inactivation;
FT                                altered localization).
FT                                {ECO:0000269|PubMed:26253506}.
FT                                /FTId=VAR_075154.
FT   VARIANT     518    518       R -> H (in TS; only with cardiac
FT                                manifestation; decreased current density;
FT                                associated with slower inactivation).
FT                                {ECO:0000269|PubMed:26253506}.
FT                                /FTId=VAR_075155.
FT   VARIANT     582    582       A -> D (in TS; only with cardiac
FT                                manifestation; gain of function effect on
FT                                channel activity; slower inactivation).
FT                                {ECO:0000269|PubMed:24728418}.
FT                                /FTId=VAR_075156.
FT   VARIANT     752    752       A -> T.
FT                                /FTId=VAR_001495.
FT   VARIANT     817    817       P -> S (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075157.
FT   VARIANT     850    850       Missing (rare variant; found in a case of
FT                                sudden unexplained death in the young;
FT                                unknown pathological significance;
FT                                results in reduced whole-cell calcium
FT                                currents). {ECO:0000269|PubMed:27218670}.
FT                                /FTId=VAR_076414.
FT   VARIANT     858    858       R -> H (in TS; only with cardiac
FT                                manifestation; gain of function effect on
FT                                channel activity; slower inactivation).
FT                                {ECO:0000269|PubMed:24728418}.
FT                                /FTId=VAR_075158.
FT   VARIANT     860    860       R -> G (in TS; only with cardiac
FT                                manifestation; gain of function
FT                                activity). {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075159.
FT   VARIANT     878    878       S -> R (found in a clear cell renal
FT                                carcinoma case; somatic mutation).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064700.
FT   VARIANT    1186   1186       I -> T (in TS; electrophysiological
FT                                phenotype, characterized by loss of
FT                                current density and gain-of-function
FT                                shift in activation leading to increased
FT                                steady-state current; gain of function
FT                                activity). {ECO:0000269|PubMed:25260352,
FT                                ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_072381.
FT   VARIANT    1186   1186       I -> V (in TS; only with cardiac
FT                                manifestation; gain of function
FT                                activity). {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075160.
FT   VARIANT    1365   1365       A -> T (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075161.
FT   VARIANT    1523   1523       I -> M (in TS; only with cardiac
FT                                manifestation; gain of function
FT                                activity). {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075162.
FT   VARIANT    1544   1544       E -> K (in TS; only with cardiac
FT                                manifestation; gain of function
FT                                activity). {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075163.
FT   VARIANT    1755   1755       V -> I (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075164.
FT   VARIANT    1765   1765       A -> G (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075165.
FT   VARIANT    1787   1787       D -> N (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075166.
FT   VARIANT    1800   1800       T -> I (in TS; only with cardiac
FT                                manifestation; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075167.
FT   VARIANT    1831   1831       G -> C (in TS; only with cardiac
FT                                manifestation; unknown pathological
FT                                significance; no effect on channel
FT                                activity). {ECO:0000269|PubMed:24728418}.
FT                                /FTId=VAR_075168.
FT   VARIANT    1835   1835       T -> M (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075169.
FT   VARIANT    1843   1843       G -> A (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075170.
FT   VARIANT    1868   1868       P -> L (in dbSNP:rs10848683).
FT                                /FTId=VAR_059223.
FT   VARIANT    1869   1869       M -> V (in dbSNP:rs10774053).
FT                                {ECO:0000269|PubMed:1316612,
FT                                ECO:0000269|PubMed:9087614,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_059224.
FT   VARIANT    1893   1893       K -> R (in dbSNP:rs10774054).
FT                                {ECO:0000269|PubMed:1316612,
FT                                ECO:0000269|PubMed:9087614,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_061102.
FT   VARIANT    1948   1948       E -> K (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075171.
FT   VARIANT    1953   1953       T -> M (in TS; only with cardiac
FT                                manifestation; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075172.
FT   VARIANT    1972   1972       R -> C (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075173.
FT   VARIANT    2056   2056       R -> Q (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075174.
FT   VARIANT    2081   2081       T -> N (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075175.
FT   VARIANT    2091   2091       A -> S (rare variant; found in a case of
FT                                sudden unexplained death in the young;
FT                                unknown pathological significance;
FT                                results in increased whole-cell calcium
FT                                currents). {ECO:0000269|PubMed:27218670}.
FT                                /FTId=VAR_076415.
FT   VARIANT    2097   2097       V -> I (in TS; only with cardiac
FT                                manifestation; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075176.
FT   VARIANT    2122   2122       A -> G (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075177.
FT   VARIANT    2169   2169       A -> T.
FT                                /FTId=VAR_001496.
FT   VARIANT    2174   2174       N -> S (polymorphism).
FT                                {ECO:0000269|PubMed:25633834}.
FT                                /FTId=VAR_075178.
FT   MUTAGEN     363    363       E->K: Loss of selectivity for divalent
FT                                over monovalent cations.
FT                                {ECO:0000269|PubMed:8099908}.
FT   MUTAGEN     954    954       G->F: Affects voltage-dependent
FT                                inhibition by dihydropyridines; when
FT                                associated with I-958.
FT                                {ECO:0000269|PubMed:7737988}.
FT   MUTAGEN     958    958       Y->I: Affects voltage-dependent
FT                                inhibition by dihydropyridines; when
FT                                associated with F-954.
FT                                {ECO:0000269|PubMed:7737988}.
FT   MUTAGEN    1135   1135       E->K: Loss of selectivity for divalent
FT                                over monovalent cations.
FT                                {ECO:0000269|PubMed:8099908}.
FT   MUTAGEN    1464   1464       E->K: Loss of selectivity for divalent
FT                                over monovalent cations.
FT                                {ECO:0000269|PubMed:8099908}.
FT   CONFLICT   1072   1072       K -> Q (in Ref. 3; Z26272).
FT                                {ECO:0000305}.
FT   CONFLICT   1157   1157       N -> K (in Ref. 15; AAA58409).
FT                                {ECO:0000305}.
FT   CONFLICT   1244   1244       L -> P (in Ref. 16; AAA74590).
FT                                {ECO:0000305}.
FT   CONFLICT   1384   1384       L -> P (in Ref. 16; AAA74590).
FT                                {ECO:0000305}.
FT   CONFLICT   1412   1412       A -> V (in Ref. 12; AAI46847).
FT                                {ECO:0000305}.
FT   CONFLICT   1459   1459       R -> K (in Ref. 3; CAA81219).
FT                                {ECO:0000305}.
FT   CONFLICT   2205   2205       R -> A (in Ref. 3; CAA84340/CAA84341/
FT                                CAA84342/CAA84343/CAA84344/CAA84345/
FT                                CAA84346/CAA84347/CAA84348/CAA84349/
FT                                CAA84350/CAA84351, 7; CAA12174 and 9;
FT                                AAX37354/AAX37355/AAX37356).
FT                                {ECO:0000305}.
FT   CONFLICT   2205   2205       R -> G (in Ref. 1; AAA17030).
FT                                {ECO:0000305}.
FT   HELIX        48     65       {ECO:0000244|PDB:2LQC}.
FT   HELIX       429    442       {ECO:0000244|PDB:1T0J}.
FT   HELIX      1609   1651       {ECO:0000244|PDB:3G43}.
FT   TURN       1661   1663       {ECO:0000244|PDB:2BE6}.
FT   HELIX      1666   1680       {ECO:0000244|PDB:2F3Z}.
SQ   SEQUENCE   2221 AA;  248977 MW;  7E755F7AF4C86769 CRC64;
     MVNENTRMYI PEENHQGSNY GSPRPAHANM NANAAAGLAP EHIPTPGAAL SWQAAIDAAR
     QAKLMGSAGN ATISTVSSTQ RKRQQYGKPK KQGSTTATRP PRALLCLTLK NPIRRACISI
     VEWKPFEIII LLTIFANCVA LAIYIPFPED DSNATNSNLE RVEYLFLIIF TVEAFLKVIA
     YGLLFHPNAY LRNGWNLLDF IIVVVGLFSA ILEQATKADG ANALGGKGAG FDVKALRAFR
     VLRPLRLVSG VPSLQVVLNS IIKAMVPLLH IALLVLFVII IYAIIGLELF MGKMHKTCYN
     QEGIADVPAE DDPSPCALET GHGRQCQNGT VCKPGWDGPK HGITNFDNFA FAMLTVFQCI
     TMEGWTDVLY WVNDAVGRDW PWIYFVTLII IGSFFVLNLV LGVLSGEFSK EREKAKARGD
     FQKLREKQQL EEDLKGYLDW ITQAEDIDPE NEDEGMDEEK PRNMSMPTSE TESVNTENVA
     GGDIEGENCG ARLAHRISKS KFSRYWRRWN RFCRRKCRAA VKSNVFYWLV IFLVFLNTLT
     IASEHYNQPN WLTEVQDTAN KALLALFTAE MLLKMYSLGL QAYFVSLFNR FDCFVVCGGI
     LETILVETKI MSPLGISVLR CVRLLRIFKI TRYWNSLSNL VASLLNSVRS IASLLLLLFL
     FIIIFSLLGM QLFGGKFNFD EMQTRRSTFD NFPQSLLTVF QILTGEDWNS VMYDGIMAYG
     GPSFPGMLVC IYFIILFICG NYILLNVFLA IAVDNLADAE SLTSAQKEEE EEKERKKLAR
     TASPEKKQEL VEKPAVGESK EEKIELKSIT ADGESPPATK INMDDLQPNE NEDKSPYPNP
     ETTGEEDEEE PEMPVGPRPR PLSELHLKEK AVPMPEASAF FIFSSNNRFR LQCHRIVNDT
     IFTNLILFFI LLSSISLAAE DPVQHTSFRN HILFYFDIVF TTIFTIEIAL KILGNADYVF
     TSIFTLEIIL KMTAYGAFLH KGSFCRNYFN ILDLLVVSVS LISFGIQSSA INVVKILRVL
     RVLRPLRAIN RAKGLKHVVQ CVFVAIRTIG NIVIVTTLLQ FMFACIGVQL FKGKLYTCSD
     SSKQTEAECK GNYITYKDGE VDHPIIQPRS WENSKFDFDN VLAAMMALFT VSTFEGWPEL
     LYRSIDSHTE DKGPIYNYRV EISIFFIIYI IIIAFFMMNI FVGFVIVTFQ EQGEQEYKNC
     ELDKNQRQCV EYALKARPLR RYIPKNQHQY KVWYVVNSTY FEYLMFVLIL LNTICLAMQH
     YGQSCLFKIA MNILNMLFTG LFTVEMILKL IAFKPKGYFS DPWNVFDFLI VIGSIIDVIL
     SETNHYFCDA WNTFDALIVV GSIVDIAITE VNPAEHTQCS PSMNAEENSR ISITFFRLFR
     VMRLVKLLSR GEGIRTLLWT FIKSFQALPY VALLIVMLFF IYAVIGMQVF GKIALNDTTE
     INRNNNFQTF PQAVLLLFRC ATGEAWQDIM LACMPGKKCA PESEPSNSTE GETPCGSSFA
     VFYFISFYML CAFLIINLFV AVIMDNFDYL TRDWSILGPH HLDEFKRIWA EYDPEAKGRI
     KHLDVVTLLR RIQPPLGFGK LCPHRVACKR LVSMNMPLNS DGTVMFNATL FALVRTALRI
     KTEGNLEQAN EELRAIIKKI WKRTSMKLLD QVVPPAGDDE VTVGKFYATF LIQEYFRKFK
     KRKEQGLVGK PSQRNALSLQ AGLRTLHDIG PEIRRAISGD LTAEEELDKA MKEAVSAASE
     DDIFRRAGGL FGNHVSYYQS DGRSAFPQTF TTQRPLHINK AGSSQGDTES PSHEKLVDST
     FTPSSYSSTG SNANINNANN TALGRLPRPA GYPSTVSTVE GHGPPLSPAI RVQEVAWKLS
     SNRERHVPMC EDLELRRDSG SAGTQAHCLL LRKANPSRCH SRESQAAMAG QEETSQDETY
     EVKMNHDTEA CSEPSLLSTE MLSYQDDENR QLTLPEEDKR DIRQSPKRGF LRSASLGRRA
     SFHLECLKRQ KDRGGDISQK TVLPLHLVHH QALAVAGLSP LLQRSHSPAS FPRPFATPPA
     TPGSRGWPPQ PVPTLRLEGV ESSEKLNSSF PSIHCGSWAE TTPGGGGSSA ARRVRPVSLM
     VPSQAGAPGR QFHGSASSLV EAVLISEGLG QFAQDPKFIE VTTQELADAC DMTIEEMESA
     ADNILSGGAP QSPNGALLPF VNCRDAGQDR AGGEEDAGCV RARGRPSEEE LQDSRVYVSS
     L
//
ID   CAC1D_HUMAN             Reviewed;        2161 AA.
AC   Q01668; B0FYA3; Q13916; Q13931; Q71UT1; Q9UDC3;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   15-FEB-2017, entry version 174.
DE   RecName: Full=Voltage-dependent L-type calcium channel subunit alpha-1D;
DE   AltName: Full=Calcium channel, L type, alpha-1 polypeptide, isoform 2;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav1.3;
GN   Name=CACNA1D; Synonyms=CACH3, CACN4, CACNL1A2, CCHL1A2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM NEURONAL-TYPE).
RC   TISSUE=Neuroblastoma;
RX   PubMed=1309651; DOI=10.1016/0896-6273(92)90109-Q;
RA   Williams M.E., Feldman D.H., McCue A.F., Brenner R., Velicelebi G.,
RA   Ellis S.B., Harpold M.M.;
RT   "Structure and functional expression of alpha 1, alpha 2, and beta
RT   subunits of a novel human neuronal calcium channel subtype.";
RL   Neuron 8:71-84(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-CELL-TYPE).
RC   TISSUE=Pancreatic islet;
RX   PubMed=1309948; DOI=10.1073/pnas.89.2.584;
RA   Seino S., Chen L., Seino M., Blondel O., Takeda J., Johnson J.H.,
RA   Bell G.I.;
RT   "Cloning of the alpha 1 subunit of a voltage-dependent calcium channel
RT   expressed in pancreatic beta cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:584-588(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM BETA-CELL-TYPE), AND
RP   VARIANT MET-1 INS.
RX   PubMed=7557998; DOI=10.1006/geno.1995.1048;
RA   Yamada Y., Masuda K., Li Q., Ihara Y., Kubota A., Miura T.,
RA   Nakamura K., Fujii Y., Seino S., Seino Y.;
RT   "The structures of the human calcium channel alpha 1 subunit
RT   (CACNL1A2) and beta subunit (CACNLB3) genes.";
RL   Genomics 27:312-319(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBUNIT, SUBCELLULAR
RP   LOCATION, AND ALTERNATIVE SPLICING (ISOFORM 4).
RC   TISSUE=Pancreas;
RX   PubMed=18482979; DOI=10.1074/jbc.M802254200;
RA   Singh A., Gebhart M., Fritsch R., Sinnegger-Brauns M.J., Poggiani C.,
RA   Hoda J.C., Engel J., Romanin C., Striessnig J., Koschak A.;
RT   "Modulation of voltage- and Ca2+-dependent gating of CaV1.3 L-type
RT   calcium channels by alternative splicing of a C-terminal regulatory
RT   domain.";
RL   J. Biol. Chem. 283:20733-20744(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-125.
RX   PubMed=9894156; DOI=10.1038/emm.1998.36;
RA   Kim H.-L., Chang Y.J., Lee S.M., Hong Y.-S.;
RT   "Genomic structure of the regulatory region of the voltage-gated
RT   calcium channel alpha 1D.";
RL   Exp. Mol. Med. 30:246-251(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 747-1039, AND TISSUE SPECIFICITY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=1335101; DOI=10.1016/S0025-6196(12)61144-6;
RA   Oguro-Okano M., Griesmann G.E., Wieben E.D., Slaymaker S.J.,
RA   Snutch T.P., Lennon V.A.;
RT   "Molecular diversity of neuronal-type calcium channels identified in
RT   small cell lung carcinoma.";
RL   Mayo Clin. Proc. 67:1150-1159(1992).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 502-510 IN COMPLEX WITH HLA.
RX   PubMed=21280120; DOI=10.1002/pro.559;
RA   Loll B., Ruckert C., Hee C.S., Saenger W., Uchanska-Ziegler B.,
RA   Ziegler A.;
RT   "Loss of recognition by cross-reactive T cells and its relation to a
RT   C-terminus-induced conformational reorientation of an HLA-B*2705-bound
RT   peptide.";
RL   Protein Sci. 20:278-290(2011).
RN   [9]
RP   VARIANT SANDD GLY-403 INS, AND CHARACTERIZATION OF VARIANT SANDD
RP   GLY-403 INS.
RX   PubMed=21131953; DOI=10.1038/nn.2694;
RA   Baig S.M., Koschak A., Lieb A., Gebhart M., Dafinger C., Nurnberg G.,
RA   Ali A., Ahmad I., Sinnegger-Brauns M.J., Brandt N., Engel J.,
RA   Mangoni M.E., Farooq M., Khan H.U., Nurnberg P., Striessnig J.,
RA   Bolz H.J.;
RT   "Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with
RT   bradycardia and congenital deafness.";
RL   Nat. Neurosci. 14:77-84(2011).
RN   [10]
RP   VARIANTS PASNA ASP-403 AND MET-750, AND CHARACTERIZATION OF VARIANTS
RP   PASNA ASP-403 AND MET-750.
RX   PubMed=23913001; DOI=10.1038/ng.2695;
RA   Scholl U.I., Goh G., Stoelting G., de Oliveira R.C., Choi M.,
RA   Overton J.D., Fonseca A.L., Korah R., Starker L.F., Kunstman J.W.,
RA   Prasad M.L., Hartung E.A., Mauras N., Benson M.R., Brady T.,
RA   Shapiro J.R., Loring E., Nelson-Williams C., Libutti S.K., Mane S.,
RA   Hellman P., Westin G., Aakerstroem G., Bjoerklund P., Carling T.,
RA   Fahlke C., Hidalgo P., Lifton R.P.;
RT   "Somatic and germline CACNA1D calcium channel mutations in
RT   aldosterone-producing adenomas and primary aldosteronism.";
RL   Nat. Genet. 45:1050-1054(2013).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1D
CC       gives rise to L-type calcium currents. Long-lasting (L-type)
CC       calcium channels belong to the 'high-voltage activated' (HVA)
CC       group. They are blocked by dihydropyridines (DHP),
CC       phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA
CC       (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-
CC       GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).
CC       {ECO:0000269|PubMed:18482979}.
CC   -!- SUBUNIT: Voltage-dependent calcium channels are multisubunit
CC       complexes, consisting of alpha-1, alpha-2, beta and delta subunits
CC       in a 1:1:1:1 ratio. The channel activity is directed by the pore-
CC       forming and voltage-sensitive alpha-1 subunit. In many cases, this
CC       subunit is sufficient to generate voltage-sensitive calcium
CC       channel activity. The auxiliary subunits beta and alpha-2/delta
CC       linked by a disulfide bridge regulate the channel activity.
CC       Channel activity is further modulated, depending on the presence
CC       of specific delta subunit isoforms. Interacts (via IQ domain) with
CC       CABP1 and CABP4 in a calcium independent manner (By similarity).
CC       Interacts with RIMBP2 (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:18482979};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:18482979}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Neuronal-type;
CC         IsoId=Q01668-1; Sequence=Displayed;
CC       Name=Beta-cell-type;
CC         IsoId=Q01668-2; Sequence=VSP_000913, VSP_000914;
CC       Name=4; Synonyms=Ca(V)1.3(42A);
CC         IsoId=Q01668-4; Sequence=VSP_047921, VSP_047922;
CC         Note=Expressed at 5% to 15% of isoform Neuronal-type in brain
CC         tissues, increased current density.;
CC       Name=3;
CC         IsoId=Q01668-3; Sequence=VSP_046743, VSP_046744;
CC   -!- TISSUE SPECIFICITY: Expressed in pancreatic islets and in brain,
CC       where it has been seen in cerebral cortex, hippocampus, basal
CC       ganglia, habenula and thalamus. Expressed in the small cell lung
CC       carcinoma cell line SCC-9. No expression in skeletal muscle.
CC       {ECO:0000269|PubMed:1335101}.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- POLYMORPHISM: A change from seven to eight ATG trinucleotide
CC       repeats, resulting in an additional N-terminal methionine, has
CC       been found in a patient with non-insulin-dependent diabetes
CC       mellitus (NIDDM). {ECO:0000269|PubMed:7557998}.
CC   -!- DISEASE: Sinoatrial node dysfunction and deafness (SANDD)
CC       [MIM:614896]: A disease characterized by congenital severe to
CC       profound deafness without vestibular dysfunction, associated with
CC       episodic syncope due to intermittent pronounced bradycardia.
CC       {ECO:0000269|PubMed:21131953}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Primary aldosteronism, seizures, and neurologic
CC       abnormalities (PASNA) [MIM:615474]: A disorder characterized by
CC       hypertension, hypokalemia, and high aldosterone levels with low
CC       plasma renin activity and an elevated aldosterone/renin ratio.
CC       Other features include generalized seizures, cerebral palsy,
CC       spasticity, intellectual disability, and developmental delay.
CC       {ECO:0000269|PubMed:23913001}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1D subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M76558; AAA58402.1; -; mRNA.
DR   EMBL; M83566; AAA35629.1; -; mRNA.
DR   EMBL; D43747; BAA07804.1; -; Genomic_DNA.
DR   EMBL; EU363339; ABY66526.1; -; mRNA.
DR   EMBL; AC005905; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC012467; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC024149; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC132810; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF055575; AAD08651.1; -; Genomic_DNA.
DR   CCDS; CCDS2872.1; -. [Q01668-2]
DR   CCDS; CCDS46848.1; -. [Q01668-1]
DR   CCDS; CCDS46849.1; -. [Q01668-3]
DR   PIR; JH0564; JH0564.
DR   RefSeq; NP_000711.1; NM_000720.3. [Q01668-2]
DR   RefSeq; NP_001122311.1; NM_001128839.2. [Q01668-3]
DR   RefSeq; NP_001122312.1; NM_001128840.2. [Q01668-1]
DR   UniGene; Hs.476358; -.
DR   PDB; 3LV3; X-ray; 1.94 A; C=502-510.
DR   PDBsum; 3LV3; -.
DR   ProteinModelPortal; Q01668; -.
DR   SMR; Q01668; -.
DR   BioGrid; 107230; 1.
DR   DIP; DIP-48998N; -.
DR   IntAct; Q01668; 1.
DR   STRING; 9606.ENSP00000288139; -.
DR   BindingDB; Q01668; -.
DR   ChEMBL; CHEMBL4138; -.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB04920; Clevidipine.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB01023; Felodipine.
DR   DrugBank; DB00270; Isradipine.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB06712; Nilvadipine.
DR   DrugBank; DB00393; Nimodipine.
DR   DrugBank; DB00401; Nisoldipine.
DR   DrugBank; DB01054; Nitrendipine.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00661; Verapamil.
DR   GuidetoPHARMACOLOGY; 530; -.
DR   iPTMnet; Q01668; -.
DR   PhosphoSitePlus; Q01668; -.
DR   DMDM; 116241275; -.
DR   PaxDb; Q01668; -.
DR   PeptideAtlas; Q01668; -.
DR   PRIDE; Q01668; -.
DR   Ensembl; ENST00000288139; ENSP00000288139; ENSG00000157388. [Q01668-2]
DR   Ensembl; ENST00000350061; ENSP00000288133; ENSG00000157388. [Q01668-1]
DR   Ensembl; ENST00000422281; ENSP00000409174; ENSG00000157388. [Q01668-3]
DR   GeneID; 776; -.
DR   KEGG; hsa:776; -.
DR   UCSC; uc003dgu.6; human. [Q01668-1]
DR   CTD; 776; -.
DR   DisGeNET; 776; -.
DR   GeneCards; CACNA1D; -.
DR   HGNC; HGNC:1391; CACNA1D.
DR   HPA; HPA020215; -.
DR   MalaCards; CACNA1D; -.
DR   MIM; 114206; gene.
DR   MIM; 614896; phenotype.
DR   MIM; 615474; phenotype.
DR   neXtProt; NX_Q01668; -.
DR   OpenTargets; ENSG00000157388; -.
DR   Orphanet; 85142; Aldosterone-producing adenoma.
DR   Orphanet; 369929; Aldosterone-producing adenoma with seizures and neurological abnormalities.
DR   Orphanet; 324321; Sinoatrial node dysfunction and deafness.
DR   PharmGKB; PA84; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128247; -.
DR   HOGENOM; HOG000231529; -.
DR   HOVERGEN; HBG050763; -.
DR   InParanoid; Q01668; -.
DR   KO; K04851; -.
DR   OMA; IQVERPE; -.
DR   OrthoDB; EOG090301A2; -.
DR   PhylomeDB; Q01668; -.
DR   TreeFam; TF312805; -.
DR   Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-5576893; Phase 2 - plateau phase.
DR   Reactome; R-HSA-5576894; Phase 1 - inactivation of fast Na+ channels.
DR   ChiTaRS; CACNA1D; human.
DR   GeneWiki; Cav1.3; -.
DR   GenomeRNAi; 776; -.
DR   PRO; PR:Q01668; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000157388; -.
DR   CleanEx; HS_CACNA1D; -.
DR   ExpressionAtlas; Q01668; baseline and differential.
DR   Genevisible; Q01668; HS.
DR   GO; GO:1990454; C:L-type voltage-gated calcium channel complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IDA:UniProtKB.
DR   GO; GO:0030018; C:Z disc; ISS:BHF-UCL.
DR   GO; GO:0051393; F:alpha-actinin binding; IPI:BHF-UCL.
DR   GO; GO:0030506; F:ankyrin binding; ISS:BHF-UCL.
DR   GO; GO:0008331; F:high voltage-gated calcium channel activity; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0086007; F:voltage-gated calcium channel activity involved in cardiac muscle cell action potential; IC:BHF-UCL.
DR   GO; GO:0086059; F:voltage-gated calcium channel activity involved SA node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G-protein coupled receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0070509; P:calcium ion import; IDA:BHF-UCL.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; ISS:BHF-UCL.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0061337; P:cardiac conduction; TAS:Reactome.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; IMP:BHF-UCL.
DR   GO; GO:0086012; P:membrane depolarization during cardiac muscle cell action potential; IC:BHF-UCL.
DR   GO; GO:0086046; P:membrane depolarization during SA node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:BHF-UCL.
DR   GO; GO:0060372; P:regulation of atrial cardiac muscle cell membrane repolarization; ISS:BHF-UCL.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:1901379; P:regulation of potassium ion transmembrane transport; ISS:BHF-UCL.
DR   GO; GO:1901016; P:regulation of potassium ion transmembrane transporter activity; ISS:BHF-UCL.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:BHF-UCL.
DR   Gene3D; 1.20.120.350; -; 5.
DR   InterPro; IPR031688; CAC1F_C.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR031649; GPHH_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR005452; LVDCC_a1dsu.
DR   InterPro; IPR014873; VDCC_a1su_IQ.
DR   InterPro; IPR005446; VDCC_L_a1su.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   PANTHER; PTHR10037:SF239; PTHR10037:SF239; 1.
DR   Pfam; PF08763; Ca_chan_IQ; 1.
DR   Pfam; PF16885; CAC1F_C; 1.
DR   Pfam; PF16905; GPHH; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01630; LVDCCALPHA1.
DR   PRINTS; PR01636; LVDCCALPHA1D.
DR   SMART; SM01062; Ca_chan_IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calcium channel;
KW   Calcium transport; Complete proteome; Deafness; Disease mutation;
KW   Disulfide bond; Epilepsy; Glycoprotein; Ion channel; Ion transport;
KW   Membrane; Metal-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix;
KW   Transport; Triplet repeat expansion; Voltage-gated channel.
FT   CHAIN         1   2161       Voltage-dependent L-type calcium channel
FT                                subunit alpha-1D.
FT                                /FTId=PRO_0000053933.
FT   TOPO_DOM      1    126       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    127    145       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    146    163       Extracellular. {ECO:0000255}.
FT   TRANSMEM    164    183       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    184    195       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    196    214       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    215    235       Extracellular. {ECO:0000255}.
FT   TRANSMEM    236    254       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    255    273       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    274    293       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    294    381       Extracellular. {ECO:0000255}.
FT   TRANSMEM    382    406       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    407    523       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    524    543       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    544    558       Extracellular. {ECO:0000255}.
FT   TRANSMEM    559    577       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    578    585       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    586    604       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    605    614       Extracellular. {ECO:0000255}.
FT   TRANSMEM    615    633       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    634    652       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    653    673       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    674    727       Extracellular. {ECO:0000255}.
FT   TRANSMEM    728    752       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    753    886       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    887    905       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    906    921       Extracellular. {ECO:0000255}.
FT   TRANSMEM    922    941       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    942    953       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    954    972       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    973    978       Extracellular. {ECO:0000255}.
FT   TRANSMEM    979    998       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    999   1017       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1018   1037       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1038   1127       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1128   1148       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1149   1205       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1206   1224       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1225   1239       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1240   1259       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1260   1266       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1267   1288       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1289   1313       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1314   1333       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1334   1352       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1353   1372       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1373   1439       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1440   1464       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1465   2161       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      113    409       I.
FT   REPEAT      509    755       II.
FT   REPEAT      873   1155       III.
FT   REPEAT     1192   1467       IV.
FT   CA_BIND    1493   1504       {ECO:0000250}.
FT   REGION      429    446       Binding to the beta subunit.
FT                                {ECO:0000250}.
FT   REGION     1075   1165       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1420   1486       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1432   1475       Phenylalkylamine binding. {ECO:0000250}.
FT   COMPBIAS      1      7       Poly-Met.
FT   COMPBIAS    653    659       Poly-Leu.
FT   COMPBIAS    827    838       Poly-Glu.
FT   SITE        364    364       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        705    705       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1101   1101       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1406   1406       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES     469    469       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02789}.
FT   MOD_RES     473    473       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02789}.
FT   MOD_RES    1475   1475       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES    1700   1700       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P07293}.
FT   CARBOHYD    155    155       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    225    225       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    329    329       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     373    392       MNDAMGFELPWVYFVSLVIF -> VNDAIGWEWPWVYFVSL
FT                                IIL (in isoform Beta-cell-type).
FT                                {ECO:0000303|PubMed:1309948}.
FT                                /FTId=VSP_000913.
FT   VAR_SEQ     493    493       C -> WCWWRRRGAAKAGPSGCRRWG (in isoform
FT                                Beta-cell-type).
FT                                {ECO:0000303|PubMed:1309948}.
FT                                /FTId=VSP_000914.
FT   VAR_SEQ    1291   1305       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18482979}.
FT                                /FTId=VSP_046743.
FT   VAR_SEQ    1642   1647       AGLRTL -> MLERML (in isoform 4).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_047921.
FT   VAR_SEQ    1648   2161       Missing (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_047922.
FT   VAR_SEQ    1803   1811       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18482979}.
FT                                /FTId=VSP_046744.
FT   VARIANT       1      1       M -> MM (in a NIDDM patient).
FT                                {ECO:0000269|PubMed:7557998}.
FT                                /FTId=VAR_001497.
FT   VARIANT     403    403       G -> D (in PASNA; the mutant channel is
FT                                activated at less depolarized potentials;
FT                                results in increased current density and
FT                                impaired channel inactivation).
FT                                {ECO:0000269|PubMed:23913001}.
FT                                /FTId=VAR_070868.
FT   VARIANT     403    403       G -> GG (in SANDD; the mutant channels
FT                                are unable to conduct calcium ions
FT                                currents and have abnormal voltage-
FT                                dependent gating).
FT                                {ECO:0000269|PubMed:21131953}.
FT                                /FTId=VAR_069170.
FT   VARIANT     750    750       I -> M (in PASNA; the mutant channel is
FT                                activated at less depolarized potentials;
FT                                results in increased current density;
FT                                dbSNP:rs41276445).
FT                                {ECO:0000269|PubMed:23913001}.
FT                                /FTId=VAR_070869.
FT   VARIANT    2097   2097       D -> N (in dbSNP:rs41276455).
FT                                /FTId=VAR_061103.
FT   CONFLICT    576    576       S -> T (in Ref. 3; BAA07804).
FT                                {ECO:0000305}.
FT   CONFLICT    637    637       S -> C (in Ref. 1; AAA58402).
FT                                {ECO:0000305}.
FT   CONFLICT    650    650       I -> S (in Ref. 1; AAA58402).
FT                                {ECO:0000305}.
FT   CONFLICT    918    918       I -> T (in Ref. 3; BAA07804).
FT                                {ECO:0000305}.
FT   CONFLICT    960    960       M -> I (in Ref. 3; BAA07804).
FT                                {ECO:0000305}.
FT   CONFLICT   1289   1290       Missing (in Ref. 3; BAA07804).
FT                                {ECO:0000305}.
FT   CONFLICT   1346   1346       S -> F (in Ref. 1; AAA58402).
FT                                {ECO:0000305}.
FT   CONFLICT   1433   1433       Y -> H (in Ref. 1; AAA58402).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2161 AA;  245141 MW;  31B0ADFCDB30B575 CRC64;
     MMMMMMMKKM QHQRQQQADH ANEANYARGT RLPLSGEGPT SQPNSSKQTV LSWQAAIDAA
     RQAKAAQTMS TSAPPPVGSL SQRKRQQYAK SKKQGNSSNS RPARALFCLS LNNPIRRACI
     SIVEWKPFDI FILLAIFANC VALAIYIPFP EDDSNSTNHN LEKVEYAFLI IFTVETFLKI
     IAYGLLLHPN AYVRNGWNLL DFVIVIVGLF SVILEQLTKE TEGGNHSSGK SGGFDVKALR
     AFRVLRPLRL VSGVPSLQVV LNSIIKAMVP LLHIALLVLF VIIIYAIIGL ELFIGKMHKT
     CFFADSDIVA EEDPAPCAFS GNGRQCTANG TECRSGWVGP NGGITNFDNF AFAMLTVFQC
     ITMEGWTDVL YWMNDAMGFE LPWVYFVSLV IFGSFFVLNL VLGVLSGEFS KEREKAKARG
     DFQKLREKQQ LEEDLKGYLD WITQAEDIDP ENEEEGGEEG KRNTSMPTSE TESVNTENVS
     GEGENRGCCG SLCQAISKSK LSRRWRRWNR FNRRRCRAAV KSVTFYWLVI VLVFLNTLTI
     SSEHYNQPDW LTQIQDIANK VLLALFTCEM LVKMYSLGLQ AYFVSLFNRF DCFVVCGGIT
     ETILVELEIM SPLGISVFRC VRLLRIFKVT RHWTSLSNLV ASLLNSMKSI ASLLLLLFLF
     IIIFSLLGMQ LFGGKFNFDE TQTKRSTFDN FPQALLTVFQ ILTGEDWNAV MYDGIMAYGG
     PSSSGMIVCI YFIILFICGN YILLNVFLAI AVDNLADAES LNTAQKEEAE EKERKKIARK
     ESLENKKNNK PEVNQIANSD NKVTIDDYRE EDEDKDPYPP CDVPVGEEEE EEEEDEPEVP
     AGPRPRRISE LNMKEKIAPI PEGSAFFILS KTNPIRVGCH KLINHHIFTN LILVFIMLSS
     AALAAEDPIR SHSFRNTILG YFDYAFTAIF TVEILLKMTT FGAFLHKGAF CRNYFNLLDM
     LVVGVSLVSF GIQSSAISVV KILRVLRVLR PLRAINRAKG LKHVVQCVFV AIRTIGNIMI
     VTTLLQFMFA CIGVQLFKGK FYRCTDEAKS NPEECRGLFI LYKDGDVDSP VVRERIWQNS
     DFNFDNVLSA MMALFTVSTF EGWPALLYKA IDSNGENIGP IYNHRVEISI FFIIYIIIVA
     FFMMNIFVGF VIVTFQEQGE KEYKNCELDK NQRQCVEYAL KARPLRRYIP KNPYQYKFWY
     VVNSSPFEYM MFVLIMLNTL CLAMQHYEQS KMFNDAMDIL NMVFTGVFTV EMVLKVIAFK
     PKGYFSDAWN TFDSLIVIGS IIDVALSEAD PTESENVPVP TATPGNSEES NRISITFFRL
     FRVMRLVKLL SRGEGIRTLL WTFIKSFQAL PYVALLIAML FFIYAVIGMQ MFGKVAMRDN
     NQINRNNNFQ TFPQAVLLLF RCATGEAWQE IMLACLPGKL CDPESDYNPG EEYTCGSNFA
     IVYFISFYML CAFLIINLFV AVIMDNFDYL TRDWSILGPH HLDEFKRIWS EYDPEAKGRI
     KHLDVVTLLR RIQPPLGFGK LCPHRVACKR LVAMNMPLNS DGTVMFNATL FALVRTALKI
     KTEGNLEQAN EELRAVIKKI WKKTSMKLLD QVVPPAGDDE VTVGKFYATF LIQDYFRKFK
     KRKEQGLVGK YPAKNTTIAL QAGLRTLHDI GPEIRRAISC DLQDDEPEET KREEEDDVFK
     RNGALLGNHV NHVNSDRRDS LQQTNTTHRP LHVQRPSIPP ASDTEKPLFP PAGNSVCHNH
     HNHNSIGKQV PTSTNANLNN ANMSKAAHGK RPSIGNLEHV SENGHHSSHK HDREPQRRSS
     VKRTRYYETY IRSDSGDEQL PTICREDPEI HGYFRDPHCL GEQEYFSSEE CYEDDSSPTW
     SRQNYGYYSR YPGRNIDSER PRGYHHPQGF LEDDDSPVCY DSRRSPRRRL LPPTPASHRR
     SSFNFECLRR QSSQEEVPSS PIFPHRTALP LHLMQQQIMA VAGLDSSKAQ KYSPSHSTRS
     WATPPATPPY RDWTPCYTPL IQVEQSEALD QVNGSLPSLH RSSWYTDEPD ISYRTFTPAS
     LTVPSSFRNK NSDKQRSADS LVEAVLISEG LGRYARDPKF VSATKHEIAD ACDLTIDEME
     SAASTLLNGN VRPRANGDVG PLSHRQDYEL QDFGPGYSDE EPDPGRDEED LADEMICITT
     L
//
ID   CAC1F_HUMAN             Reviewed;        1977 AA.
AC   O60840; A6NI29; F5CIQ9; O43901; O95226; Q9UHB1;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   14-APR-2009, sequence version 2.
DT   15-FEB-2017, entry version 173.
DE   RecName: Full=Voltage-dependent L-type calcium channel subunit alpha-1F;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav1.4;
GN   Name=CACNA1F; Synonyms=CACNAF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2), AND VARIANTS
RP   CSNB2A ASP-369; GLN-519; TRP-1060 AND HIS-1375.
RC   TISSUE=Retina;
RX   PubMed=9662399; DOI=10.1038/940;
RA   Strom T.M., Nyakatura G., Apfelstedt-Sylla E., Hellebrand H.,
RA   Lorenz B., Weber B.H.F., Wutz K., Gutwillinger N., Ruether K.,
RA   Drescher B., Sauer C., Zrenner E., Meitinger T., Rosenthal A.,
RA   Meindl A.;
RT   "An L-type calcium-channel gene mutated in incomplete X-linked
RT   congenital stationary night blindness.";
RL   Nat. Genet. 19:260-263(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND INVOLVEMENT IN CSNB2A.
RX   PubMed=9662400; DOI=10.1038/947;
RA   Bech-Hansen N.T., Naylor M.J., Maybaum T.A., Pearce W.G., Koop B.,
RA   Fishman G.A., Mets M., Musarella M.A., Boycott K.M.;
RT   "Loss-of-function mutations in a calcium-channel alpha1-subunit gene
RT   in Xp11.23 cause incomplete X-linked congenital stationary night
RT   blindness.";
RL   Nat. Genet. 19:264-267(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=10873387; DOI=10.1006/geno.2000.6204;
RA   Naylor M.J., Rancourt D.E., Bech-Hansen N.T.;
RT   "Isolation and characterization of a calcium channel gene, cacna1f,
RT   the murine orthologue of the gene for incomplete X-linked congenital
RT   stationary night blindness.";
RL   Genomics 66:324-327(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Retina;
RX   PubMed=19029287; DOI=10.1124/mol.108.049981;
RA   Sinnegger-Brauns M.J., Huber I.G., Koschak A., Wild C., Obermair G.J.,
RA   Einzinger U., Hoda J.C., Sartori S.B., Striessnig J.;
RT   "Expression and 1,4-dihydropyridine-binding properties of brain L-type
RT   calcium channel isoforms.";
RL   Mol. Pharmacol. 75:407-414(2009).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1211-1977.
RX   PubMed=9344658; DOI=10.1006/geno.1997.4941;
RA   Fisher S.E., Ciccodicola A., Tanaka K., Curci A., Desicato S.,
RA   D'Urso M., Craig I.W.;
RT   "Sequence-based exon prediction around the synaptophysin locus reveals
RT   a gene-rich area containing novel genes in human proximal Xp.";
RL   Genomics 45:340-347(1997).
RN   [7]
RP   VARIANTS CSNB2A ASP-369; ASP-674 AND ASP-928.
RX   PubMed=11281458; DOI=10.1007/s004390100461;
RA   Boycott K.M., Maybaum T.A., Naylor M.J., Weleber R.G., Robitaille J.,
RA   Miyake Y., Bergen A.A.B., Pierpont M.E., Pearce W.G.,
RA   Bech-Hansen N.T.;
RT   "A summary of 20 CACNA1F mutations identified in 36 families with
RT   incomplete X-linked congenital stationary night blindness, and
RT   characterization of splice variants.";
RL   Hum. Genet. 108:91-97(2001).
RN   [8]
RP   VARIANTS CSNB2A ARG-74; PRO-229; ARG-261; ASP-369; CYS-753; PRO-860;
RP   ARG-1018; TRP-1060; PRO-1079; ARG-1499; ARG-1500 AND PRO-1508.
RX   PubMed=12111638; DOI=10.1038/sj.ejhg.5200828;
RA   Wutz K., Sauer C., Zrenner E., Lorenz B., Alitalo T., Broghammer M.,
RA   Hergersberg M., de la Chapelle A., Weber B.H.F., Wissinger B.,
RA   Meindl A., Pusch C.M.;
RT   "Thirty distinct CACNA1F mutations in 33 families with incomplete type
RT   of XLCSNB and Cacna1f expression profiling in mouse retina.";
RL   Eur. J. Hum. Genet. 10:449-456(2002).
RN   [9]
RP   VARIANTS CSNB2A ARG-150 AND ILE-635.
RX   PubMed=12187427; DOI=10.1076/opge.23.2.71.2214;
RA   Weleber R.G.;
RT   "Infantile and childhood retinal blindness: a molecular perspective
RT   (The Franceschetti Lecture).";
RL   Ophthalmic Genet. 23:71-97(2002).
RN   [10]
RP   VARIANT CSNB2A THR-756, AND CHARACTERIZATION OF VARIANT CSNB2A
RP   THR-756.
RX   PubMed=15897456; DOI=10.1073/pnas.0501907102;
RA   Hemara-Wahanui A., Berjukow S., Hope C.I., Dearden P.K., Wu S.-B.,
RA   Wilson-Wheeler J., Sharp D.M., Lundon-Treweek P., Clover G.M.,
RA   Hoda J.-C., Striessnig J., Marksteiner R., Hering S., Maw M.A.;
RT   "A CACNA1F mutation identified in an X-linked retinal disorder shifts
RT   the voltage dependence of Cav1.4 channel activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7553-7558(2005).
RN   [11]
RP   VARIANT THR-746.
RX   PubMed=16960802; DOI=10.1086/508067;
RA   Zeitz C., Kloeckener-Gruissem B., Forster U., Kohl S., Magyar I.,
RA   Wissinger B., Matyas G., Borruat F.-X., Schorderet D.F., Zrenner E.,
RA   Munier F.L., Berger W.;
RT   "Mutations in CABP4, the gene encoding the Ca2+-binding protein 4,
RT   cause autosomal recessive night blindness.";
RL   Am. J. Hum. Genet. 79:657-667(2006).
RN   [12]
RP   INVOLVEMENT IN CORDX3.
RX   PubMed=16505158; DOI=10.1136/jmg.2006.040741;
RA   Jalkanen R., Maentyjaervi M., Tobias R., Isosomppi J., Sankila E.-M.,
RA   Alitalo T., Bech-Hansen N.T.;
RT   "X linked cone-rod dystrophy, CORDX3, is caused by a mutation in the
RT   CACNA1F gene.";
RL   J. Med. Genet. 43:699-704(2006).
RN   [13]
RP   INVOLVEMENT IN AIED.
RX   PubMed=17525176; DOI=10.1167/iovs.06-1103;
RA   Jalkanen R., Bech-Hansen N.T., Tobias R., Sankila E.-M.,
RA   Maentyjaervi M., Forsius H., de la Chapelle A., Alitalo T.;
RT   "A novel CACNA1F gene mutation causes Aland Island eye disease.";
RL   Invest. Ophthalmol. Vis. Sci. 48:2498-2502(2007).
RN   [14]
RP   VARIANT CSNB2A ARG-603, AND VARIANT AIED ARG-603.
RX   PubMed=22194652;
RA   Vincent A., Wright T., Day M.A., Westall C.A., Heon E.;
RT   "A novel p.Gly603Arg mutation in CACNA1F causes Aland island eye
RT   disease and incomplete congenital stationary night blindness
RT   phenotypes in a family.";
RL   Mol. Vis. 17:3262-3270(2011).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1F
CC       gives rise to L-type calcium currents. Long-lasting (L-type)
CC       calcium channels belong to the 'high-voltage activated' (HVA)
CC       group. They are blocked by dihydropyridines (DHP),
CC       phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA
CC       (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-
CC       GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).
CC   -!- SUBUNIT: Voltage-dependent calcium channels are multisubunit
CC       complexes, consisting of alpha-1, alpha-2, beta and delta subunits
CC       in a 1:1:1:1 ratio. The channel activity is directed by the pore-
CC       forming and voltage-sensitive alpha-1 subunit. In many cases, this
CC       subunit is sufficient to generate voltage-sensitive calcium
CC       channel activity. The auxiliary subunits beta and alpha-2/delta
CC       linked by a disulfide bridge regulate the channel activity.
CC       Interacts (via IQ domain) with CABP4; in a calcium independent
CC       manner (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O60840-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O60840-2; Sequence=VSP_036785;
CC       Name=3;
CC         IsoId=O60840-4; Sequence=VSP_045172;
CC   -!- TISSUE SPECIFICITY: Expression in skeletal muscle and retina.
CC       {ECO:0000269|PubMed:10873387}.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- DISEASE: Night blindness, congenital stationary, 2A (CSNB2A)
CC       [MIM:300071]: A non-progressive retinal disorder characterized by
CC       impaired night vision, often associated with nystagmus and myopia.
CC       {ECO:0000269|PubMed:11281458, ECO:0000269|PubMed:12111638,
CC       ECO:0000269|PubMed:12187427, ECO:0000269|PubMed:15897456,
CC       ECO:0000269|PubMed:22194652, ECO:0000269|PubMed:9662399,
CC       ECO:0000269|PubMed:9662400}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cone-rod dystrophy, X-linked 3 (CORDX3) [MIM:300476]: An
CC       inherited retinal dystrophy characterized by retinal pigment
CC       deposits visible on fundus examination, predominantly in the
CC       macular region, and initial loss of cone photoreceptors followed
CC       by rod degeneration. This leads to decreased visual acuity and
CC       sensitivity in the central visual field, followed by loss of
CC       peripheral vision. Severe loss of vision occurs earlier than in
CC       retinitis pigmentosa. {ECO:0000269|PubMed:16505158}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Aaland island eye disease (AIED) [MIM:300600]: A retinal
CC       disease characterized by a combination of fundus hypopigmentation,
CC       decreased visual acuity due to foveal hypoplasia, nystagmus,
CC       astigmatism, protan color vision defect, myopia, and defective
CC       dark adaptation. Except for progression of axial myopia, the
CC       disease can be considered to be a stationary condition.
CC       Electroretinography reveals abnormalities in both photopic and
CC       scotopic functions. {ECO:0000269|PubMed:17525176,
CC       ECO:0000269|PubMed:22194652}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1F subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB92359.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Mutations of the CCNA1F gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.org/files/sci-news/cacnamut.htm";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ006216; CAA06916.1; -; Genomic_DNA.
DR   EMBL; AF067227; AAD03587.1; -; mRNA.
DR   EMBL; AJ224874; CAA12175.1; -; mRNA.
DR   EMBL; AF201304; AAF15290.1; -; mRNA.
DR   EMBL; JF701915; AED89557.1; -; mRNA.
DR   EMBL; AF196779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF235097; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U93305; AAB92359.1; ALT_SEQ; Genomic_DNA.
DR   CCDS; CCDS35253.1; -. [O60840-1]
DR   CCDS; CCDS59166.1; -. [O60840-4]
DR   CCDS; CCDS59167.1; -. [O60840-2]
DR   RefSeq; NP_001243718.1; NM_001256789.2. [O60840-2]
DR   RefSeq; NP_001243719.1; NM_001256790.2. [O60840-4]
DR   RefSeq; NP_005174.2; NM_005183.3. [O60840-1]
DR   UniGene; Hs.632799; -.
DR   ProteinModelPortal; O60840; -.
DR   BioGrid; 107232; 1.
DR   IntAct; O60840; 2.
DR   STRING; 9606.ENSP00000365441; -.
DR   BindingDB; O60840; -.
DR   ChEMBL; CHEMBL2363032; -.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB04920; Clevidipine.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB00393; Nimodipine.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00661; Verapamil.
DR   GuidetoPHARMACOLOGY; 531; -.
DR   TCDB; 1.A.1.11.11; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; O60840; -.
DR   PhosphoSitePlus; O60840; -.
DR   BioMuta; CACNA1F; -.
DR   PaxDb; O60840; -.
DR   PeptideAtlas; O60840; -.
DR   PRIDE; O60840; -.
DR   Ensembl; ENST00000323022; ENSP00000321618; ENSG00000102001. [O60840-2]
DR   Ensembl; ENST00000376251; ENSP00000365427; ENSG00000102001. [O60840-4]
DR   Ensembl; ENST00000376265; ENSP00000365441; ENSG00000102001. [O60840-1]
DR   GeneID; 778; -.
DR   KEGG; hsa:778; -.
DR   UCSC; uc004dnb.3; human. [O60840-1]
DR   CTD; 778; -.
DR   DisGeNET; 778; -.
DR   GeneCards; CACNA1F; -.
DR   GeneReviews; CACNA1F; -.
DR   HGNC; HGNC:1393; CACNA1F.
DR   MalaCards; CACNA1F; -.
DR   MIM; 300071; phenotype.
DR   MIM; 300110; gene.
DR   MIM; 300476; phenotype.
DR   MIM; 300600; phenotype.
DR   neXtProt; NX_O60840; -.
DR   OpenTargets; ENSG00000102001; -.
DR   Orphanet; 178333; Aland Islands eye disease.
DR   Orphanet; 1872; Cone rod dystrophy.
DR   Orphanet; 215; Congenital stationary night blindness.
DR   PharmGKB; PA26010; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128247; -.
DR   HOGENOM; HOG000231529; -.
DR   HOVERGEN; HBG050763; -.
DR   InParanoid; O60840; -.
DR   KO; K04853; -.
DR   OMA; DGHNAPR; -.
DR   OrthoDB; EOG090301A2; -.
DR   PhylomeDB; O60840; -.
DR   TreeFam; TF312805; -.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-5576893; Phase 2 - plateau phase.
DR   Reactome; R-HSA-5576894; Phase 1 - inactivation of fast Na+ channels.
DR   ChiTaRS; CACNA1F; human.
DR   GeneWiki; Cav1.4; -.
DR   GenomeRNAi; 778; -.
DR   PRO; PR:O60840; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102001; -.
DR   CleanEx; HS_CACNA1F; -.
DR   ExpressionAtlas; O60840; baseline and differential.
DR   Genevisible; O60840; HS.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0001750; C:photoreceptor outer segment; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IDA:UniProtKB.
DR   GO; GO:0008331; F:high voltage-gated calcium channel activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0061337; P:cardiac conduction; TAS:Reactome.
DR   GO; GO:0050908; P:detection of light stimulus involved in visual perception; IMP:UniProtKB.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0050856; P:regulation of T cell receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0043029; P:T cell homeostasis; IEA:InterPro.
DR   GO; GO:0007601; P:visual perception; IMP:UniProtKB.
DR   Gene3D; 1.20.120.350; -; 5.
DR   InterPro; IPR031688; CAC1F_C.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR031649; GPHH_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR014873; VDCC_a1su_IQ.
DR   InterPro; IPR030157; VDCC_L_a1F.
DR   InterPro; IPR005446; VDCC_L_a1su.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   PANTHER; PTHR10037:SF234; PTHR10037:SF234; 1.
DR   Pfam; PF08763; Ca_chan_IQ; 1.
DR   Pfam; PF16885; CAC1F_C; 1.
DR   Pfam; PF16905; GPHH; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01630; LVDCCALPHA1.
DR   SMART; SM01062; Ca_chan_IQ; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Calcium channel; Calcium transport;
KW   Complete proteome; Cone-rod dystrophy;
KW   Congenital stationary night blindness; Disease mutation;
KW   Disulfide bond; Glycoprotein; Ion channel; Ion transport; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Sensory transduction; Transmembrane; Transmembrane helix;
KW   Transport; Vision; Voltage-gated channel.
FT   CHAIN         1   1977       Voltage-dependent L-type calcium channel
FT                                subunit alpha-1F.
FT                                /FTId=PRO_0000053950.
FT   TOPO_DOM      1     92       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     93    111       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    112    129       Extracellular. {ECO:0000255}.
FT   TRANSMEM    130    149       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    150    161       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    162    180       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    181    201       Extracellular. {ECO:0000255}.
FT   TRANSMEM    202    220       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    221    239       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    240    259       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    260    347       Extracellular. {ECO:0000255}.
FT   TRANSMEM    348    372       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    373    529       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    530    549       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    550    564       Extracellular. {ECO:0000255}.
FT   TRANSMEM    565    583       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    584    591       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    592    610       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    611    620       Extracellular. {ECO:0000255}.
FT   TRANSMEM    621    639       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    640    658       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    659    679       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    680    733       Extracellular. {ECO:0000255}.
FT   TRANSMEM    734    758       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    759    871       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    872    890       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    891    906       Extracellular. {ECO:0000255}.
FT   TRANSMEM    907    926       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    927    938       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    939    957       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    958    963       Extracellular. {ECO:0000255}.
FT   TRANSMEM    964    983       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM    984   1002       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1003   1022       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1023   1112       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1113   1133       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1134   1190       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1191   1209       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1210   1224       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1225   1244       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1245   1251       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1252   1273       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1274   1290       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1291   1310       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1311   1329       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1330   1349       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1350   1416       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1417   1441       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1442   1977       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       79    375       I.
FT   REPEAT      515    761       II.
FT   REPEAT      858   1140       III.
FT   REPEAT     1177   1444       IV.
FT   CA_BIND    1470   1481       {ECO:0000250}.
FT   REGION      395    412       Binding to the beta subunit.
FT                                {ECO:0000250}.
FT   REGION     1060   1150       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1397   1463       Dihydropyridine binding. {ECO:0000250}.
FT   REGION     1409   1452       Phenylalkylamine binding. {ECO:0000250}.
FT   COMPBIAS    659    665       Poly-Leu.
FT   COMPBIAS    794    799       Poly-Glu.
FT   COMPBIAS    809    825       Poly-Glu.
FT   COMPBIAS   1121   1124       Poly-Ile.
FT   COMPBIAS   1640   1645       Poly-Glu.
FT   SITE        330    330       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        711    711       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1086   1086       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1383   1383       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES    1452   1452       Phosphoserine; by PKA. {ECO:0000255}.
FT   CARBOHYD    295    295       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ       9     86       DTTPEPSPANGAGPGPEWGLCPGPPAVEGESSGASGLGTPK
FT                                RRNQHSKHKTVAVASAQRSPRALFCLTLANPLRRSCI ->
FT                                GERILPSLQTLGA (in isoform 3).
FT                                {ECO:0000303|PubMed:9662400}.
FT                                /FTId=VSP_045172.
FT   VAR_SEQ     427    437       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:19029287,
FT                                ECO:0000303|PubMed:9662399}.
FT                                /FTId=VSP_036785.
FT   VARIANT      14     14       P -> L (in dbSNP:rs6520408).
FT                                /FTId=VAR_030807.
FT   VARIANT      74     74       C -> R (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030808.
FT   VARIANT     150    150       G -> R (in CSNB2A).
FT                                {ECO:0000269|PubMed:12187427}.
FT                                /FTId=VAR_030809.
FT   VARIANT     229    229       S -> P (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030810.
FT   VARIANT     261    261       G -> R (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030811.
FT   VARIANT     369    369       G -> D (in CSNB2A; dbSNP:rs122456133).
FT                                {ECO:0000269|PubMed:11281458,
FT                                ECO:0000269|PubMed:12111638,
FT                                ECO:0000269|PubMed:9662399}.
FT                                /FTId=VAR_001504.
FT   VARIANT     519    519       R -> Q (in CSNB2A; dbSNP:rs34162630).
FT                                {ECO:0000269|PubMed:9662399}.
FT                                /FTId=VAR_001505.
FT   VARIANT     603    603       G -> R (in AIED and CSNB2A;
FT                                dbSNP:rs201654095).
FT                                {ECO:0000269|PubMed:22194652}.
FT                                /FTId=VAR_071433.
FT   VARIANT     635    635       V -> I (in CSNB2A; dbSNP:rs141010716).
FT                                {ECO:0000269|PubMed:12187427}.
FT                                /FTId=VAR_030812.
FT   VARIANT     674    674       G -> D (in CSNB2A).
FT                                {ECO:0000269|PubMed:11281458}.
FT                                /FTId=VAR_030813.
FT   VARIANT     746    746       N -> T (in dbSNP:rs141159097).
FT                                {ECO:0000269|PubMed:16960802}.
FT                                /FTId=VAR_029376.
FT   VARIANT     753    753       F -> C (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030814.
FT   VARIANT     756    756       I -> T (in CSNB2A; increases the number
FT                                of mutant channels open at physiologic
FT                                membrane potential and allows for
FT                                persistent Ca(2+) entry due to reduced
FT                                channel inactivation resulting in a gain-
FT                                of-function defect; dbSNP:rs122456136).
FT                                {ECO:0000269|PubMed:15897456}.
FT                                /FTId=VAR_030815.
FT   VARIANT     860    860       L -> P (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030816.
FT   VARIANT     928    928       A -> D (in CSNB2A).
FT                                {ECO:0000269|PubMed:11281458}.
FT                                /FTId=VAR_030817.
FT   VARIANT    1018   1018       G -> R (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030818.
FT   VARIANT    1060   1060       R -> W (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638,
FT                                ECO:0000269|PubMed:9662399}.
FT                                /FTId=VAR_001506.
FT   VARIANT    1079   1079       L -> P (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030819.
FT   VARIANT    1259   1259       A -> T (in dbSNP:rs34308720).
FT                                /FTId=VAR_055662.
FT   VARIANT    1270   1270       A -> T (in dbSNP:rs34308720).
FT                                /FTId=VAR_031822.
FT   VARIANT    1375   1375       L -> H (in CSNB2A).
FT                                {ECO:0000269|PubMed:9662399}.
FT                                /FTId=VAR_001507.
FT   VARIANT    1499   1499       C -> R (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030820.
FT   VARIANT    1500   1500       P -> R (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030821.
FT   VARIANT    1508   1508       L -> P (in CSNB2A).
FT                                {ECO:0000269|PubMed:12111638}.
FT                                /FTId=VAR_030822.
FT   VARIANT    1930   1930       R -> H (in dbSNP:rs33910054).
FT                                /FTId=VAR_054818.
FT   CONFLICT   1236   1236       E -> V (in Ref. 6; AAB92359).
FT                                {ECO:0000305}.
FT   CONFLICT   1860   1860       A -> G (in Ref. 6; AAB92359).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1977 AA;  220678 MW;  354336550C6D8E73 CRC64;
     MSESEGGKDT TPEPSPANGA GPGPEWGLCP GPPAVEGESS GASGLGTPKR RNQHSKHKTV
     AVASAQRSPR ALFCLTLANP LRRSCISIVE WKPFDILILL TIFANCVALG VYIPFPEDDS
     NTANHNLEQV EYVFLVIFTV ETVLKIVAYG LVLHPSAYIR NGWNLLDFII VVVGLFSVLL
     EQGPGRPGDA PHTGGKPGGF DVKALRAFRV LRPLRLVSGV PSLHIVLNSI MKALVPLLHI
     ALLVLFVIII YAIIGLELFL GRMHKTCYFL GSDMEAEEDP SPCASSGSGR ACTLNQTECR
     GRWPGPNGGI TNFDNFFFAM LTVFQCVTME GWTDVLYWMQ DAMGYELPWV YFVSLVIFGS
     FFVLNLVLGV LSGEFSKERE KAKARGDFQK QREKQQMEED LRGYLDWITQ AEELDMEDPS
     ADDNLGSMAE EGRAGHRPQL AELTNRRRGR LRWFSHSTRS THSTSSHASL PASDTGSMTE
     TQGDEDEEEG ALASCTRCLN KIMKTRVCRR LRRANRVLRA RCRRAVKSNA CYWAVLLLVF
     LNTLTIASEH HGQPVWLTQI QEYANKVLLC LFTVEMLLKL YGLGPSAYVS SFFNRFDCFV
     VCGGILETTL VEVGAMQPLG ISVLRCVRLL RIFKVTRHWA SLSNLVASLL NSMKSIASLL
     LLLFLFIIIF SLLGMQLFGG KFNFDQTHTK RSTFDTFPQA LLTVFQILTG EDWNVVMYDG
     IMAYGGPFFP GMLVCIYFII LFICGNYILL NVFLAIAVDN LASGDAGTAK DKGGEKSNEK
     DLPQENEGLV PGVEKEEEEG ARREGADMEE EEEEEEEEEE EEEEEGAGGV ELLQEVVPKE
     KVVPIPEGSA FFCLSQTNPL RKGCHTLIHH HVFTNLILVF IILSSVSLAA EDPIRAHSFR
     NHILGYFDYA FTSIFTVEIL LKMTVFGAFL HRGSFCRSWF NMLDLLVVSV SLISFGIHSS
     AISVVKILRV LRVLRPLRAI NRAKGLKHVV QCVFVAIRTI GNIMIVTTLL QFMFACIGVQ
     LFKGKFYTCT DEAKHTPQEC KGSFLVYPDG DVSRPLVRER LWVNSDFNFD NVLSAMMALF
     TVSTFEGWPA LLYKAIDAYA EDHGPIYNYR VEISVFFIVY IIIIAFFMMN IFVGFVIITF
     RAQGEQEYQN CELDKNQRQC VEYALKAQPL RRYIPKNPHQ YRVWATVNSA AFEYLMFLLI
     LLNTVALAMQ HYEQTAPFNY AMDILNMVFT GLFTIEMVLK IIAFKPKHYF TDAWNTFDAL
     IVVGSIVDIA VTEVNNGGHL GESSEDSSRI SITFFRLFRV MRLVKLLSKG EGIRTLLWTF
     IKSFQALPYV ALLIAMIFFI YAVIGMQMFG KVALQDGTQI NRNNNFQTFP QAVLLLFRCA
     TGEAWQEIML ASLPGNRCDP ESDFGPGEEF TCGSNFAIAY FISFFMLCAF LIINLFVAVI
     MDNFDYLTRD WSILGPHHLD EFKRIWSEYD PGAKGRIKHL DVVALLRRIQ PPLGFGKLCP
     HRVACKRLVA MNMPLNSDGT VTFNATLFAL VRTSLKIKTE GNLEQANQEL RIVIKKIWKR
     MKQKLLDEVI PPPDEEEVTV GKFYATFLIQ DYFRKFRRRK EKGLLGNDAA PSTSSALQAG
     LRSLQDLGPE MRQALTCDTE EEEEEGQEGV EEEDEKDLET NKATMVSQPS ARRGSGISVS
     LPVGDRLPDS LSFGPSDDDR GTPTSSQPSV PQAGSNTHRR GSGALIFTIP EEGNSQPKGT
     KGQNKQDEDE EVPDRLSYLD EQAGTPPCSV LLPPHRAQRY MDGHLVPRRR LLPPTPAGRK
     PSFTIQCLQR QGSCEDLPIP GTYHRGRNSG PNRAQGSWAT PPQRGRLLYA PLLLVEEGAA
     GEGYLGRSSG PLRTFTCLHV PGTHSDPSHG KRGSADSLVE AVLISEGLGL FARDPRFVAL
     AKQEIADACR LTLDEMDNAA SDLLAQGTSS LYSDEESILS RFDEEDLGDE MACVHAL
//
ID   CAC1A_HUMAN             Reviewed;        2505 AA.
AC   O00555; J3KP41; P78510; P78511; Q16290; Q92690; Q99790; Q99791;
AC   Q99792; Q99793; Q9NS88; Q9UDC4;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   15-FEB-2017, entry version 178.
DE   RecName: Full=Voltage-dependent P/Q-type calcium channel subunit alpha-1A;
DE   AltName: Full=Brain calcium channel I;
DE            Short=BI;
DE   AltName: Full=Calcium channel, L type, alpha-1 polypeptide isoform 4;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav2.1;
GN   Name=CACNA1A; Synonyms=CACH4, CACN3, CACNL1A4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Neuron;
RX   PubMed=10049321; DOI=10.1016/S0006-3495(99)77300-5;
RA   Hans M., Urrutia A., Deal C., Brust P.F., Stauderman K., Ellis S.B.,
RA   Harpold M.M., Johnson E.C., Williams M.E.;
RT   "Structural elements in domain IV that influence biophysical and
RT   pharmacological properties of human alpha1A-containing high-voltage-
RT   activated calcium channels.";
RL   Biophys. J. 76:1384-1400(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 3), VARIANTS FHM1
RP   GLN-192; MET-666; ALA-714 AND LEU-1810, VARIANT THR-454, AND
RP   INVOLVEMENT IN EA2.
RC   TISSUE=Cerebellum;
RX   PubMed=8898206; DOI=10.1016/S0092-8674(00)81373-2;
RA   Ophoff R.A., Terwindt G.M., Vergouwe M.N., van Eijk R., Oefner P.J.,
RA   Hoffman S.M.G., Lamerdin J.E., Mohrenweiser H.W., Bulman D.E.,
RA   Ferrari M., Haan J., Lindhout D., van Ommen G.-J.B., Hofker M.H.,
RA   Ferrari M.D., Frants R.R.;
RT   "Familial hemiplegic migraine and episodic ataxia type-2 are caused by
RT   mutations in the Ca2+ channel gene CACNL1A4.";
RL   Cell 87:543-552(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1313-2505 (ISOFORMS 1; 2; 3 AND 6), ALTERNATIVE SPLICING, AND
RP   INVOLVEMENT IN SCA6.
RC   TISSUE=Brain;
RX   PubMed=8988170; DOI=10.1038/ng0197-62;
RA   Zhuchenko O., Bailey J., Bonnen P.E., Ashizawa T., Stockton D.W.,
RA   Amos C., Dobyns W.B., Subramony S.H., Zoghbi H.Y., Lee C.C.;
RT   "Autosomal dominant cerebellar ataxia (SCA6) associated with small
RT   polyglutamine expansions in the alpha 1A-voltage-dependent calcium
RT   channel.";
RL   Nat. Genet. 15:62-69(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8), VARIANT SER-1105, AND
RP   FUNCTION.
RC   TISSUE=Cerebellum;
RX   PubMed=10753886; DOI=10.1074/jbc.275.15.10893;
RA   Toru S., Murakoshi T., Ishikawa K., Saegusa H., Fujigasaki H.,
RA   Uchihara T., Nagayama S., Osanai M., Mizusawa H., Tanabe T.;
RT   "Spinocerebellar ataxia type 6 mutation alters P-type calcium channel
RT   function.";
RL   J. Biol. Chem. 275:10893-10898(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1693-1807.
RC   TISSUE=Lung carcinoma;
RX   PubMed=7823133;
RA   Barry E.L.R., Viglione M.P., Kim Y.I., Froehner S.C.;
RT   "Expression and antibody inhibition of P-type calcium channels in
RT   human small-cell lung carcinoma cells.";
RL   J. Neurosci. 15:274-283(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1702-1822, AND TISSUE SPECIFICITY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=1335101; DOI=10.1016/S0025-6196(12)61144-6;
RA   Oguro-Okano M., Griesmann G.E., Wieben E.D., Slaymaker S.J.,
RA   Snutch T.P., Lennon V.A.;
RT   "Molecular diversity of neuronal-type calcium channels identified in
RT   small cell lung carcinoma.";
RL   Mayo Clin. Proc. 67:1150-1159(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2038-2258 (ISOFORMS 1/2/3/4).
RC   TISSUE=Frontal cortex;
RX   PubMed=8525433; DOI=10.1007/BF02255782;
RA   Margolis R.L., Breschel T.S., Li S.H., Kidwai A.S., Antonarakis S.E.,
RA   McInnis M.G., Ross C.A.;
RT   "Characterization of cDNA clones containing CCA trinucleotide repeats
RT   derived from human brain.";
RL   Somat. Cell Mol. Genet. 21:279-284(1995).
RN   [9]
RP   INTERACTION WITH CABP1.
RX   PubMed=11865310; DOI=10.1038/nn805;
RA   Lee A., Westenbroek R.E., Haeseleer F., Palczewski K., Scheuer T.,
RA   Catterall W.A.;
RT   "Differential modulation of Ca(v)2.1 channels by calmodulin and Ca2+-
RT   binding protein 1.";
RL   Nat. Neurosci. 5:210-217(2002).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 1955-1975.
RX   PubMed=18400181; DOI=10.1016/j.str.2008.01.011;
RA   Mori M.X., Vander Kooi C.W., Leahy D.J., Yue D.T.;
RT   "Crystal structure of the CaV2 IQ domain in complex with
RT   Ca2+/calmodulin: high-resolution mechanistic implications for channel
RT   regulation by Ca2+.";
RL   Structure 16:607-620(2008).
RN   [11]
RP   VARIANT SCA6 ARG-293.
RX   PubMed=9345107; DOI=10.1086/301613;
RA   Yue Q., Jen J.C., Nelson S.F., Baloh R.W.;
RT   "Progressive ataxia due to a missense mutation in a calcium-channel
RT   gene.";
RL   Am. J. Hum. Genet. 61:1078-1087(1997).
RN   [12]
RP   POLYMORPHISM, AND INVOLVEMENT IN SCA6 AND EA2.
RX   PubMed=9302278; DOI=10.1093/hmg/6.11.1973;
RA   Jodice C., Mantuano E., Veneziano L., Trettel F., Sabbadini G.,
RA   Calandriello L., Francia A., Spadaro M., Pierelli F., Salvi F.,
RA   Ophoff R.A., Frants R.R., Frontali M.;
RT   "Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6)
RT   due to CAG repeat expansion in the CACNA1A gene on chromosome 19p.";
RL   Hum. Mol. Genet. 6:1973-1978(1997).
RN   [13]
RP   VARIANT EA2 HIS-1661.
RX   PubMed=10987655; DOI=10.1007/s004390051099;
RA   Friend K.L., Crimmins D., Phan T.G., Sue C.M., Colley A., Fung V.S.,
RA   Morris J.G., Sutherland G.R., Richards R.I.;
RT   "Detection of a novel missense mutation and second recurrent mutation
RT   in the CACNA1A gene in individuals with EA-2 and FHM.";
RL   Hum. Genet. 105:261-265(1999).
RN   [14]
RP   VARIANT VAL-993, AND VARIANT FHM1 LEU-1456.
RX   PubMed=10408532; DOI=10.1212/WNL.53.1.26;
RA   Carrera P., Piatti M., Stenirri S., Grimaldi L.M., Marchioni E.,
RA   Curcio M., Righetti P.G., Ferrari M., Gelfi C.;
RT   "Genetic heterogeneity in Italian families with familial hemiplegic
RT   migraine.";
RL   Neurology 53:26-33(1999).
RN   [15]
RP   VARIANT FHM1 LEU-218.
RX   PubMed=11409427; DOI=10.1002/ana.1031;
RA   Kors E.E., Terwindt G.M., Vermeulen F.L., Fitzsimons R.B.,
RA   Jardine P.E., Heywood P., Love S., van den Maagdenberg A.M., Haan J.,
RA   Frants R.R., Ferrari M.D.;
RT   "Delayed cerebral edema and fatal coma after minor head trauma: role
RT   of the CACNA1A calcium channel subunit gene and relationship with
RT   familial hemiplegic migraine.";
RL   Ann. Neurol. 49:753-760(2001).
RN   [16]
RP   VARIANT EA2 LYS-1756.
RX   PubMed=11176968; DOI=10.1001/archneur.58.2.292;
RA   Denier C., Ducros A., Durr A., Eymard B., Chassande B.,
RA   Tournier-Lasserve E.;
RT   "Missense CACNA1A mutation causing episodic ataxia type 2.";
RL   Arch. Neurol. 58:292-295(2001).
RN   [17]
RP   VARIANTS FHM1 LYS-195; GLN-583; MET-666; GLU-715; GLU-1335; CYS-1384;
RP   TRP-1667; ARG-1683 AND ILE-1695.
RX   PubMed=11439943; DOI=10.1056/NEJM200107053450103;
RA   Ducros A., Denier C., Joutel A., Cecillon M., Lescoat C., Vahedi K.,
RA   Darcel F., Vicaut E., Bousser M.G., Tournier-Lasserve E.;
RT   "The clinical spectrum of familial hemiplegic migraine associated with
RT   mutations in a neuronal calcium channel.";
RL   N. Engl. J. Med. 345:17-24(2001).
RN   [18]
RP   VARIANT EA2 CYS-1403, CHARACTERIZATION OF VARIANT EA2 CYS-1403, AND
RP   FUNCTION.
RX   PubMed=11723274; DOI=10.1212/WNL.57.10.1843;
RA   Jen J., Wan J., Graves M., Yu H., Mock A.F., Coulin C.J., Kim G.,
RA   Yue Q., Papazian D.M., Baloh R.W.;
RT   "Loss-of-function EA2 mutations are associated with impaired
RT   neuromuscular transmission.";
RL   Neurology 57:1843-1848(2001).
RN   [19]
RP   VARIANT EA2 TYR-253.
RX   PubMed=12420090; DOI=10.1007/s00415-002-0860-8;
RA   van den Maagdenberg A.M., Kors E.E., Brunt E.R., van Paesschen W.,
RA   Pascual J., Ravine D., Keeling S., Vanmolkot K.R., Vermeulen F.L.,
RA   Terwindt G.M., Haan J., Frants R.R., Ferrari M.D.;
RT   "Episodic ataxia type 2. Three novel truncating mutations and one
RT   novel missense mutation in the CACNA1A gene.";
RL   J. Neurol. 249:1515-1519(2002).
RN   [20]
RP   VARIANT EA2 LEU-1736, CHARACTERIZATION OF VARIANT EA2 LEU-1736, AND
RP   FUNCTION.
RX   PubMed=15293273; DOI=10.1002/ana.20169;
RA   Spacey S.D., Hildebrand M.E., Materek L.A., Bird T.D., Snutch T.P.;
RT   "Functional implications of a novel EA2 mutation in the P/Q-type
RT   calcium channel.";
RL   Ann. Neurol. 56:213-220(2004).
RN   [21]
RP   VARIANT FHM1 GLN-1346.
RX   PubMed=15032980; DOI=10.1111/j..2004.00187.x;
RA   Alonso I., Barros J., Tuna A., Seixas A., Coutinho P., Sequeiros J.,
RA   Silveira I.;
RT   "A novel R1347Q mutation in the predicted voltage sensor segment of
RT   the P/Q-type calcium-channel alpha-subunit in a family with
RT   progressive cerebellar ataxia and hemiplegic migraine.";
RL   Clin. Genet. 65:70-72(2004).
RN   [22]
RP   VARIANTS EA2 ARG-256; ARG-1482; SER-1490; ILE-1493 AND CYS-2135.
RX   PubMed=15173248; DOI=10.1136/jmg.2003.015396;
RA   Mantuano E., Veneziano L., Spadaro M., Giunti P., Guida S.,
RA   Leggio M.G., Verriello L., Wood N., Jodice C., Frontali M.;
RT   "Clusters of non-truncating mutations of P/Q type Ca2+ channel subunit
RT   Ca(v)2.1 causing episodic ataxia 2.";
RL   J. Med. Genet. 41:E82-E82(2004).
RN   [23]
RP   VARIANTS EA2 TYR-287; ARG-293 AND MET-666.
RX   PubMed=14718690; DOI=10.1212/01.WNL.0000101675.61074.50;
RA   Jen J., Kim G.W., Baloh R.W.;
RT   "Clinical spectrum of episodic ataxia type 2.";
RL   Neurology 62:17-22(2004).
RN   [24]
RP   VARIANTS ASP-918; VAL-993 AND SER-1105.
RX   PubMed=16866717; DOI=10.1111/j.1526-4610.2006.00504.x;
RA   von Brevern M., Ta N., Shankar A., Wiste A., Siegel A., Radtke A.,
RA   Sander T., Escayg A.;
RT   "Migrainous vertigo: mutation analysis of the candidate genes CACNA1A,
RT   ATP1A2, SCN1A, and CACNB4.";
RL   Headache 46:1136-1141(2006).
RN   [25]
RP   VARIANT SCA6 GLN-1664.
RX   PubMed=16325861; DOI=10.1016/j.jns.2005.10.007;
RA   Tonelli A., D'Angelo M.G., Salati R., Villa L., Germinasi C.,
RA   Frattini T., Meola G., Turconi A.C., Bresolin N., Bassi M.T.;
RT   "Early onset, non fluctuating spinocerebellar ataxia and a novel
RT   missense mutation in CACNA1A gene.";
RL   J. Neurol. Sci. 241:13-17(2006).
RN   [26]
RP   VARIANT FHM1 GLN-1346.
RX   PubMed=18400034; DOI=10.1111/j.1399-0004.2008.00996.x;
RA   Stam A.H., Vanmolkot K.R., Kremer H.P., Gartner J., Brown J.,
RA   Leshinsky-Silver E., Gilad R., Kors E.E., Frankhuizen W.S.,
RA   Ginjaar H.B., Haan J., Frants R.R., Ferrari M.D.,
RA   van den Maagdenberg A.M., Terwindt G.M.;
RT   "CACNA1A R1347Q: a frequent recurrent mutation in hemiplegic
RT   migraine.";
RL   Clin. Genet. 74:481-485(2008).
RN   [27]
RP   VARIANT EA2 CYS-248.
RX   PubMed=18602318; DOI=10.1016/j.ejpn.2008.02.011;
RA   Zafeiriou D.I., Lehmann-Horn F., Vargiami E., Teflioudi E.,
RA   Ververi A., Jurkat-Rott K.;
RT   "Episodic ataxia type 2 showing ictal hyperhidrosis with hypothermia
RT   and interictal chronic diarrhea due to a novel CACNA1A mutation.";
RL   Eur. J. Paediatr. Neurol. 13:191-193(2009).
RN   [28]
RP   VARIANT EA2 ASP-638, CHARACTERIZATION OF VARIANT EA2 ASP-638, AND
RP   FUNCTION.
RX   PubMed=19232643; DOI=10.1016/j.jns.2009.01.005;
RA   Cuenca-Leon E., Banchs I., Serra S.A., Latorre P.,
RA   Fernandez-Castillo N., Corominas R., Valverde M.A., Volpini V.,
RA   Fernandez-Fernandez J.M., Macaya A., Cormand B.;
RT   "Late-onset episodic ataxia type 2 associated with a novel loss-of-
RT   function mutation in the CACNA1A gene.";
RL   J. Neurol. Sci. 280:10-14(2009).
RN   [29]
RP   VARIANTS ASP-918 AND VAL-993.
RX   PubMed=19429006; DOI=10.1016/j.neulet.2009.01.081;
RA   D'Onofrio M., Ambrosini A., Di Mambro A., Arisi I., Santorelli F.M.,
RA   Grieco G.S., Nicoletti F., Nappi G., Pierelli F., Schoenen J.,
RA   Buzzi M.G.;
RT   "The interplay of two single nucleotide polymorphisms in the CACNA1A
RT   gene may contribute to migraine susceptibility.";
RL   Neurosci. Lett. 453:12-15(2009).
RN   [30]
RP   VARIANT SCA6 THR-405.
RX   PubMed=20682717; DOI=10.1136/jnnp.2008.163402;
RA   Romaniello R., Zucca C., Tonelli A., Bonato S., Baschirotto C.,
RA   Zanotta N., Epifanio R., Righini A., Bresolin N., Bassi M.T.,
RA   Borgatti R.;
RT   "A wide spectrum of clinical, neurophysiological and neuroradiological
RT   abnormalities in a family with a novel CACNA1A mutation.";
RL   J. Neurol. Neurosurg. Psych. 81:840-843(2010).
RN   [31]
RP   VARIANTS EA2 PHE-389; MET-501; THR-798; ARG-897; CYS-1679 AND
RP   ARG-1869.
RX   PubMed=20129625; DOI=10.1016/j.jns.2010.01.010;
RA   Mantuano E., Romano S., Veneziano L., Gellera C., Castellotti B.,
RA   Caimi S., Testa D., Estienne M., Zorzi G., Bugiani M., Rajabally Y.A.,
RA   Barcina M.J., Servidei S., Panico A., Frontali M., Mariotti C.;
RT   "Identification of novel and recurrent CACNA1A gene mutations in
RT   fifteen patients with episodic ataxia type 2.";
RL   J. Neurol. Sci. 291:30-36(2010).
RN   [32]
RP   VARIANT EA2 LYS-388.
RX   PubMed=21696515; DOI=10.1111/j.1442-200X.2011.03390.x;
RA   Nikaido K., Tachi N., Ohya K., Wada T., Tsutsumi H.;
RT   "New mutation of CACNA1A gene in episodic ataxia type 2.";
RL   Pediatr. Int. 53:415-416(2011).
RN   [33]
RP   VARIANT FHM1 PHE-1502 DEL, CHARACTERIZATION OF VARIANT FHM1 PHE-1502
RP   DEL, AND FUNCTION.
RX   PubMed=24836863; DOI=10.1016/j.jns.2014.04.027;
RA   Garcia Segarra N., Gautschi I., Mittaz-Crettol L., Kallay Zetchi C.,
RA   Al-Qusairi L., Van Bemmelen M.X., Maeder P., Bonafe L., Schild L.,
RA   Roulet-Perez E.;
RT   "Congenital ataxia and hemiplegic migraine with cerebral edema
RT   associated with a novel gain of function mutation in the calcium
RT   channel CACNA1A.";
RL   J. Neurol. Sci. 342:69-78(2014).
RN   [34]
RP   VARIANT FHM1 PHE-1502 DEL, CHARACTERIZATION OF VARIANT FHM1 PHE-1502
RP   DEL, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=26716990; DOI=10.1371/journal.pone.0146035;
RA   Bahamonde M.I., Serra S.A., Drechsel O., Rahman R., Marce-Grau A.,
RA   Prieto M., Ossowski S., Macaya A., Fernandez-Fernandez J.M.;
RT   "A single amino acid deletion (deltaf1502) in the s6 segment of cav2.1
RT   domain iii associated with congenital ataxia increases channel
RT   activity and promotes ca2+ influx.";
RL   PLoS ONE 10:E0146035-E0146035(2015).
RN   [35]
RP   INVOLVEMENT IN EIEE42, AND VARIANTS EIEE42 GLN-101; THR-713 AND
RP   SER-1508.
RX   PubMed=27476654; DOI=10.1016/j.ajhg.2016.06.003;
RG   Epi4K Consortium;
RT   "De novo mutations in SLC1A2 and CACNA1A are important causes of
RT   epileptic encephalopathies.";
RL   Am. J. Hum. Genet. 99:287-298(2016).
RN   [36]
RP   VARIANT EIEE42 ARG-1436.
RX   PubMed=27250579; DOI=10.1002/ajmg.a.37678;
RA   Reinson K., Oiglane-Shlik E., Talvik I., Vaher U., Ounapuu A.,
RA   Ennok M., Teek R., Pajusalu S., Murumets U., Tomberg T., Puusepp S.,
RA   Piirsoo A., Reimand T., Ounap K.;
RT   "Biallelic CACNA1A mutations cause early onset epileptic
RT   encephalopathy with progressive cerebral, cerebellar, and optic nerve
RT   atrophy.";
RL   Am. J. Med. Genet. A 170:2173-2176(2016).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1A
CC       gives rise to P and/or Q-type calcium currents. P/Q-type calcium
CC       channels belong to the 'high-voltage activated' (HVA) group and
CC       are blocked by the funnel toxin (Ftx) and by the omega-agatoxin-
CC       IVA (omega-Aga-IVA). They are however insensitive to
CC       dihydropyridines (DHP), and omega-conotoxin-GVIA (omega-CTx-GVIA).
CC       {ECO:0000269|PubMed:10049321, ECO:0000269|PubMed:10753886,
CC       ECO:0000269|PubMed:11723274, ECO:0000269|PubMed:15293273,
CC       ECO:0000269|PubMed:19232643, ECO:0000269|PubMed:24836863,
CC       ECO:0000269|PubMed:26716990}.
CC   -!- SUBUNIT: Voltage-dependent calcium channels are multisubunit
CC       complexes, consisting of alpha-1, alpha-2, beta and delta subunits
CC       in a 1:1:1:1 ratio. The channel activity is directed by the pore-
CC       forming and voltage-sensitive alpha-1 subunit. In many cases, this
CC       subunit is sufficient to generate voltage-sensitive calcium
CC       channel activity. The auxiliary subunits beta and alpha-2/delta
CC       linked by a disulfide bridge regulate the channel activity.
CC       Interact (via C-terminal CDB motif) with CABP1 in the pre- and
CC       postsynaptic membranes.
CC   -!- INTERACTION:
CC       Q8IZP0:ABI1; NbExp=2; IntAct=EBI-766279, EBI-375446;
CC       O94910:ADGRL1; NbExp=2; IntAct=EBI-766279, EBI-3389315;
CC       Q86SJ2:AMIGO2; NbExp=2; IntAct=EBI-766279, EBI-3866830;
CC       Q7Z5H3:ARHGAP22; NbExp=2; IntAct=EBI-766279, EBI-3866859;
CC       P67870:CSNK2B; NbExp=2; IntAct=EBI-766279, EBI-348169;
CC       O75953:DNAJB5; NbExp=2; IntAct=EBI-766279, EBI-5655937;
CC       P28799:GRN; NbExp=2; IntAct=EBI-766279, EBI-747754;
CC       P15822:HIVEP1; NbExp=2; IntAct=EBI-766279, EBI-722264;
CC       Q8N2S1:LTBP4; NbExp=2; IntAct=EBI-766279, EBI-947718;
CC       O00339:MATN2; NbExp=2; IntAct=EBI-766279, EBI-949020;
CC       O75095:MEGF6; NbExp=2; IntAct=EBI-766279, EBI-947597;
CC       Q7Z7M0:MEGF8; NbExp=2; IntAct=EBI-766279, EBI-947617;
CC       Q9UHX1:PUF60; NbExp=2; IntAct=EBI-766279, EBI-1053259;
CC       Q8IXT5:RBM12B; NbExp=2; IntAct=EBI-766279, EBI-3044077;
CC       O95153:TSPOAP1; NbExp=2; IntAct=EBI-766279, EBI-5915931;
CC       Q9BVA1:TUBB2B; NbExp=2; IntAct=EBI-766279, EBI-355665;
CC       P22695:UQCRC2; NbExp=2; IntAct=EBI-766279, EBI-1051424;
CC       P49750:YLPM1; NbExp=2; IntAct=EBI-766279, EBI-712871;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10049321,
CC       ECO:0000269|PubMed:26716990}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=1A-1, BI-1-GGCAG;
CC         IsoId=O00555-1; Sequence=Displayed;
CC       Name=2; Synonyms=1A-2,BI-1;
CC         IsoId=O00555-2; Sequence=VSP_000875;
CC       Name=3; Synonyms=BI-1(V1);
CC         IsoId=O00555-3; Sequence=VSP_000871, VSP_000875;
CC       Name=4; Synonyms=BI-1(V1)-GGCAG;
CC         IsoId=O00555-4; Sequence=VSP_000871;
CC       Name=5; Synonyms=BI-1(V2);
CC         IsoId=O00555-5; Sequence=VSP_000872, VSP_000875;
CC       Name=6; Synonyms=BI-1(V2)-GGCAG;
CC         IsoId=O00555-6; Sequence=VSP_000872;
CC       Name=8;
CC         IsoId=O00555-8; Sequence=VSP_046165, VSP_046166;
CC   -!- TISSUE SPECIFICITY: Brain specific; mainly found in cerebellum,
CC       cerebral cortex, thalamus and hypothalamus. Expressed in the small
CC       cell lung carcinoma cell line SCC-9. No expression in heart,
CC       kidney, liver or muscle. Purkinje cells contain predominantly P-
CC       type VSCC, the Q-type being a prominent calcium current in
CC       cerebellar granule cells. {ECO:0000269|PubMed:1335101}.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- POLYMORPHISM: The poly-Gln region of CACNA1A is polymorphic: 6 to
CC       17 repeats in the normal population, expanded to about 21 to 30
CC       repeats in SCA6. Repeat expansion has been reported also in a EA2
CC       family. {ECO:0000269|PubMed:9302278}.
CC   -!- DISEASE: Spinocerebellar ataxia 6 (SCA6) [MIM:183086]:
CC       Spinocerebellar ataxia is a clinically and genetically
CC       heterogeneous group of cerebellar disorders. Patients show
CC       progressive incoordination of gait and often poor coordination of
CC       hands, speech and eye movements, due to degeneration of the
CC       cerebellum with variable involvement of the brainstem and spinal
CC       cord. SCA6 is an autosomal dominant cerebellar ataxia (ADCA),
CC       mainly caused by expansion of a CAG repeat in the coding region of
CC       CACNA1A. There seems to be a correlation between the repeat number
CC       and earlier onset of the disorder. {ECO:0000269|PubMed:16325861,
CC       ECO:0000269|PubMed:20682717, ECO:0000269|PubMed:8988170,
CC       ECO:0000269|PubMed:9302278, ECO:0000269|PubMed:9345107}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Migraine, familial hemiplegic, 1 (FHM1) [MIM:141500]: A
CC       subtype of migraine with aura associated with ictal hemiparesis
CC       and, in some families, cerebellar ataxia and atrophy. Migraine is
CC       a disabling symptom complex of periodic headaches, usually
CC       temporal and unilateral. Headaches are often accompanied by
CC       irritability, nausea, vomiting and photophobia, preceded by
CC       constriction of the cranial arteries. Migraine with aura is
CC       characterized by recurrent attacks of reversible neurological
CC       symptoms (aura) that precede or accompany the headache. Aura may
CC       include a combination of sensory disturbances, such as blurred
CC       vision, hallucinations, vertigo, numbness and difficulty in
CC       concentrating and speaking. {ECO:0000269|PubMed:10408532,
CC       ECO:0000269|PubMed:11409427, ECO:0000269|PubMed:11439943,
CC       ECO:0000269|PubMed:15032980, ECO:0000269|PubMed:18400034,
CC       ECO:0000269|PubMed:24836863, ECO:0000269|PubMed:26716990,
CC       ECO:0000269|PubMed:8898206}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Episodic ataxia 2 (EA2) [MIM:108500]: An autosomal
CC       dominant disorder characterized by acetozolamide-responsive
CC       attacks of ataxia, migraine-like symptoms, interictal nystagmus,
CC       and cerebellar atrophy. {ECO:0000269|PubMed:10987655,
CC       ECO:0000269|PubMed:11176968, ECO:0000269|PubMed:11723274,
CC       ECO:0000269|PubMed:12420090, ECO:0000269|PubMed:14718690,
CC       ECO:0000269|PubMed:15173248, ECO:0000269|PubMed:15293273,
CC       ECO:0000269|PubMed:18602318, ECO:0000269|PubMed:19232643,
CC       ECO:0000269|PubMed:20129625, ECO:0000269|PubMed:21696515,
CC       ECO:0000269|PubMed:8898206, ECO:0000269|PubMed:9302278}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 42 (EIEE42)
CC       [MIM:617106]: A form of epileptic encephalopathy, a heterogeneous
CC       group of severe childhood onset epilepsies characterized by
CC       refractory seizures, neurodevelopmental impairment, and poor
CC       prognosis. Development is normal prior to seizure onset, after
CC       which cognitive and motor delays become apparent. EIEE42
CC       inheritance is autosomal dominant. {ECO:0000269|PubMed:27250579,
CC       ECO:0000269|PubMed:27476654}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1A subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB49678.1; Type=Miscellaneous discrepancy; Note=Aberrant splicing.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Calcium channel, voltage-dependent, P/Q type,
CC       alpha 1A subunit (CACNA1A); Note=Leiden Open Variation Database
CC       (LOVD);
CC       URL="http://chromium.liacs.nl/LOVD2/home.php?select_db=CACNA1A";
CC   -!- WEB RESOURCE: Name=Familial hemiplegic migraine (FHM) variation
CC       database, calcium channel, voltage-dependent, P/Q type, alpha 1A
CC       subunit (CACNA1A); Note=Leiden Open Variation Database (LOVD);
CC       URL="http://grenada.lumc.nl/LOVD2/FHM/home.php?select_db=CACNA1A";
CC   -!- WEB RESOURCE: Name=Undiagnosed Disease Network; Note=CACNA1A;
CC       URL="https://undiagnosed.hms.harvard.edu/updates/genes-of-interest/cacna1a-gene/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF004883; AAB61612.1; -; mRNA.
DR   EMBL; AF004884; AAB61613.1; -; mRNA.
DR   EMBL; X99897; CAA68172.1; -; mRNA.
DR   EMBL; Z80114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z80115; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U79663; AAB49674.1; -; mRNA.
DR   EMBL; U79664; AAB49675.1; -; mRNA.
DR   EMBL; U79665; AAB49676.1; -; mRNA.
DR   EMBL; U79666; AAB64179.1; -; mRNA.
DR   EMBL; U79667; AAB49677.1; -; mRNA.
DR   EMBL; U79668; AAB49678.1; ALT_SEQ; mRNA.
DR   EMBL; AB035727; BAA94766.2; -; mRNA.
DR   EMBL; AC005305; AAC26839.1; -; Genomic_DNA.
DR   EMBL; AC005513; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC008540; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011446; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022436; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026805; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093062; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC098781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC124224; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S76537; AAB33068.1; -; mRNA.
DR   EMBL; U06702; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS45998.1; -. [O00555-8]
DR   CCDS; CCDS45999.1; -. [O00555-3]
DR   RefSeq; NP_000059.3; NM_000068.3.
DR   RefSeq; NP_001120693.1; NM_001127221.1. [O00555-3]
DR   RefSeq; NP_001120694.1; NM_001127222.1. [O00555-8]
DR   RefSeq; NP_001167551.1; NM_001174080.1.
DR   RefSeq; NP_075461.2; NM_023035.2.
DR   UniGene; Hs.501632; -.
DR   PDB; 3BXK; X-ray; 2.55 A; B/D=1955-1975.
DR   PDBsum; 3BXK; -.
DR   ProteinModelPortal; O00555; -.
DR   SMR; O00555; -.
DR   BioGrid; 107227; 98.
DR   IntAct; O00555; 92.
DR   STRING; 9606.ENSP00000353362; -.
DR   BindingDB; O00555; -.
DR   ChEMBL; CHEMBL4266; -.
DR   DrugBank; DB01244; Bepridil.
DR   DrugBank; DB00836; Loperamide.
DR   DrugBank; DB00230; Pregabalin.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00661; Verapamil.
DR   TCDB; 1.A.1.11.27; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; O00555; -.
DR   PhosphoSitePlus; O00555; -.
DR   BioMuta; CACNA1A; -.
DR   MaxQB; O00555; -.
DR   PaxDb; O00555; -.
DR   PeptideAtlas; O00555; -.
DR   PRIDE; O00555; -.
DR   DNASU; 773; -.
DR   Ensembl; ENST00000360228; ENSP00000353362; ENSG00000141837. [O00555-8]
DR   Ensembl; ENST00000635895; ENSP00000490323; ENSG00000141837. [O00555-2]
DR   Ensembl; ENST00000637276; ENSP00000489777; ENSG00000141837. [O00555-5]
DR   Ensembl; ENST00000638009; ENSP00000489913; ENSG00000141837. [O00555-3]
DR   GeneID; 773; -.
DR   KEGG; hsa:773; -.
DR   UCSC; uc002mwy.5; human. [O00555-1]
DR   CTD; 773; -.
DR   DisGeNET; 773; -.
DR   GeneCards; CACNA1A; -.
DR   GeneReviews; CACNA1A; -.
DR   HGNC; HGNC:1388; CACNA1A.
DR   HPA; HPA064258; -.
DR   MalaCards; CACNA1A; -.
DR   MIM; 108500; phenotype.
DR   MIM; 141500; phenotype.
DR   MIM; 183086; phenotype.
DR   MIM; 601011; gene.
DR   MIM; 617106; phenotype.
DR   neXtProt; NX_O00555; -.
DR   OpenTargets; ENSG00000141837; -.
DR   Orphanet; 2131; Alternating hemiplegia of childhood.
DR   Orphanet; 71518; Benign paroxysmal torticollis of infancy.
DR   Orphanet; 569; Familial or sporadic hemiplegic migraine.
DR   Orphanet; 97; Familial paroxysmal ataxia.
DR   Orphanet; 98758; Spinocerebellar ataxia type 6.
DR   PharmGKB; PA26007; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128247; -.
DR   HOGENOM; HOG000231530; -.
DR   HOVERGEN; HBG050763; -.
DR   InParanoid; O00555; -.
DR   KO; K04344; -.
DR   PhylomeDB; O00555; -.
DR   TreeFam; TF312805; -.
DR   Reactome; R-HSA-112308; Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   ChiTaRS; CACNA1A; human.
DR   EvolutionaryTrace; O00555; -.
DR   GeneWiki; Cav2.1; -.
DR   GenomeRNAi; 773; -.
DR   PRO; PR:O00555; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000141837; -.
DR   ExpressionAtlas; O00555; baseline and differential.
DR   Genevisible; O00555; HS.
DR   GO; GO:0042995; C:cell projection; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IEA:Ensembl.
DR   GO; GO:0005262; F:calcium channel activity; TAS:Reactome.
DR   GO; GO:0008331; F:high voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019905; F:syntaxin binding; IDA:UniProtKB.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0048791; P:calcium ion-regulated exocytosis of neurotransmitter; IEA:Ensembl.
DR   GO; GO:0008219; P:cell death; IDA:UniProtKB.
DR   GO; GO:0016049; P:cell growth; IEA:Ensembl.
DR   GO; GO:0030644; P:cellular chloride ion homeostasis; IEA:Ensembl.
DR   GO; GO:0021679; P:cerebellar molecular layer development; IEA:Ensembl.
DR   GO; GO:0021702; P:cerebellar Purkinje cell differentiation; IEA:Ensembl.
DR   GO; GO:0021590; P:cerebellum maturation; IEA:Ensembl.
DR   GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0014051; P:gamma-aminobutyric acid secretion; IEA:Ensembl.
DR   GO; GO:0007214; P:gamma-aminobutyric acid signaling pathway; IEA:Ensembl.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl.
DR   GO; GO:0051899; P:membrane depolarization; TAS:Reactome.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0050883; P:musculoskeletal movement, spinal reflex action; IEA:Ensembl.
DR   GO; GO:0032353; P:negative regulation of hormone biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0007274; P:neuromuscular synaptic transmission; IEA:Ensembl.
DR   GO; GO:0042133; P:neurotransmitter metabolic process; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0043113; P:receptor clustering; IEA:Ensembl.
DR   GO; GO:0014056; P:regulation of acetylcholine secretion, neurotransmission; IEA:Ensembl.
DR   GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0017158; P:regulation of calcium ion-dependent exocytosis; IEA:Ensembl.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0060024; P:rhythmic synaptic transmission; IEA:Ensembl.
DR   GO; GO:0021522; P:spinal cord motor neuron differentiation; IEA:Ensembl.
DR   GO; GO:0000096; P:sulfur amino acid metabolic process; IEA:Ensembl.
DR   GO; GO:0007416; P:synapse assembly; IEA:Ensembl.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0019226; P:transmission of nerve impulse; IEA:Ensembl.
DR   GO; GO:0021750; P:vestibular nucleus development; IEA:Ensembl.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR005448; CACNA1A.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR031649; GPHH_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR014873; VDCC_a1su_IQ.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   Pfam; PF08763; Ca_chan_IQ; 1.
DR   Pfam; PF16905; GPHH; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01632; PQVDCCALPHA1.
DR   SMART; SM01062; Ca_chan_IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calcium channel;
KW   Calcium transport; Cell membrane; Complete proteome; Disease mutation;
KW   Disulfide bond; Epilepsy; Glycoprotein; Ion channel; Ion transport;
KW   Membrane; Metal-binding; Neurodegeneration; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Spinocerebellar ataxia;
KW   Transmembrane; Transmembrane helix; Transport;
KW   Triplet repeat expansion; Voltage-gated channel.
FT   CHAIN         1   2505       Voltage-dependent P/Q-type calcium
FT                                channel subunit alpha-1A.
FT                                /FTId=PRO_0000053916.
FT   TOPO_DOM      1     98       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     99    117       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    118    135       Extracellular. {ECO:0000255}.
FT   TRANSMEM    136    155       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    156    167       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    168    185       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    186    190       Extracellular. {ECO:0000255}.
FT   TRANSMEM    191    209       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    210    228       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    229    248       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    249    335       Extracellular. {ECO:0000255}.
FT   TRANSMEM    336    360       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    361    487       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    488    506       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    507    521       Extracellular. {ECO:0000255}.
FT   TRANSMEM    522    541       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    542    549       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    550    568       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    569    578       Extracellular. {ECO:0000255}.
FT   TRANSMEM    579    597       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    598    616       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    617    636       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    637    689       Extracellular. {ECO:0000255}.
FT   TRANSMEM    690    714       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    715   1242       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1243   1261       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1262   1277       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1278   1297       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1298   1309       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1310   1328       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1329   1339       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1340   1358       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1359   1377       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1378   1397       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1398   1484       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1485   1509       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1510   1564       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1565   1593       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1594   1598       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1599   1618       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1619   1626       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1627   1645       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1646   1652       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1653   1671       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1672   1690       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1691   1710       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1711   1782       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1783   1807       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1808   2505       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       85    363       I.
FT   REPEAT      473    717       II.
FT   REPEAT     1231   1514       III.
FT   REPEAT     1551   1814       IV.
FT   CA_BIND    1840   1851       {ECO:0000250}.
FT   REGION      383    400       Binding to the beta subunit.
FT                                {ECO:0000250}.
FT   COMPBIAS     13     18       Poly-Gly.
FT   COMPBIAS    727    732       Poly-Glu.
FT   COMPBIAS   1002   1007       Poly-Arg.
FT   COMPBIAS   1204   1207       Poly-Glu.
FT   COMPBIAS   2211   2220       Poly-His.
FT   COMPBIAS   2221   2224       Poly-Pro.
FT   COMPBIAS   2314   2324       Poly-Gln.
FT   SITE        318    318       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        668    668       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1460   1460       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1649   1649       Binds to omega-Aga-IVA. {ECO:0000250}.
FT   SITE       1756   1756       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES     409    409       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES     448    448       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES     451    451       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES     750    750       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES     753    753       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES     790    790       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES    1085   1085       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES    1094   1094       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES    1822   1822       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES    1984   1984       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES    2047   2047       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P54282}.
FT   MOD_RES    2065   2065       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES    2077   2077       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P54282}.
FT   MOD_RES    2079   2079       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P54282}.
FT   MOD_RES    2120   2120       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97445}.
FT   MOD_RES    2140   2140       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P54282}.
FT   CARBOHYD    283    283       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     419    419       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:10753886}.
FT                                /FTId=VSP_046165.
FT   VAR_SEQ    1844   1875       WGRMPYLDMYQMLRHMSPPLGLGKKCPARVAY -> CGRIH
FT                                YKDMYSLLRVISPPLGLGKKCPHRVAC (in isoform 3
FT                                and isoform 4).
FT                                {ECO:0000303|PubMed:8898206,
FT                                ECO:0000303|PubMed:8988170}.
FT                                /FTId=VSP_000871.
FT   VAR_SEQ    2103   2114       Missing (in isoform 5 and isoform 6).
FT                                {ECO:0000303|PubMed:8988170}.
FT                                /FTId=VSP_000872.
FT   VAR_SEQ    2262   2505       Missing (in isoform 2, isoform 3 and
FT                                isoform 5). {ECO:0000303|PubMed:10049321,
FT                                ECO:0000303|PubMed:8898206,
FT                                ECO:0000303|PubMed:8988170}.
FT                                /FTId=VSP_000875.
FT   VAR_SEQ    2314   2314       Q -> QQQ (in isoform 8).
FT                                {ECO:0000303|PubMed:10753886}.
FT                                /FTId=VSP_046166.
FT   VARIANT      21     21       A -> V (in dbSNP:rs15999).
FT                                /FTId=VAR_014456.
FT   VARIANT     101    101       E -> Q (in EIEE42).
FT                                {ECO:0000269|PubMed:27476654}.
FT                                /FTId=VAR_077071.
FT   VARIANT     192    192       R -> Q (in FHM1; dbSNP:rs121908211).
FT                                {ECO:0000269|PubMed:8898206}.
FT                                /FTId=VAR_001491.
FT   VARIANT     195    195       R -> K (in FHM1; dbSNP:rs121908222).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_043820.
FT   VARIANT     218    218       S -> L (in FHM1; dbSNP:rs121908225).
FT                                {ECO:0000269|PubMed:11409427}.
FT                                /FTId=VAR_043821.
FT   VARIANT     248    248       Y -> C (in EA2; dbSNP:rs121908238).
FT                                {ECO:0000269|PubMed:18602318}.
FT                                /FTId=VAR_063683.
FT   VARIANT     253    253       H -> Y (in EA2; dbSNP:rs121908228).
FT                                {ECO:0000269|PubMed:12420090}.
FT                                /FTId=VAR_043822.
FT   VARIANT     256    256       C -> R (in EA2; dbSNP:rs121908231).
FT                                {ECO:0000269|PubMed:15173248}.
FT                                /FTId=VAR_043823.
FT   VARIANT     287    287       C -> Y (in EA2; dbSNP:rs121908236).
FT                                {ECO:0000269|PubMed:14718690}.
FT                                /FTId=VAR_043824.
FT   VARIANT     293    293       G -> R (in EA2 and SCA6;
FT                                dbSNP:rs121908215).
FT                                {ECO:0000269|PubMed:14718690,
FT                                ECO:0000269|PubMed:9345107}.
FT                                /FTId=VAR_043825.
FT   VARIANT     388    388       E -> K (in EA2).
FT                                {ECO:0000269|PubMed:21696515}.
FT                                /FTId=VAR_067342.
FT   VARIANT     389    389       L -> F (in EA2; dbSNP:rs121908239).
FT                                {ECO:0000269|PubMed:20129625}.
FT                                /FTId=VAR_063684.
FT   VARIANT     405    405       A -> T (in SCA6; dbSNP:rs121908245).
FT                                {ECO:0000269|PubMed:20682717}.
FT                                /FTId=VAR_063685.
FT   VARIANT     454    454       A -> T (in dbSNP:rs41276886).
FT                                {ECO:0000269|PubMed:8898206}.
FT                                /FTId=VAR_063686.
FT   VARIANT     501    501       T -> M (in EA2; dbSNP:rs121908240).
FT                                {ECO:0000269|PubMed:20129625}.
FT                                /FTId=VAR_063687.
FT   VARIANT     583    583       R -> Q (in FHM1; dbSNP:rs121908217).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_043826.
FT   VARIANT     638    638       G -> D (in EA2; reduces P/Q current
FT                                densities; dbSNP:rs121908246).
FT                                {ECO:0000269|PubMed:19232643}.
FT                                /FTId=VAR_063688.
FT   VARIANT     666    666       T -> M (in FHM1 and EA2;
FT                                dbSNP:rs121908212).
FT                                {ECO:0000269|PubMed:11439943,
FT                                ECO:0000269|PubMed:14718690,
FT                                ECO:0000269|PubMed:8898206}.
FT                                /FTId=VAR_001492.
FT   VARIANT     713    713       A -> T (in EIEE42).
FT                                {ECO:0000269|PubMed:27476654}.
FT                                /FTId=VAR_077072.
FT   VARIANT     714    714       V -> A (in FHM1; dbSNP:rs121908213).
FT                                {ECO:0000269|PubMed:8898206}.
FT                                /FTId=VAR_001493.
FT   VARIANT     715    715       D -> E (in FHM1; dbSNP:rs121908218).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_043827.
FT   VARIANT     732    732       E -> A (in dbSNP:rs16019).
FT                                /FTId=VAR_059221.
FT   VARIANT     798    798       M -> T (in EA2; dbSNP:rs121908241).
FT                                {ECO:0000269|PubMed:20129625}.
FT                                /FTId=VAR_063689.
FT   VARIANT     897    897       P -> R (in EA2; dbSNP:rs121908242).
FT                                {ECO:0000269|PubMed:20129625}.
FT                                /FTId=VAR_063690.
FT   VARIANT     914    914       P -> S (in dbSNP:rs16020).
FT                                /FTId=VAR_014458.
FT   VARIANT     918    918       E -> D (in dbSNP:rs16022).
FT                                {ECO:0000269|PubMed:16866717,
FT                                ECO:0000269|PubMed:19429006}.
FT                                /FTId=VAR_014459.
FT   VARIANT     993    993       E -> V (in dbSNP:rs16023).
FT                                {ECO:0000269|PubMed:10408532,
FT                                ECO:0000269|PubMed:16866717,
FT                                ECO:0000269|PubMed:19429006}.
FT                                /FTId=VAR_043828.
FT   VARIANT    1015   1015       E -> K (in dbSNP:rs16024).
FT                                /FTId=VAR_014461.
FT   VARIANT    1105   1105       G -> S (in dbSNP:rs16027).
FT                                {ECO:0000269|PubMed:10753886,
FT                                ECO:0000269|PubMed:16866717}.
FT                                /FTId=VAR_014462.
FT   VARIANT    1173   1173       P -> L (in dbSNP:rs16028).
FT                                /FTId=VAR_059222.
FT   VARIANT    1335   1335       K -> E (in FHM1; dbSNP:rs121908223).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_043829.
FT   VARIANT    1346   1346       R -> Q (in FHM1; with progressive
FT                                cerebellar ataxia; dbSNP:rs121908230).
FT                                {ECO:0000269|PubMed:15032980,
FT                                ECO:0000269|PubMed:18400034}.
FT                                /FTId=VAR_043830.
FT   VARIANT    1384   1384       Y -> C (in FHM1; dbSNP:rs121908219).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_043831.
FT   VARIANT    1403   1403       F -> C (in EA2; loss of function;
FT                                dbSNP:rs121908227).
FT                                {ECO:0000269|PubMed:11723274}.
FT                                /FTId=VAR_043832.
FT   VARIANT    1436   1436       W -> R (in EIEE42).
FT                                {ECO:0000269|PubMed:27250579}.
FT                                /FTId=VAR_077073.
FT   VARIANT    1456   1456       V -> L (in FHM1; dbSNP:rs121908237).
FT                                {ECO:0000269|PubMed:10408532}.
FT                                /FTId=VAR_043833.
FT   VARIANT    1482   1482       G -> R (in EA2; dbSNP:rs121908232).
FT                                {ECO:0000269|PubMed:15173248}.
FT                                /FTId=VAR_043834.
FT   VARIANT    1490   1490       F -> S (in EA2; dbSNP:rs121908233).
FT                                {ECO:0000269|PubMed:15173248}.
FT                                /FTId=VAR_043835.
FT   VARIANT    1493   1493       V -> I (in EA2; dbSNP:rs121908234).
FT                                {ECO:0000269|PubMed:15173248}.
FT                                /FTId=VAR_043836.
FT   VARIANT    1502   1502       Missing (in FHM1; increased high voltage-
FT                                gated calcium channel activity).
FT                                {ECO:0000269|PubMed:24836863,
FT                                ECO:0000269|PubMed:26716990}.
FT                                /FTId=VAR_077074.
FT   VARIANT    1508   1508       A -> S (in EIEE42).
FT                                {ECO:0000269|PubMed:27476654}.
FT                                /FTId=VAR_077075.
FT   VARIANT    1661   1661       R -> H (in EA2; dbSNP:rs121908216).
FT                                {ECO:0000269|PubMed:10987655}.
FT                                /FTId=VAR_043837.
FT   VARIANT    1664   1664       R -> Q (in SCA6; dbSNP:rs121908247).
FT                                {ECO:0000269|PubMed:16325861}.
FT                                /FTId=VAR_063691.
FT   VARIANT    1667   1667       R -> W (in FHM1; dbSNP:rs121908220).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_043838.
FT   VARIANT    1679   1679       R -> C (in EA2; dbSNP:rs121908243).
FT                                {ECO:0000269|PubMed:20129625}.
FT                                /FTId=VAR_063692.
FT   VARIANT    1683   1683       W -> R (in FHM1; dbSNP:rs121908221).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_043839.
FT   VARIANT    1695   1695       V -> I (in FHM1; dbSNP:rs121908224).
FT                                {ECO:0000269|PubMed:11439943}.
FT                                /FTId=VAR_063706.
FT   VARIANT    1736   1736       H -> L (in EA2; changed high voltage-
FT                                gated calcium channel activity;
FT                                dbSNP:rs121908229).
FT                                {ECO:0000269|PubMed:15293273}.
FT                                /FTId=VAR_043840.
FT   VARIANT    1756   1756       E -> K (in EA2; dbSNP:rs121908226).
FT                                {ECO:0000269|PubMed:11176968}.
FT                                /FTId=VAR_043841.
FT   VARIANT    1810   1810       I -> L (in FHM1; dbSNP:rs121908214).
FT                                {ECO:0000269|PubMed:8898206}.
FT                                /FTId=VAR_001494.
FT   VARIANT    1869   1869       C -> R (in EA2; dbSNP:rs121908244).
FT                                {ECO:0000269|PubMed:20129625}.
FT                                /FTId=VAR_063693.
FT   VARIANT    2135   2135       R -> C (in EA2; dbSNP:rs121908235).
FT                                {ECO:0000269|PubMed:15173248}.
FT                                /FTId=VAR_043842.
FT   VARIANT    2394   2394       P -> S (in dbSNP:rs16056).
FT                                /FTId=VAR_014463.
FT   CONFLICT    725    725       K -> KVEA (in Ref. 1; AAB61613/AAB61612).
FT                                {ECO:0000305}.
FT   CONFLICT    896    896       G -> D (in Ref. 2; CAA68172 and 4;
FT                                BAA94766). {ECO:0000305}.
FT   CONFLICT    953    953       D -> N (in Ref. 4; BAA94766).
FT                                {ECO:0000305}.
FT   CONFLICT    964    964       R -> S (in Ref. 4; BAA94766).
FT                                {ECO:0000305}.
FT   CONFLICT   1207   1207       E -> EE (in Ref. 2; CAA68172).
FT                                {ECO:0000305}.
FT   CONFLICT   1313   1315       WNI -> ILP (in Ref. 3; AAB49674/AAB49675/
FT                                AAB49676/AAB49677/AAB49678).
FT                                {ECO:0000305}.
FT   CONFLICT   1459   1459       G -> A (in Ref. 2; CAA68172).
FT                                {ECO:0000305}.
FT   CONFLICT   1604   1604       V -> A (in Ref. 2; CAA68172).
FT                                {ECO:0000305}.
FT   CONFLICT   1617   1617       V -> A (in Ref. 2; CAA68172).
FT                                {ECO:0000305}.
FT   CONFLICT   1651   1651       G -> GNP (in Ref. 1; AAB61613/AAB61612).
FT                                {ECO:0000305}.
FT   CONFLICT   1693   1693       P -> A (in Ref. 6; AAB33068).
FT                                {ECO:0000305}.
FT   CONFLICT   2038   2038       E -> G (in Ref. 8; U06702).
FT                                {ECO:0000305}.
FT   CONFLICT   2314   2314       Q -> QQ (in Ref. 3; AAB49676).
FT                                {ECO:0000305}.
FT   HELIX      1956   1970       {ECO:0000244|PDB:3BXK}.
SQ   SEQUENCE   2505 AA;  282365 MW;  2F2F378ACE02FD56 CRC64;
     MARFGDEMPA RYGGGGSGAA AGVVVGSGGG RGAGGSRQGG QPGAQRMYKQ SMAQRARTMA
     LYNPIPVRQN CLTVNRSLFL FSEDNVVRKY AKKITEWPPF EYMILATIIA NCIVLALEQH
     LPDDDKTPMS ERLDDTEPYF IGIFCFEAGI KIIALGFAFH KGSYLRNGWN VMDFVVVLTG
     ILATVGTEFD LRTLRAVRVL RPLKLVSGIP SLQVVLKSIM KAMIPLLQIG LLLFFAILIF
     AIIGLEFYMG KFHTTCFEEG TDDIQGESPA PCGTEEPART CPNGTKCQPY WEGPNNGITQ
     FDNILFAVLT VFQCITMEGW TDLLYNSNDA SGNTWNWLYF IPLIIIGSFF MLNLVLGVLS
     GEFAKERERV ENRRAFLKLR RQQQIERELN GYMEWISKAE EVILAEDETD GEQRHPFDGA
     LRRTTIKKSK TDLLNPEEAE DQLADIASVG SPFARASIKS AKLENSTFFH KKERRMRFYI
     RRMVKTQAFY WTVLSLVALN TLCVAIVHYN QPEWLSDFLY YAEFIFLGLF MSEMFIKMYG
     LGTRPYFHSS FNCFDCGVII GSIFEVIWAV IKPGTSFGIS VLRALRLLRI FKVTKYWASL
     RNLVVSLLNS MKSIISLLFL LFLFIVVFAL LGMQLFGGQF NFDEGTPPTN FDTFPAAIMT
     VFQILTGEDW NEVMYDGIKS QGGVQGGMVF SIYFIVLTLF GNYTLLNVFL AIAVDNLANA
     QELTKDEQEE EEAANQKLAL QKAKEVAEVS PLSAANMSIA VKEQQKNQKP AKSVWEQRTS
     EMRKQNLLAS REALYNEMDP DERWKAAYTR HLRPDMKTHL DRPLVVDPQE NRNNNTNKSR
     AAEPTVDQRL GQQRAEDFLR KQARYHDRAR DPSGSAGLDA RRPWAGSQEA ELSREGPYGR
     ESDHHAREGS LEQPGFWEGE AERGKAGDPH RRHVHRQGGS RESRSGSPRT GADGEHRRHR
     AHRRPGEEGP EDKAERRARH REGSRPARGG EGEGEGPDGG ERRRRHRHGA PATYEGDARR
     EDKERRHRRR KENQGSGVPV SGPNLSTTRP IQQDLGRQDP PLAEDIDNMK NNKLATAESA
     APHGSLGHAG LPQSPAKMGN STDPGPMLAI PAMATNPQNA ASRRTPNNPG NPSNPGPPKT
     PENSLIVTNP SGTQTNSAKT ARKPDHTTVD IPPACPPPLN HTVVQVNKNA NPDPLPKKEE
     EKKEEEEDDR GEDGPKPMPP YSSMFILSTT NPLRRLCHYI LNLRYFEMCI LMVIAMSSIA
     LAAEDPVQPN APRNNVLRYF DYVFTGVFTF EMVIKMIDLG LVLHQGAYFR DLWNILDFIV
     VSGALVAFAF TGNSKGKDIN TIKSLRVLRV LRPLKTIKRL PKLKAVFDCV VNSLKNVFNI
     LIVYMLFMFI FAVVAVQLFK GKFFHCTDES KEFEKDCRGK YLLYEKNEVK ARDREWKKYE
     FHYDNVLWAL LTLFTVSTGE GWPQVLKHSV DATFENQGPS PGYRMEMSIF YVVYFVVFPF
     FFVNIFVALI IITFQEQGDK MMEEYSLEKN ERACIDFAIS AKPLTRHMPQ NKQSFQYRMW
     QFVVSPPFEY TIMAMIALNT IVLMMKFYGA SVAYENALRV FNIVFTSLFS LECVLKVMAF
     GILNYFRDAW NIFDFVTVLG SITDILVTEF GNNFINLSFL RLFRAARLIK LLRQGYTIRI
     LLWTFVQSFK ALPYVCLLIA MLFFIYAIIG MQVFGNIGID VEDEDSDEDE FQITEHNNFR
     TFFQALMLLF RSATGEAWHN IMLSCLSGKP CDKNSGILTR ECGNEFAYFY FVSFIFLCSF
     LMLNLFVAVI MDNFEYLTRD SSILGPHHLD EYVRVWAEYD PAAWGRMPYL DMYQMLRHMS
     PPLGLGKKCP ARVAYKRLLR MDLPVADDNT VHFNSTLMAL IRTALDIKIA KGGADKQQMD
     AELRKEMMAI WPNLSQKTLD LLVTPHKSTD LTVGKIYAAM MIMEYYRQSK AKKLQAMREE
     QDRTPLMFQR MEPPSPTQEG GPGQNALPST QLDPGGALMA HESGLKESPS WVTQRAQEMF
     QKTGTWSPEQ GPPTDMPNSQ PNSQSVEMRE MGRDGYSDSE HYLPMEGQGR AASMPRLPAE
     NQRRRGRPRG NNLSTISDTS PMKRSASVLG PKARRLDDYS LERVPPEENQ RHHQRRRDRS
     HRASERSLGR YTDVDTGLGT DLSMTTQSGD LPSKERDQER GRPKDRKHRQ HHHHHHHHHH
     PPPPDKDRYA QERPDHGRAR ARDQRWSRSP SEGREHMAHR QGSSSVSGSP APSTSGTSTP
     RRGRRQLPQT PSTPRPHVSY SPVIRKAGGS GPPQQQQQQQ QQQQAVARPG RAATSGPRRY
     PGPTAEPLAG DRPPTGGHSS GRSPRMERRV PGPARSESPR ACRHGGARWP ASGPHVSEGP
     PGPRHHGYYR GSDYDEADGP GSGGGEEAMA GAYDAPPPVR HASSGATGRS PRTPRASGPA
     CASPSRHGRR LPNGYYPAHG LARPRGPGSR KGLHEPYSES DDDWC
//
ID   CAC1B_HUMAN             Reviewed;        2339 AA.
AC   Q00975; B1AQK5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   15-FEB-2017, entry version 164.
DE   RecName: Full=Voltage-dependent N-type calcium channel subunit alpha-1B;
DE   AltName: Full=Brain calcium channel III;
DE            Short=BIII;
DE   AltName: Full=Calcium channel, L type, alpha-1 polypeptide isoform 5;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav2.2;
GN   Name=CACNA1B; Synonyms=CACH5, CACNL1A5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA-1B-1 AND ALPHA-1B-2).
RC   TISSUE=Brain;
RX   PubMed=1321501; DOI=10.1126/science.1321501;
RA   Williams M.E., Brust P.F., Feldman D.H., Patthi S., Simerson S.,
RA   Maroufi A., McCue A.F., Velicelebi G., Ellis S.B., Harpold M.M.;
RT   "Structure and functional expression of an omega-conotoxin-sensitive
RT   human N-type calcium channel.";
RL   Science 257:389-395(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-94.
RC   TISSUE=Lung fibroblast;
RX   PubMed=9030575; DOI=10.1074/jbc.272.8.5098;
RA   Kim D.S., Jung H.-H., Park S.-H., Chin H.;
RT   "Isolation and characterization of the 5'-upstream region of the human
RT   N-type calcium channel alpha1B subunit gene. Chromosomal localization
RT   and promoter analysis.";
RL   J. Biol. Chem. 272:5098-5104(1997).
RN   [4]
RP   INVOLVEMENT IN DYT23, VARIANT DYT23 HIS-1389, AND CHARACTERIZATION OF
RP   VARIANT DYT23 HIS-1389.
RX   PubMed=25296916; DOI=10.1093/hmg/ddu513;
RA   Groen J.L., Andrade A., Ritz K., Jalalzadeh H., Haagmans M.,
RA   Bradley T.E., Jongejan A., Verbeek D.S., Nuernberg P., Denome S.,
RA   Hennekam R.C., Lipscombe D., Baas F., Tijssen M.A.;
RT   "CACNA1B mutation is linked to unique myoclonus-dystonia syndrome.";
RL   Hum. Mol. Genet. 24:987-993(2015).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1B
CC       gives rise to N-type calcium currents. N-type calcium channels
CC       belong to the 'high-voltage activated' (HVA) group and are blocked
CC       by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin-
CC       IIIA (omega-Aga-IIIA). They are however insensitive to
CC       dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA).
CC       Calcium channels containing alpha-1B subunit may play a role in
CC       directed migration of immature neurons.
CC   -!- SUBUNIT: Multisubunit complex consisting of alpha-1, alpha-2, beta
CC       and delta subunits in a 1:1:1:1 ratio. The channel activity is
CC       directed by the pore-forming and voltage-sensitive alpha-1
CC       subunit. In many cases, this subunit is sufficient to generate
CC       voltage-sensitive calcium channel activity. The auxiliary subunits
CC       beta and alpha-2/delta linked by a disulfide bridge regulate the
CC       channel activity. Interacts with RIMS1. Interacts with FMR1 (via
CC       C-terminus); this interaction induces a deacrease in the number of
CC       presynaptic functional CACNA1B channels at the cell surface.
CC       {ECO:0000250|UniProtKB:O55017}.
CC   -!- INTERACTION:
CC       P20650:Ppm1a (xeno); NbExp=3; IntAct=EBI-1055161, EBI-7491743;
CC       P28702:RXRB; NbExp=3; IntAct=EBI-1055161, EBI-748576;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha-1B-1;
CC         IsoId=Q00975-1; Sequence=Displayed;
CC       Name=Alpha-1B-2;
CC         IsoId=Q00975-2; Sequence=VSP_000882;
CC         Note=Ref.1 (AAA51898) sequence is in conflict in position:
CC         2215:L->R. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Isoform Alpha-1b-1 and isoform Alpha-1b-2 are
CC       expressed in the central nervous system, but not in skeletal
CC       muscle or aorta.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- PTM: Phosphorylated in vitro by CaM-kinase II, PKA, PKC and CGPK.
CC       {ECO:0000250}.
CC   -!- DISEASE: Dystonia 23 (DYT23) [MIM:614860]: A form of dystonia, a
CC       disorder defined by the presence of sustained involuntary muscle
CC       contraction, often leading to abnormal postures. DYT23 is an
CC       autosomal dominant dystonia affecting the face, neck, limbs. Some
CC       DYT23 patients manifest generalized myoclonus in addition to
CC       progressive action-induced multifocal dystonia.
CC       {ECO:0000269|PubMed:25296916}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1B subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M94172; AAA51897.1; -; mRNA.
DR   EMBL; M94173; AAA51898.1; -; mRNA.
DR   EMBL; AL591424; CAI40687.1; -; Genomic_DNA.
DR   EMBL; AL772363; CAI40687.1; JOINED; Genomic_DNA.
DR   EMBL; AL772363; CAI17144.1; -; Genomic_DNA.
DR   EMBL; AL591424; CAI17144.1; JOINED; Genomic_DNA.
DR   EMBL; U76666; AAC51138.1; -; Genomic_DNA.
DR   CCDS; CCDS59522.1; -. [Q00975-1]
DR   CCDS; CCDS59523.1; -. [Q00975-2]
DR   PIR; A42566; A42566.
DR   PIR; T45115; T45115.
DR   RefSeq; NP_000709.1; NM_000718.3. [Q00975-1]
DR   RefSeq; NP_001230741.1; NM_001243812.1. [Q00975-2]
DR   UniGene; Hs.495522; -.
DR   PDB; 2LCM; NMR; -; A=1242-1269.
DR   PDBsum; 2LCM; -.
DR   ProteinModelPortal; Q00975; -.
DR   SMR; Q00975; -.
DR   BioGrid; 107228; 7.
DR   IntAct; Q00975; 7.
DR   MINT; MINT-102376; -.
DR   STRING; 9606.ENSP00000360406; -.
DR   BindingDB; Q00975; -.
DR   ChEMBL; CHEMBL4478; -.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00996; Gabapentin.
DR   DrugBank; DB01202; Levetiracetam.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00661; Verapamil.
DR   GuidetoPHARMACOLOGY; 533; -.
DR   iPTMnet; Q00975; -.
DR   PhosphoSitePlus; Q00975; -.
DR   BioMuta; CACNA1B; -.
DR   DMDM; 1705854; -.
DR   EPD; Q00975; -.
DR   PaxDb; Q00975; -.
DR   PeptideAtlas; Q00975; -.
DR   PRIDE; Q00975; -.
DR   Ensembl; ENST00000277551; ENSP00000277551; ENSG00000148408. [Q00975-2]
DR   Ensembl; ENST00000371372; ENSP00000360423; ENSG00000148408. [Q00975-1]
DR   GeneID; 774; -.
DR   KEGG; hsa:774; -.
DR   UCSC; uc064xny.1; human. [Q00975-1]
DR   CTD; 774; -.
DR   DisGeNET; 774; -.
DR   GeneCards; CACNA1B; -.
DR   HGNC; HGNC:1389; CACNA1B.
DR   HPA; HPA044347; -.
DR   MalaCards; CACNA1B; -.
DR   MIM; 601012; gene.
DR   MIM; 614860; phenotype.
DR   neXtProt; NX_Q00975; -.
DR   OpenTargets; ENSG00000148408; -.
DR   PharmGKB; PA26008; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128247; -.
DR   HOGENOM; HOG000231530; -.
DR   HOVERGEN; HBG050763; -.
DR   InParanoid; Q00975; -.
DR   KO; K04849; -.
DR   PhylomeDB; Q00975; -.
DR   Reactome; R-HSA-112308; Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels.
DR   SIGNOR; Q00975; -.
DR   ChiTaRS; CACNA1B; human.
DR   GeneWiki; N-type_calcium_channel; -.
DR   GenomeRNAi; 774; -.
DR   PRO; PR:Q00975; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000148408; -.
DR   CleanEx; HS_CACNA1B; -.
DR   ExpressionAtlas; Q00975; baseline and differential.
DR   Genevisible; Q00975; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005262; F:calcium channel activity; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0008331; F:high voltage-gated calcium channel activity; IBA:GO_Central.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; TAS:ProtInc.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0051899; P:membrane depolarization; TAS:Reactome.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0007269; P:neurotransmitter secretion; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0008016; P:regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0048265; P:response to pain; IEA:Ensembl.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR031649; GPHH_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR014873; VDCC_a1su_IQ.
DR   InterPro; IPR005447; VDCC_N_a1su.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   Pfam; PF08763; Ca_chan_IQ; 1.
DR   Pfam; PF16905; GPHH; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01631; NVDCCALPHA1.
DR   SMART; SM01062; Ca_chan_IQ; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calcium;
KW   Calcium channel; Calcium transport; Complete proteome;
KW   Congenital generalized lipodystrophy; Disease mutation;
KW   Disulfide bond; Dystonia; Glycoprotein; Ion channel; Ion transport;
KW   Membrane; Mental retardation; Metal-binding; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1   2339       Voltage-dependent N-type calcium channel
FT                                subunit alpha-1B.
FT                                /FTId=PRO_0000053921.
FT   TOPO_DOM      1     95       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     96    114       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    115    132       Extracellular. {ECO:0000255}.
FT   TRANSMEM    133    152       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    153    163       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    164    183       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    184    187       Extracellular. {ECO:0000255}.
FT   TRANSMEM    188    206       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    207    225       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    226    245       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    246    331       Extracellular. {ECO:0000255}.
FT   TRANSMEM    332    356       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    357    482       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    483    501       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    502    516       Extracellular. {ECO:0000255}.
FT   TRANSMEM    517    536       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    537    544       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    545    562       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    563    573       Extracellular. {ECO:0000255}.
FT   TRANSMEM    574    592       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    593    611       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    612    631       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    632    684       Extracellular. {ECO:0000255}.
FT   TRANSMEM    685    709       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    710   1151       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1152   1169       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1170   1185       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1186   1205       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1206   1217       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1218   1236       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1237   1246       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1247   1265       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1266   1284       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1285   1304       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1305   1391       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1392   1416       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1417   1471       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1472   1490       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1491   1505       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1506   1525       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1526   1533       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1534   1552       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1553   1563       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1564   1582       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1583   1601       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1602   1621       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1622   1683       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1684   1708       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1709   2339       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       82    359       I.
FT   REPEAT      468    712       II.
FT   REPEAT     1137   1419       III.
FT   REPEAT     1456   1711       IV.
FT   DOMAIN     1724   1759       EF-hand. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   NP_BIND     451    458       ATP. {ECO:0000255}.
FT   CA_BIND    1737   1748       {ECO:0000255|PROSITE-ProRule:PRU00448}.
FT   REGION      379    396       Binding to the beta subunit.
FT                                {ECO:0000250}.
FT   COMPBIAS   2050   2054       Poly-His.
FT   COMPBIAS   2118   2122       Poly-Ser.
FT   SITE        314    314       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        663    663       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1365   1365       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1655   1655       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES      22     22       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES     411    411       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES     745    745       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES     748    748       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES     783    783       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES    1069   1069       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES    1719   1719       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES    2066   2066       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES    2224   2224       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES    2233   2233       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   MOD_RES    2256   2256       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O55017}.
FT   CARBOHYD    256    256       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1563   1563       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1675   1675       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ    2164   2339       GSGSVNGSPLLSTSGASTPGRGGRRQLPQTPLTPRPSITYK
FT                                TANSSPIHFAGAQTSLPAFSPGRLSRGLSEHNALLQRDPLS
FT                                QPLAPGSRIGSDPYLGQRLDSEASVHALPEDTLTFEEAVAT
FT                                NSGRSSRTSYVSSLTSQSHPLRRVPNGYHCTLGLSSGGRAR
FT                                HSYHHPDQDHWC -> AGSAVGFPNTTPCCRETPSASPWPL
FT                                ALELALTLTWGSVWTVRPLSTPCLRTLSLSRRLWPPTRAAP
FT                                PGLPTCPP (in isoform Alpha-1B-2).
FT                                {ECO:0000303|PubMed:1321501}.
FT                                /FTId=VSP_000882.
FT   VARIANT     167    167       N -> K (in dbSNP:rs4422842).
FT                                /FTId=VAR_048741.
FT   VARIANT     862    862       A -> S (in dbSNP:rs7873074).
FT                                /FTId=VAR_061100.
FT   VARIANT     996    996       T -> A (in dbSNP:rs11137342).
FT                                /FTId=VAR_061101.
FT   VARIANT    1389   1389       R -> H (in DYT23; gain of function
FT                                mutation; dbSNP:rs184841813).
FT                                {ECO:0000269|PubMed:25296916}.
FT                                /FTId=VAR_073432.
FT   VARIANT    1436   1436       E -> K (in dbSNP:rs12377346).
FT                                /FTId=VAR_048742.
FT   VARIANT    1500   1500       E -> K (in dbSNP:rs12377346).
FT                                /FTId=VAR_048743.
FT   HELIX      1244   1263       {ECO:0000244|PDB:2LCM}.
FT   TURN       1264   1266       {ECO:0000244|PDB:2LCM}.
SQ   SEQUENCE   2339 AA;  262496 MW;  17A45C6D1E76B39D CRC64;
     MVRFGDELGG RYGGPGGGER ARGGGAGGAG GPGPGGLQPG QRVLYKQSIA QRARTMALYN
     PIPVKQNCFT VNRSLFVFSE DNVVRKYAKR ITEWPPFEYM ILATIIANCI VLALEQHLPD
     GDKTPMSERL DDTEPYFIGI FCFEAGIKII ALGFVFHKGS YLRNGWNVMD FVVVLTGILA
     TAGTDFDLRT LRAVRVLRPL KLVSGIPSLQ VVLKSIMKAM VPLLQIGLLL FFAILMFAII
     GLEFYMGKFH KACFPNSTDA EPVGDFPCGK EAPARLCEGD TECREYWPGP NFGITNFDNI
     LFAILTVFQC ITMEGWTDIL YNTNDAAGNT WNWLYFIPLI IIGSFFMLNL VLGVLSGEFA
     KERERVENRR AFLKLRRQQQ IERELNGYLE WIFKAEEVML AEEDRNAEEK SPLDVLKRAA
     TKKSRNDLIH AEEGEDRFAD LCAVGSPFAR ASLKSGKTES SSYFRRKEKM FRFFIRRMVK
     AQSFYWVVLC VVALNTLCVA MVHYNQPRRL TTTLYFAEFV FLGLFLTEMS LKMYGLGPRS
     YFRSSFNCFD FGVIVGSVFE VVWAAIKPGS SFGISVLRAL RLLRIFKVTK YWSSLRNLVV
     SLLNSMKSII SLLFLLFLFI VVFALLGMQL FGGQFNFQDE TPTTNFDTFP AAILTVFQIL
     TGEDWNAVMY HGIESQGGVS KGMFSSFYFI VLTLFGNYTL LNVFLAIAVD NLANAQELTK
     DEEEMEEAAN QKLALQKAKE VAEVSPMSAA NISIAARQQN SAKARSVWEQ RASQLRLQNL
     RASCEALYSE MDPEERLRFA TTRHLRPDMK THLDRPLVVE LGRDGARGPV GGKARPEAAE
     APEGVDPPRR HHRHRDKDKT PAAGDQDRAE APKAESGEPG AREERPRPHR SHSKEAAGPP
     EARSERGRGP GPEGGRRHHR RGSPEEAAER EPRRHRAHRH QDPSKECAGA KGERRARHRG
     GPRAGPREAE SGEEPARRHR ARHKAQPAHE AVEKETTEKE ATEKEAEIVE ADKEKELRNH
     QPREPHCDLE TSGTVTVGPM HTLPSTCLQK VEEQPEDADN QRNVTRMGSQ PPDPNTIVHI
     PVMLTGPLGE ATVVPSGNVD LESQAEGKKE VEADDVMRSG PRPIVPYSSM FCLSPTNLLR
     RFCHYIVTMR YFEVVILVVI ALSSIALAAE DPVRTDSPRN NALKYLDYIF TGVFTFEMVI
     KMIDLGLLLH PGAYFRDLWN ILDFIVVSGA LVAFAFSGSK GKDINTIKSL RVLRVLRPLK
     TIKRLPKLKA VFDCVVNSLK NVLNILIVYM LFMFIFAVIA VQLFKGKFFY CTDESKELER
     DCRGQYLDYE KEEVEAQPRQ WKKYDFHYDN VLWALLTLFT VSTGEGWPMV LKHSVDATYE
     EQGPSPGYRM ELSIFYVVYF VVFPFFFVNI FVALIIITFQ EQGDKVMSEC SLEKNERACI
     DFAISAKPLT RYMPQNRQSF QYKTWTFVVS PPFEYFIMAM IALNTVVLMM KFYDAPYEYE
     LMLKCLNIVF TSMFSMECVL KIIAFGVLNY FRDAWNVFDF VTVLGSITDI LVTEIAETNN
     FINLSFLRLF RAARLIKLLR QGYTIRILLW TFVQSFKALP YVCLLIAMLF FIYAIIGMQV
     FGNIALDDDT SINRHNNFRT FLQALMLLFR SATGEAWHEI MLSCLSNQAC DEQANATECG
     SDFAYFYFVS FIFLCSFLML NLFVAVIMDN FEYLTRDSSI LGPHHLDEFI RVWAEYDPAA
     CGRISYNDMF EMLKHMSPPL GLGKKCPARV AYKRLVRMNM PISNEDMTVH FTSTLMALIR
     TALEIKLAPA GTKQHQCDAE LRKEISVVWA NLPQKTLDLL VPPHKPDEMT VGKVYAALMI
     FDFYKQNKTT RDQMQQAPGG LSQMGPVSLF HPLKATLEQT QPAVLRGARV FLRQKSSTSL
     SNGGAIQNQE SGIKESVSWG TQRTQDAPHE ARPPLERGHS TEIPVGRSGA LAVDVQMQSI
     TRRGPDGEPQ PGLESQGRAA SMPRLAAETQ PVTDASPMKR SISTLAQRPR GTHLCSTTPD
     RPPPSQASSH HHHHRCHRRR DRKQRSLEKG PSLSADMDGA PSSAVGPGLP PGEGPTGCRR
     ERERRQERGR SQERRQPSSS SSEKQRFYSC DRFGGREPPK PKPSLSSHPT SPTAGQEPGP
     HPQGSGSVNG SPLLSTSGAS TPGRGGRRQL PQTPLTPRPS ITYKTANSSP IHFAGAQTSL
     PAFSPGRLSR GLSEHNALLQ RDPLSQPLAP GSRIGSDPYL GQRLDSEASV HALPEDTLTF
     EEAVATNSGR SSRTSYVSSL TSQSHPLRRV PNGYHCTLGL SSGGRARHSY HHPDQDHWC
//
ID   CAC1E_HUMAN             Reviewed;        2313 AA.
AC   Q15878; B1AM12; B1AM13; B1AM14; Q14580; Q14581;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 3.
DT   15-FEB-2017, entry version 164.
DE   RecName: Full=Voltage-dependent R-type calcium channel subunit alpha-1E;
DE   AltName: Full=Brain calcium channel II;
DE            Short=BII;
DE   AltName: Full=Calcium channel, L type, alpha-1 polypeptide, isoform 6;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav2.3;
GN   Name=CACNA1E; Synonyms=CACH6, CACNL1A6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-1955.
RC   TISSUE=Brain;
RX   PubMed=7536609;
RA   Schneider T., Wei X., Olcese R., Costantin J.L., Neely A., Palade P.,
RA   Perez-Reyes E., Qin N., Zhou J., Crawford G.D., Smith R.G.,
RA   Appel S.H., Stefani E., Birnbaumer M.;
RT   "Molecular analysis and functional expression of the human type E
RT   neuronal Ca2+ channel alpha 1 subunit.";
RL   Recept. Channels 2:255-270(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Hippocampus;
RX   PubMed=8071363;
RA   Williams M.E., Marubio L.M., Deal C.R., Hans M., Brust P.F.,
RA   Philipson L.H., Miller R.J., Johnson E.C., Harpold M.M., Ellis S.B.;
RT   "Structure and functional characterization of neuronal alpha 1E
RT   calcium channel subtypes.";
RL   J. Biol. Chem. 269:22347-22357(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   INTERACTION WITH CACNA1E.
RX   PubMed=15258581; DOI=10.1038/ng1393;
RA   Suzuki T., Delgado-Escueta A.V., Aguan K., Alonso M.E., Shi J.,
RA   Hara Y., Nishida M., Numata T., Medina M.T., Takeuchi T., Morita R.,
RA   Bai D., Ganesh S., Sugimoto Y., Inazawa J., Bailey J.N., Ochoa A.,
RA   Jara-Prado A., Rasmussen A., Ramos-Peek J., Cordova S.,
RA   Rubio-Donnadieu F., Inoue Y., Osawa M., Kaneko S., Oguni H., Mori Y.,
RA   Yamakawa K.;
RT   "Mutations in EFHC1 cause juvenile myoclonic epilepsy.";
RL   Nat. Genet. 36:842-849(2004).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1867-1885.
RX   PubMed=18400181; DOI=10.1016/j.str.2008.01.011;
RA   Mori M.X., Vander Kooi C.W., Leahy D.J., Yue D.T.;
RT   "Crystal structure of the CaV2 IQ domain in complex with
RT   Ca2+/calmodulin: high-resolution mechanistic implications for channel
RT   regulation by Ca2+.";
RL   Structure 16:607-620(2008).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1E
CC       gives rise to R-type calcium currents. R-type calcium channels
CC       belong to the 'high-voltage activated' (HVA) group and are blocked
CC       by nickel, and partially by omega-agatoxin-IIIA (omega-Aga-IIIA).
CC       They are however insensitive to dihydropyridines (DHP), omega-
CC       conotoxin-GVIA (omega-CTx-GVIA), and omega-agatoxin-IVA (omega-
CC       Aga-IVA). Calcium channels containing alpha-1E subunit could be
CC       involved in the modulation of firing patterns of neurons which is
CC       important for information processing.
CC   -!- SUBUNIT: Interacts with EFHC1. Voltage-dependent calcium channels
CC       are multisubunit complexes, consisting of alpha-1, alpha-2, beta
CC       and delta subunits in a 1:1:1:1 ratio. The channel activity is
CC       directed by the pore-forming and voltage-sensitive alpha-1
CC       subunit. In many cases, this subunit is sufficient to generate
CC       voltage-sensitive calcium channel activity. The auxiliary subunits
CC       beta and alpha-2/delta linked by a disulfide bridge regulate the
CC       channel activity. {ECO:0000269|PubMed:15258581}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Alpha-1E;
CC         IsoId=Q15878-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha-1E-1;
CC         IsoId=Q15878-2; Sequence=VSP_000937, VSP_024817;
CC       Name=3; Synonyms=Alpha-1E-3;
CC         IsoId=Q15878-3; Sequence=VSP_024817;
CC   -!- TISSUE SPECIFICITY: Expressed in neuronal tissues and in kidney.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1E subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L27745; AAA72125.1; -; mRNA.
DR   EMBL; L29384; AAA59204.1; -; mRNA.
DR   EMBL; L29385; AAA59205.1; -; mRNA.
DR   EMBL; AL161734; CAH72675.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAH72675.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAH72675.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAH72675.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAH72676.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAH72676.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAH72676.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAH72676.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAH72677.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAH72677.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAH72677.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAH72677.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI14653.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAI14653.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAI14653.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI14653.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI14654.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAI14654.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAI14654.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI14654.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI14655.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAI14655.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAI14655.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI14655.1; JOINED; Genomic_DNA.
DR   EMBL; AL160059; CAI17081.1; -; Genomic_DNA.
DR   EMBL; AL161734; CAI17081.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI17081.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI17081.1; JOINED; Genomic_DNA.
DR   EMBL; AL160059; CAI17082.1; -; Genomic_DNA.
DR   EMBL; AL161734; CAI17082.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI17082.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI17082.1; JOINED; Genomic_DNA.
DR   EMBL; AL160059; CAI17083.1; -; Genomic_DNA.
DR   EMBL; AL161734; CAI17083.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI17083.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI17083.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI22327.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAI22327.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAI22327.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI22327.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI22328.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAI22328.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAI22328.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI22328.1; JOINED; Genomic_DNA.
DR   EMBL; AL590998; CAI22329.1; -; Genomic_DNA.
DR   EMBL; AL160059; CAI22329.1; JOINED; Genomic_DNA.
DR   EMBL; AL161734; CAI22329.1; JOINED; Genomic_DNA.
DR   EMBL; AL359270; CAI22329.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS53443.1; -. [Q15878-3]
DR   CCDS; CCDS55664.1; -. [Q15878-1]
DR   CCDS; CCDS55665.1; -. [Q15878-2]
DR   PIR; A54972; A54972.
DR   PIR; B54972; B54972.
DR   RefSeq; NP_000712.2; NM_000721.3. [Q15878-3]
DR   RefSeq; NP_001192222.1; NM_001205293.1. [Q15878-1]
DR   RefSeq; NP_001192223.1; NM_001205294.1. [Q15878-2]
DR   UniGene; Hs.437444; -.
DR   UniGene; Hs.611396; -.
DR   PDB; 3BXL; X-ray; 2.30 A; B=1867-1887.
DR   PDBsum; 3BXL; -.
DR   ProteinModelPortal; Q15878; -.
DR   SMR; Q15878; -.
DR   BioGrid; 107231; 2.
DR   STRING; 9606.ENSP00000356545; -.
DR   BindingDB; Q15878; -.
DR   ChEMBL; CHEMBL1687682; -.
DR   GuidetoPHARMACOLOGY; 534; -.
DR   iPTMnet; Q15878; -.
DR   PhosphoSitePlus; Q15878; -.
DR   BioMuta; CACNA1E; -.
DR   DMDM; 209572758; -.
DR   MaxQB; Q15878; -.
DR   PaxDb; Q15878; -.
DR   PeptideAtlas; Q15878; -.
DR   PRIDE; Q15878; -.
DR   Ensembl; ENST00000358338; ENSP00000351101; ENSG00000198216. [Q15878-2]
DR   Ensembl; ENST00000367567; ENSP00000356539; ENSG00000198216. [Q15878-3]
DR   Ensembl; ENST00000367570; ENSP00000356542; ENSG00000198216. [Q15878-3]
DR   Ensembl; ENST00000367573; ENSP00000356545; ENSG00000198216. [Q15878-1]
DR   Ensembl; ENST00000621551; ENSP00000483914; ENSG00000198216. [Q15878-1]
DR   Ensembl; ENST00000621791; ENSP00000481619; ENSG00000198216. [Q15878-2]
DR   GeneID; 777; -.
DR   KEGG; hsa:777; -.
DR   UCSC; uc001gow.5; human. [Q15878-1]
DR   CTD; 777; -.
DR   DisGeNET; 777; -.
DR   GeneCards; CACNA1E; -.
DR   HGNC; HGNC:1392; CACNA1E.
DR   HPA; HPA042515; -.
DR   MIM; 601013; gene.
DR   neXtProt; NX_Q15878; -.
DR   OpenTargets; ENSG00000198216; -.
DR   PharmGKB; PA26009; -.
DR   eggNOG; ENOG410INF5; Eukaryota.
DR   eggNOG; ENOG410YD06; LUCA.
DR   GeneTree; ENSGT00830000128247; -.
DR   HOGENOM; HOG000231530; -.
DR   HOVERGEN; HBG050763; -.
DR   InParanoid; Q15878; -.
DR   KO; K04852; -.
DR   OMA; SVQPSNH; -.
DR   OrthoDB; EOG090300O8; -.
DR   PhylomeDB; Q15878; -.
DR   TreeFam; TF312805; -.
DR   Reactome; R-HSA-112308; Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   ChiTaRS; CACNA1E; human.
DR   EvolutionaryTrace; Q15878; -.
DR   GeneWiki; R-type_calcium_channel; -.
DR   GenomeRNAi; 777; -.
DR   PRO; PR:Q15878; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000198216; -.
DR   CleanEx; HS_CACNA1E; -.
DR   ExpressionAtlas; Q15878; baseline and differential.
DR   Genevisible; Q15878; HS.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; TAS:ProtInc.
DR   GO; GO:0005262; F:calcium channel activity; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0008331; F:high voltage-gated calcium channel activity; IBA:GO_Central.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:MGI.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0051899; P:membrane depolarization; TAS:Reactome.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR031649; GPHH_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR014873; VDCC_a1su_IQ.
DR   InterPro; IPR005449; VDCC_R_a1su.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   PANTHER; PTHR10037:SF253; PTHR10037:SF253; 1.
DR   Pfam; PF08763; Ca_chan_IQ; 1.
DR   Pfam; PF16905; GPHH; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01633; RVDCCALPHA1.
DR   SMART; SM01062; Ca_chan_IQ; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calcium channel;
KW   Calcium transport; Complete proteome; Disulfide bond; Glycoprotein;
KW   Ion channel; Ion transport; Membrane; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Transmembrane;
KW   Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN         1   2313       Voltage-dependent R-type calcium channel
FT                                subunit alpha-1E.
FT                                /FTId=PRO_0000053938.
FT   TOPO_DOM      1     89       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     90    108       Helical; Name=S1 of repeat I.
FT   TOPO_DOM    109    127       Extracellular. {ECO:0000255}.
FT   TRANSMEM    128    146       Helical; Name=S2 of repeat I.
FT   TOPO_DOM    147    158       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    159    173       Helical; Name=S3 of repeat I.
FT   TOPO_DOM    174    185       Extracellular. {ECO:0000255}.
FT   TRANSMEM    186    205       Helical; Name=S4 of repeat I.
FT   TOPO_DOM    206    223       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    224    244       Helical; Name=S5 of repeat I.
FT   TOPO_DOM    245    326       Extracellular. {ECO:0000255}.
FT   TRANSMEM    327    350       Helical; Name=S6 of repeat I.
FT   TOPO_DOM    351    476       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    477    496       Helical; Name=S1 of repeat II.
FT   TOPO_DOM    497    509       Extracellular. {ECO:0000255}.
FT   TRANSMEM    510    529       Helical; Name=S2 of repeat II.
FT   TOPO_DOM    530    538       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    539    557       Helical; Name=S3 of repeat II.
FT   TOPO_DOM    558    567       Extracellular. {ECO:0000255}.
FT   TRANSMEM    568    586       Helical; Name=S4 of repeat II.
FT   TOPO_DOM    587    605       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    606    625       Helical; Name=S5 of repeat II.
FT   TOPO_DOM    626    678       Extracellular. {ECO:0000255}.
FT   TRANSMEM    679    703       Helical; Name=S6 of repeat II.
FT   TOPO_DOM    704   1148       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1149   1165       Helical; Name=S1 of repeat III.
FT   TOPO_DOM   1166   1189       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1190   1209       Helical; Name=S2 of repeat III.
FT   TOPO_DOM   1210   1217       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1218   1240       Helical; Name=S3 of repeat III.
FT   TOPO_DOM   1241   1254       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1255   1272       Helical; Name=S4 of repeat III.
FT   TOPO_DOM   1273   1291       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1292   1311       Helical; Name=S5 of repeat III.
FT   TOPO_DOM   1312   1398       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1399   1422       Helical; Name=S6 of repeat III.
FT   TOPO_DOM   1423   1479       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1480   1498       Helical; Name=S1 of repeat IV.
FT   TOPO_DOM   1499   1513       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1514   1533       Helical; Name=S2 of repeat IV.
FT   TOPO_DOM   1534   1541       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1542   1560       Helical; Name=S3 of repeat IV.
FT   TOPO_DOM   1561   1571       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1572   1590       Helical; Name=S4 of repeat IV.
FT   TOPO_DOM   1591   1609       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1610   1629       Helical; Name=S5 of repeat IV.
FT   TOPO_DOM   1630   1698       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1699   1724       Helical; Name=S6 of repeat IV.
FT   TOPO_DOM   1725   2313       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       76    354       I.
FT   REPEAT      462    706       II.
FT   REPEAT     1140   1426       III.
FT   REPEAT     1463   1726       IV.
FT   DOMAIN     1739   1774       EF-hand. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   CA_BIND     426    437       {ECO:0000255|PROSITE-ProRule:PRU00448}.
FT   CA_BIND    1752   1763       {ECO:0000255|PROSITE-ProRule:PRU00448}.
FT   REGION      374    391       Binding to the beta subunit.
FT                                {ECO:0000250}.
FT   COMPBIAS    716    721       Poly-Glu.
FT   COMPBIAS    748    753       Poly-Arg.
FT   COMPBIAS    767    772       Poly-Arg.
FT   COMPBIAS   1228   1231       Poly-Val.
FT   COMPBIAS   2284   2288       Poly-Arg.
FT   SITE        309    309       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        657    657       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1372   1372       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1663   1663       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES      14     14       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES      19     19       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES     427    427       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES     440    440       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES     736    736       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q07652}.
FT   MOD_RES     745    745       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES     793    793       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q07652}.
FT   MOD_RES     815    815       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES     855    855       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES     947    947       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q07652}.
FT   MOD_RES    1097   1097       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q07652}.
FT   MOD_RES    1734   1734       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES    2094   2094       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61290}.
FT   MOD_RES    2113   2113       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q07652}.
FT   CARBOHYD    254    254       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1566   1566       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1571   1571       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     748    766       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8071363}.
FT                                /FTId=VSP_000937.
FT   VAR_SEQ    1967   2009       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:8071363}.
FT                                /FTId=VSP_024817.
FT   VARIANT     859    859       D -> E (in dbSNP:rs35737760).
FT                                /FTId=VAR_031912.
FT   VARIANT    1955   1955       A -> T (in dbSNP:rs704326).
FT                                {ECO:0000269|PubMed:7536609}.
FT                                /FTId=VAR_046996.
FT   CONFLICT    648    648       M -> I (in Ref. 1; AAA72125).
FT                                {ECO:0000305}.
FT   CONFLICT    836    838       LAL -> WP (in Ref. 1; AAA72125).
FT                                {ECO:0000305}.
FT   CONFLICT   2077   2077       R -> P (in Ref. 2; AAA59204/AAA59205).
FT                                {ECO:0000305}.
FT   CONFLICT   2084   2084       G -> R (in Ref. 2; AAA59204/AAA59205).
FT                                {ECO:0000305}.
FT   CONFLICT   2206   2206       C -> W (in Ref. 2; AAA59204/AAA59205).
FT                                {ECO:0000305}.
FT   CONFLICT   2219   2219       S -> R (in Ref. 2; AAA59204/AAA59205).
FT                                {ECO:0000305}.
FT   CONFLICT   2245   2245       G -> V (in Ref. 2; AAA59204/AAA59205).
FT                                {ECO:0000305}.
FT   HELIX      1868   1882       {ECO:0000244|PDB:3BXL}.
SQ   SEQUENCE   2313 AA;  261731 MW;  CCC7F309C27C42F1 CRC64;
     MARFGEAVVA RPGSGDGDSD QSRNRQGTPV PASGQAAAYK QTKAQRARTM ALYNPIPVRQ
     NCFTVNRSLF IFGEDNIVRK YAKKLIDWPP FEYMILATII ANCIVLALEQ HLPEDDKTPM
     SRRLEKTEPY FIGIFCFEAG IKIVALGFIF HKGSYLRNGW NVMDFIVVLS GILATAGTHF
     NTHVDLRTLR AVRVLRPLKL VSGIPSLQIV LKSIMKAMVP LLQIGLLLFF AILMFAIIGL
     EFYSGKLHRA CFMNNSGILE GFDPPHPCGV QGCPAGYECK DWIGPNDGIT QFDNILFAVL
     TVFQCITMEG WTTVLYNTND ALGATWNWLY FIPLIIIGSF FVLNLVLGVL SGEFAKERER
     VENRRAFMKL RRQQQIEREL NGYRAWIDKA EEVMLAEENK NAGTSALEVL RRATIKRSRT
     EAMTRDSSDE HCVDISSVGT PLARASIKSA KVDGVSYFRH KERLLRISIR HMVKSQVFYW
     IVLSLVALNT ACVAIVHHNQ PQWLTHLLYY AEFLFLGLFL LEMSLKMYGM GPRLYFHSSF
     NCFDFGVTVG SIFEVVWAIF RPGTSFGISV LRALRLLRIF KITKYWASLR NLVVSLMSSM
     KSIISLLFLL FLFIVVFALL GMQLFGGRFN FNDGTPSANF DTFPAAIMTV FQILTGEDWN
     EVMYNGIRSQ GGVSSGMWSA IYFIVLTLFG NYTLLNVFLA IAVDNLANAQ ELTKDEQEEE
     EAFNQKHALQ KAKEVSPMSA PNMPSIERDR RRRHHMSMWE PRSSHLRERR RRHHMSVWEQ
     RTSQLRKHMQ MSSQEALNRE EAPTMNPLNP LNPLSSLNPL NAHPSLYRRP RAIEGLALGL
     ALEKFEEERI SRGGSLKGDG GDRSSALDNQ RTPLSLGQRE PPWLARPCHG NCDPTQQEAG
     GGEAVVTFED RARHRQSQRR SRHRRVRTEG KESSSASRSR SASQERSLDE AMPTEGEKDH
     ELRGNHGAKE PTIQEERAQD LRRTNSLMVS RGSGLAGGLD EADTPLVLPH PELEVGKHVV
     LTEQEPEGSS EQALLGNVQL DMGRVISQSE PDLSCITANT DKATTESTSV TVAIPDVDPL
     VDSTVVHISN KTDGEASPLK EAEIREDEEE VEKKKQKKEK RETGKAMVPH SSMFIFSTTN
     PIRRACHYIV NLRYFEMCIL LVIAASSIAL AAEDPVLTNS ERNKVLRYFD YVFTGVFTFE
     MVIKMIDQGL ILQDGSYFRD LWNILDFVVV VGALVAFALA NALGTNKGRD IKTIKSLRVL
     RVLRPLKTIK RLPKLKAVFD CVVTSLKNVF NILIVYKLFM FIFAVIAVQL FKGKFFYCTD
     SSKDTEKECI GNYVDHEKNK MEVKGREWKR HEFHYDNIIW ALLTLFTVST GEGWPQVLQH
     SVDVTEEDRG PSRSNRMEMS IFYVVYFVVF PFFFVNIFVA LIIITFQEQG DKMMEECSLE
     KNERACIDFA ISAKPLTRYM PQNRHTFQYR VWHFVVSPSF EYTIMAMIAL NTVVLMMKYY
     SAPCTYELAL KYLNIAFTMV FSLECVLKVI AFGFLNYFRD TWNIFDFITV IGSITEIILT
     DSKLVNTSGF NMSFLKLFRA ARLIKLLRQG YTIRILLWTF VQSFKALPYV CLLIAMLFFI
     YAIIGMQVFG NIKLDEESHI NRHNNFRSFF GSLMLLFRSA TGEAWQEIML SCLGEKGCEP
     DTTAPSGQNE NERCGTDLAY VYFVSFIFFC SFLMLNLFVA VIMDNFEYLT RDSSILGPHH
     LDEFVRVWAE YDRAACGRIH YTEMYEMLTL MSPPLGLGKR CPSKVAYKRL VLMNMPVAED
     MTVHFTSTLM ALIRTALDIK IAKGGADRQQ LDSELQKETL AIWPHLSQKM LDLLVPMPKA
     SDLTVGKIYA AMMIMDYYKQ SKVKKQRQQL EEQKNAPMFQ RMEPSSLPQE IIANAKALPY
     LQQDPVSGLS GRSGYPSMSP LSPQDIFQLA CMDPADDGQF QERQSLEPEV SELKSVQPSN
     HGIYLPSDTQ EHAGSGRASS MPRLTVDPQV VTDPSSMRRS FSTIRDKRSN SSWLEEFSME
     RSSENTYKSR RRSYHSSLRL SAHRLNSDSG HKSDTHRSGG RERGRSKERK HLLSPDVSRC
     NSEERGTQAD WESPERRQSR SPSEGRSQTP NRQGTGSLSE SSIPSVSDTS TPRRSRRQLP
     PVPPKPRPLL SYSSLIRHAG SISPPADGSE EGSPLTSQAL ESNNACLTES SNSPHPQQSQ
     HASPQRYISE PYLALHEDSH ASDCGEEETL TFEAAVATSL GRSNTIGSAP PLRHSWQMPN
     GHYRRRRRGG PGPGMMCGAV NNLLSDTEED DKC
//
ID   CAC1G_HUMAN             Reviewed;        2377 AA.
AC   O43497; D6RA64; E7EPR0; O43498; O94770; Q19QY8; Q19QY9; Q19QZ0;
AC   Q19QZ1; Q19QZ2; Q19QZ3; Q19QZ4; Q19QZ5; Q19QZ6; Q19QZ7; Q19QZ8;
AC   Q19QZ9; Q19R00; Q19R01; Q19R02; Q19R03; Q19R04; Q19R05; Q19R06;
AC   Q19R07; Q19R08; Q19R09; Q19R10; Q19R11; Q19R12; Q19R13; Q19R15;
AC   Q19R16; Q19R17; Q19R18; Q2TAC4; Q9NYU4; Q9NYU5; Q9NYU6; Q9NYU7;
AC   Q9NYU8; Q9NYU9; Q9NYV0; Q9NYV1; Q9UHN9; Q9UHP0; Q9ULU6; Q9UNG7;
AC   Q9Y5T2; Q9Y5T3;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 3.
DT   15-FEB-2017, entry version 153.
DE   RecName: Full=Voltage-dependent T-type calcium channel subunit alpha-1G;
DE   AltName: Full=Cav3.1c;
DE   AltName: Full=NBR13;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav3.1;
GN   Name=CACNA1G; Synonyms=KIAA1123;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND GENE STRUCTURE.
RC   TISSUE=Prostatic carcinoma;
RX   PubMed=10493502;
RA   Toyota M., Ho C., Ohe-Toyota M., Baylin S.B., Issa J.-P.J.;
RT   "Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant
RT   methylation of its 5' CpG island in human tumors.";
RL   Cancer Res. 59:4535-4541(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING (ISOFORMS 4 AND
RP   5).
RC   TISSUE=Brain;
RX   PubMed=10548410; DOI=10.1016/S0304-3940(99)00716-8;
RA   Mittman S., Guo J., Agnew W.S.;
RT   "Structure and alternative splicing of the gene encoding alpha1G, a
RT   human brain T calcium channel alpha1 subunit.";
RL   Neurosci. Lett. 274:143-146(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Brain;
RX   PubMed=10648811; DOI=10.1016/S0014-5793(99)01756-1;
RA   Cribbs L.L., Gomora J.C., Daud A.N., Lee J.-H., Perez-Reyes E.;
RT   "Molecular cloning and functional expression of ca(v)3.1c, a T-type
RT   calcium channel from human brain.";
RL   FEBS Lett. 466:54-58(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING (ISOFORMS 1-2 AND
RP   6-13), AND FUNCTION.
RC   TISSUE=Brain;
RX   PubMed=10692398; DOI=10.1074/jbc.275.9.6090;
RA   Monteil A., Chemin J., Bourinet E., Mennessier G., Lory P.,
RA   Nargeot J.;
RT   "Molecular and functional properties of the human alpha1G subunit that
RT   forms T-type calcium channels.";
RL   J. Biol. Chem. 275:6090-6100(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 4; 6; 7; 8; 9; 11; 12; 13;
RP   14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30;
RP   31; 33; 34 AND 35), AND DEVELOPMENTAL STAGE.
RC   TISSUE=Brain, and Fetal brain;
RX   PubMed=16671074; DOI=10.1002/prot.20877;
RA   Emerick M.C., Stein R., Kunze R., McNulty M.M., Regan M.R.,
RA   Hanck D.A., Agnew W.S.;
RT   "Profiling the array of Ca(v)3.1 variants from the human T-type
RT   calcium channel gene CACNA1G: alternative structures, developmental
RT   expression, and biophysical variations.";
RL   Proteins 64:320-342(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 550-2377 (ISOFORM 13).
RC   TISSUE=Brain;
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis
RT   from size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [9]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1126-1444; 1778-1927 AND 2021-2312.
RC   TISSUE=Brain;
RX   PubMed=9495342; DOI=10.1038/36110;
RA   Perez-Reyes E., Cribbs L.L., Daud A., Lacerda A.E., Barclay J.,
RA   Williamson M.P., Fox M., Rees M., Lee J.-H.;
RT   "Molecular characterization of a neuronal low-voltage-activated T-type
RT   calcium channel.";
RL   Nature 391:896-900(1998).
RN   [11]
RP   INVOLVEMENT IN SCA42, VARIANT SCA42 HIS-1715, CHARACTERIZATION OF
RP   VARIANT SCA42 HIS-1715, AND FUNCTION.
RX   PubMed=26456284; DOI=10.1016/j.ajhg.2015.09.007;
RA   Coutelier M., Blesneac I., Monteil A., Monin M.L., Ando K.,
RA   Mundwiller E., Brusco A., Le Ber I., Anheim M., Castrioto A.,
RA   Duyckaerts C., Brice A., Durr A., Lory P., Stevanin G.;
RT   "A recurrent mutation in CACNA1G alters Cav3.1 T-type calcium-channel
RT   conduction and causes autosomal-dominant cerebellar ataxia.";
RL   Am. J. Hum. Genet. 97:726-737(2015).
RN   [12]
RP   INVOLVEMENT IN SCA42, VARIANT SCA42 HIS-1715, CHARACTERIZATION OF
RP   VARIANT SCA42 HIS-1715, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=26715324; DOI=10.1186/s13041-015-0180-4;
RA   Morino H., Matsuda Y., Muguruma K., Miyamoto R., Ohsawa R., Ohtake T.,
RA   Otobe R., Watanabe M., Maruyama H., Hashimoto K., Kawakami H.;
RT   "A mutation in the low voltage-gated calcium channel CACNA1G alters
RT   the physiological properties of the channel, causing spinocerebellar
RT   ataxia.";
RL   Mol. Brain 8:89-89(2015).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1G
CC       gives rise to T-type calcium currents. T-type calcium channels
CC       belong to the "low-voltage activated (LVA)" group and are strongly
CC       blocked by mibefradil. A particularity of this type of channel is
CC       an opening at quite negative potentials and a voltage-dependent
CC       inactivation. T-type channels serve pacemaking functions in both
CC       central neurons and cardiac nodal cells and support calcium
CC       signaling in secretory cells and vascular smooth muscle. They may
CC       also be involved in the modulation of firing patterns of neurons
CC       which is important for information processing as well as in cell
CC       growth processes. {ECO:0000269|PubMed:10648811,
CC       ECO:0000269|PubMed:10692398, ECO:0000269|PubMed:26456284,
CC       ECO:0000269|PubMed:26715324}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26715324};
CC       Multi-pass membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000269|PubMed:26715324}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=35;
CC       Name=5;
CC         IsoId=O43497-1; Sequence=Displayed;
CC       Name=1; Synonyms=Variant 89;
CC         IsoId=O43497-2; Sequence=VSP_000940, VSP_000943, VSP_000946;
CC       Name=2; Synonyms=Variant 25;
CC         IsoId=O43497-3; Sequence=VSP_000940, VSP_000944, VSP_000946;
CC       Name=3;
CC         IsoId=O43497-4; Sequence=VSP_000940;
CC       Name=4; Synonyms=Variant 88;
CC         IsoId=O43497-5; Sequence=VSP_000940, VSP_000943, VSP_000946,
CC                                  VSP_000948;
CC       Name=6; Synonyms=Variant 217;
CC         IsoId=O43497-6; Sequence=VSP_000943, VSP_000946;
CC       Name=7; Synonyms=Variant 221;
CC         IsoId=O43497-7; Sequence=VSP_000943, VSP_000947;
CC       Name=8; Synonyms=Variant 93;
CC         IsoId=O43497-8; Sequence=VSP_000940, VSP_000943, VSP_000947;
CC       Name=9; Synonyms=Variant 57;
CC         IsoId=O43497-9; Sequence=VSP_000940, VSP_000946;
CC       Name=10;
CC         IsoId=O43497-10; Sequence=VSP_000940, VSP_000945;
CC       Name=11; Synonyms=Variant 185;
CC         IsoId=O43497-11; Sequence=VSP_000946;
CC       Name=12; Synonyms=Variant 189;
CC         IsoId=O43497-12; Sequence=VSP_000947;
CC       Name=13; Synonyms=Variant 153;
CC         IsoId=O43497-13; Sequence=VSP_000944, VSP_000946;
CC       Name=14; Synonyms=Variant 137;
CC         IsoId=O43497-15; Sequence=VSP_000944, VSP_047550, VSP_000946;
CC       Name=15; Synonyms=Variant 157;
CC         IsoId=O43497-16; Sequence=VSP_000944, VSP_000947;
CC       Name=16; Synonyms=Variant 169;
CC         IsoId=O43497-17; Sequence=VSP_047550, VSP_000946;
CC       Name=17; Synonyms=Variant 184;
CC         IsoId=O43497-18; Sequence=VSP_000946, VSP_000948;
CC       Name=18; Synonyms=Variant 216;
CC         IsoId=O43497-19; Sequence=VSP_000943, VSP_000946, VSP_000948;
CC       Name=19; Synonyms=Variant 223;
CC         IsoId=O43497-20; Sequence=VSP_000943;
CC       Name=20; Synonyms=Variant 249;
CC         IsoId=O43497-21; Sequence=VSP_047548, VSP_000946;
CC       Name=21; Synonyms=Variant 313;
CC         IsoId=O43497-22; Sequence=VSP_000940, VSP_047545, VSP_000946;
CC       Name=22; Synonyms=Variant 409;
CC         IsoId=O43497-23; Sequence=VSP_047545, VSP_000944, VSP_000946;
CC       Name=23; Synonyms=Variant 441;
CC         IsoId=O43497-24; Sequence=VSP_047545, VSP_000946;
CC       Name=24; Synonyms=Variant 477;
CC         IsoId=O43497-25; Sequence=VSP_047545, VSP_000943, VSP_000947;
CC       Name=25; Synonyms=Variant 473;
CC         IsoId=O43497-26; Sequence=VSP_047545, VSP_000943, VSP_000946;
CC       Name=26; Synonyms=Variant 17;
CC         IsoId=O43497-27; Sequence=VSP_000940, VSP_000944, VSP_047551,
CC                                   VSP_047553;
CC       Name=27; Synonyms=Variant 33;
CC         IsoId=O43497-28; Sequence=VSP_000940, VSP_047549, VSP_047552;
CC       Name=28; Synonyms=Variant 49;
CC         IsoId=O43497-29; Sequence=VSP_000940, VSP_047551, VSP_047553;
CC       Name=29; Synonyms=Variant 145;
CC         IsoId=O43497-30; Sequence=VSP_000944, VSP_047551, VSP_047553;
CC       Name=30; Synonyms=Variant 177;
CC         IsoId=O43497-31; Sequence=VSP_047551, VSP_047553;
CC       Name=31; Synonyms=Variant 209;
CC         IsoId=O43497-32; Sequence=VSP_000943, VSP_047551, VSP_047553;
CC       Name=32;
CC         IsoId=O43497-33; Sequence=VSP_000940, VSP_000943;
CC         Note=Gene prediction based on EST data.;
CC       Name=33; Synonyms=Variant 441-d81;
CC         IsoId=O43497-34; Sequence=VSP_047546, VSP_000946;
CC       Name=34; Synonyms=Variant 473-d75;
CC         IsoId=O43497-35; Sequence=VSP_047547, VSP_000943, VSP_000946;
CC       Name=35; Synonyms=Variant 473-d81;
CC         IsoId=O43497-36; Sequence=VSP_047546, VSP_000943, VSP_000946;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, in particular in
CC       the amygdala, subthalamic nuclei, cerebellum and thalamus.
CC       Moderate expression in heart; low expression in placenta, kidney
CC       and lung. Also expressed in colon and bone marrow and in tumoral
CC       cells to a lesser extent. Highly expressed in fetal brain, but
CC       also in peripheral fetal tissues as heart, kidney and lung,
CC       suggesting a developmentally regulated expression.
CC   -!- DEVELOPMENTAL STAGE: Isoform 4, isoform 7, isoform 18, isoform 19,
CC       isoform 24, isoform 25 and isoform 31 are adult-specific. Isoform
CC       8, isoform 14, isoform 15, isoform 16, isoform 17, isoform 20,
CC       isoform 21, isoform 22, isoform 23, isoform 26, isoform 27,
CC       isoform 28, isoform 29 and isoform 30 are fetal-specific. Isoform
CC       1, isoform 2, isoform 6, isoform 9, isoform 11, isoform 12 and
CC       isoform 13 are expressed in both fetus and adult.
CC       {ECO:0000269|PubMed:16671074}.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- DOMAIN: The linker region between repeat III and IV probably plays
CC       a role in the inactivation of the channel. The C-terminal part may
CC       be implicated in the anchoring of the protein to the membrane by
CC       interfering with or restricting its lateral diffusion.
CC   -!- PTM: In response to raising of intracellular calcium, the T-type
CC       channels are activated by CaM-kinase II.
CC   -!- DISEASE: Spinocerebellar ataxia 42 (SCA42) [MIM:616795]: A form of
CC       spinocerebellar ataxia, a clinically and genetically heterogeneous
CC       group of cerebellar disorders. Patients show progressive
CC       incoordination of gait and often poor coordination of hands,
CC       speech and eye movements, due to degeneration of the cerebellum
CC       with variable involvement of the brainstem and spinal cord. SCA42
CC       is a slowly progressive, autosomal dominant form with variable
CC       severity. {ECO:0000269|PubMed:26456284,
CC       ECO:0000269|PubMed:26715324}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1G subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF124351; AAD34352.1; -; mRNA.
DR   EMBL; AF134985; AAF19346.1; -; mRNA.
DR   EMBL; AF134986; AAF19347.1; -; mRNA.
DR   EMBL; AF190860; AAF35287.1; -; mRNA.
DR   EMBL; AF126965; AAD29400.1; -; mRNA.
DR   EMBL; AF126966; AAD29401.1; -; mRNA.
DR   EMBL; AF227744; AAF37689.1; -; mRNA.
DR   EMBL; AF227745; AAF37690.1; -; mRNA.
DR   EMBL; AF227746; AAF37691.1; -; mRNA.
DR   EMBL; AF227747; AAF37692.1; -; mRNA.
DR   EMBL; AF227748; AAF37693.1; -; mRNA.
DR   EMBL; AF227749; AAF37694.1; -; mRNA.
DR   EMBL; AF227750; AAF37695.1; -; mRNA.
DR   EMBL; AF227751; AAF37696.1; -; mRNA.
DR   EMBL; DQ494449; ABF69900.1; -; mRNA.
DR   EMBL; DQ494450; ABF69901.1; -; mRNA.
DR   EMBL; DQ494451; ABF69902.1; -; mRNA.
DR   EMBL; DQ494452; ABF69903.1; -; mRNA.
DR   EMBL; DQ494453; ABF69904.1; -; mRNA.
DR   EMBL; DQ494454; ABF69905.1; -; mRNA.
DR   EMBL; DQ494455; ABF69906.1; -; mRNA.
DR   EMBL; DQ494456; ABF69907.1; -; mRNA.
DR   EMBL; DQ494457; ABF69908.1; -; mRNA.
DR   EMBL; DQ494458; ABF69909.1; -; mRNA.
DR   EMBL; DQ494459; ABF69910.1; -; mRNA.
DR   EMBL; DQ494460; ABF69911.1; -; mRNA.
DR   EMBL; DQ494461; ABF69912.1; -; mRNA.
DR   EMBL; DQ494462; ABF69913.1; -; mRNA.
DR   EMBL; DQ494463; ABF69914.1; -; mRNA.
DR   EMBL; DQ494464; ABF69915.1; -; mRNA.
DR   EMBL; DQ494465; ABF69916.1; -; mRNA.
DR   EMBL; DQ494466; ABF69917.1; -; mRNA.
DR   EMBL; DQ494467; ABF69918.1; -; mRNA.
DR   EMBL; DQ494468; ABF69919.1; -; mRNA.
DR   EMBL; DQ494469; ABF69920.1; -; mRNA.
DR   EMBL; DQ494470; ABF69921.1; -; mRNA.
DR   EMBL; DQ494471; ABF69922.1; -; mRNA.
DR   EMBL; DQ494472; ABF69923.1; -; mRNA.
DR   EMBL; DQ494473; ABF69924.1; -; mRNA.
DR   EMBL; DQ494474; ABF69925.1; -; mRNA.
DR   EMBL; DQ494475; ABF69926.1; -; mRNA.
DR   EMBL; DQ494476; ABF69927.1; -; mRNA.
DR   EMBL; DQ494477; ABF69928.1; -; mRNA.
DR   EMBL; DQ494478; ABF69929.1; -; mRNA.
DR   EMBL; DQ494479; ABF69930.1; -; mRNA.
DR   EMBL; AC004590; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC021491; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC110995; AAI10996.1; -; mRNA.
DR   EMBL; AB032949; BAA86437.2; -; mRNA.
DR   EMBL; AF029228; AAD12731.1; -; mRNA.
DR   EMBL; AF029229; AAD12732.1; -; mRNA.
DR   CCDS; CCDS45730.1; -. [O43497-1]
DR   CCDS; CCDS45731.1; -. [O43497-12]
DR   CCDS; CCDS45732.1; -. [O43497-11]
DR   CCDS; CCDS45733.1; -. [O43497-13]
DR   CCDS; CCDS45734.1; -. [O43497-33]
DR   CCDS; CCDS45735.1; -. [O43497-2]
DR   CCDS; CCDS45736.1; -. [O43497-5]
DR   CCDS; CCDS45737.1; -. [O43497-10]
DR   CCDS; CCDS54142.1; -. [O43497-7]
DR   CCDS; CCDS54143.1; -. [O43497-6]
DR   CCDS; CCDS54144.1; -. [O43497-9]
DR   CCDS; CCDS54145.1; -. [O43497-3]
DR   CCDS; CCDS54146.1; -. [O43497-8]
DR   CCDS; CCDS58565.1; -. [O43497-17]
DR   CCDS; CCDS58566.1; -. [O43497-18]
DR   CCDS; CCDS58567.1; -. [O43497-15]
DR   CCDS; CCDS58568.1; -. [O43497-16]
DR   CCDS; CCDS58569.1; -. [O43497-21]
DR   CCDS; CCDS58570.1; -. [O43497-20]
DR   CCDS; CCDS58571.1; -. [O43497-19]
DR   CCDS; CCDS58572.1; -. [O43497-24]
DR   CCDS; CCDS58573.1; -. [O43497-23]
DR   CCDS; CCDS58574.1; -. [O43497-25]
DR   CCDS; CCDS58575.1; -. [O43497-26]
DR   CCDS; CCDS58576.1; -. [O43497-22]
DR   RefSeq; NP_001243253.1; NM_001256324.1. [O43497-16]
DR   RefSeq; NP_001243254.1; NM_001256325.1. [O43497-21]
DR   RefSeq; NP_001243255.1; NM_001256326.1. [O43497-25]
DR   RefSeq; NP_001243256.1; NM_001256327.1. [O43497-17]
DR   RefSeq; NP_001243257.1; NM_001256328.1. [O43497-15]
DR   RefSeq; NP_001243258.1; NM_001256329.1. [O43497-24]
DR   RefSeq; NP_001243259.1; NM_001256330.1. [O43497-26]
DR   RefSeq; NP_001243260.1; NM_001256331.1. [O43497-23]
DR   RefSeq; NP_001243261.1; NM_001256332.1. [O43497-22]
DR   RefSeq; NP_001243262.1; NM_001256333.1. [O43497-18]
DR   RefSeq; NP_001243263.1; NM_001256334.1. [O43497-19]
DR   RefSeq; NP_001243288.1; NM_001256359.1. [O43497-34]
DR   RefSeq; NP_001243289.1; NM_001256360.1. [O43497-35]
DR   RefSeq; NP_001243290.1; NM_001256361.1. [O43497-36]
DR   RefSeq; NP_061496.2; NM_018896.4. [O43497-1]
DR   RefSeq; NP_938190.1; NM_198376.2. [O43497-5]
DR   RefSeq; NP_938191.2; NM_198377.2. [O43497-20]
DR   RefSeq; NP_938192.1; NM_198378.2. [O43497-6]
DR   RefSeq; NP_938193.1; NM_198379.2. [O43497-8]
DR   RefSeq; NP_938194.1; NM_198380.2. [O43497-7]
DR   RefSeq; NP_938196.1; NM_198382.2. [O43497-9]
DR   RefSeq; NP_938197.1; NM_198383.2. [O43497-10]
DR   RefSeq; NP_938198.1; NM_198384.2. [O43497-11]
DR   RefSeq; NP_938199.1; NM_198385.2. [O43497-12]
DR   RefSeq; NP_938200.1; NM_198386.2. [O43497-13]
DR   RefSeq; NP_938201.1; NM_198387.2. [O43497-2]
DR   RefSeq; NP_938202.1; NM_198388.2. [O43497-3]
DR   RefSeq; NP_938406.1; NM_198396.2. [O43497-33]
DR   UniGene; Hs.591169; -.
DR   ProteinModelPortal; O43497; -.
DR   BioGrid; 114427; 2.
DR   IntAct; O43497; 2.
DR   MINT; MINT-2796172; -.
DR   STRING; 9606.ENSP00000352011; -.
DR   BindingDB; O43497; -.
DR   ChEMBL; CHEMBL4641; -.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00593; Ethosuximide.
DR   DrugBank; DB04841; Flunarizine.
DR   DrugBank; DB05246; Methsuximide.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00347; Trimethadione.
DR   DrugBank; DB00661; Verapamil.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 535; -.
DR   iPTMnet; O43497; -.
DR   PhosphoSitePlus; O43497; -.
DR   BioMuta; CACNA1G; -.
DR   PaxDb; O43497; -.
DR   PeptideAtlas; O43497; -.
DR   PRIDE; O43497; -.
DR   Ensembl; ENST00000352832; ENSP00000339302; ENSG00000006283. [O43497-2]
DR   Ensembl; ENST00000354983; ENSP00000347078; ENSG00000006283. [O43497-33]
DR   Ensembl; ENST00000358244; ENSP00000350979; ENSG00000006283. [O43497-5]
DR   Ensembl; ENST00000359106; ENSP00000352011; ENSG00000006283. [O43497-1]
DR   Ensembl; ENST00000360761; ENSP00000353990; ENSG00000006283. [O43497-9]
DR   Ensembl; ENST00000429973; ENSP00000414388; ENSG00000006283. [O43497-13]
DR   Ensembl; ENST00000442258; ENSP00000409759; ENSG00000006283. [O43497-3]
DR   Ensembl; ENST00000502264; ENSP00000425522; ENSG00000006283. [O43497-10]
DR   Ensembl; ENST00000503436; ENSP00000427231; ENSG00000006283. [O43497-29]
DR   Ensembl; ENST00000503485; ENSP00000427238; ENSG00000006283. [O43497-24]
DR   Ensembl; ENST00000503607; ENSP00000426558; ENSG00000006283. [O43497-27]
DR   Ensembl; ENST00000504076; ENSP00000425153; ENSG00000006283. [O43497-32]
DR   Ensembl; ENST00000505165; ENSP00000422268; ENSG00000006283. [O43497-18]
DR   Ensembl; ENST00000506406; ENSP00000426313; ENSG00000006283. [O43497-31]
DR   Ensembl; ENST00000507336; ENSP00000420918; ENSG00000006283. [O43497-20]
DR   Ensembl; ENST00000507510; ENSP00000423112; ENSG00000006283. [O43497-12]
DR   Ensembl; ENST00000507609; ENSP00000423045; ENSG00000006283. [O43497-17]
DR   Ensembl; ENST00000507896; ENSP00000421518; ENSG00000006283. [O43497-19]
DR   Ensembl; ENST00000510115; ENSP00000427173; ENSG00000006283. [O43497-8]
DR   Ensembl; ENST00000510366; ENSP00000426814; ENSG00000006283. [O43497-23]
DR   Ensembl; ENST00000511765; ENSP00000427247; ENSG00000006283. [O43497-30]
DR   Ensembl; ENST00000511768; ENSP00000424664; ENSG00000006283. [O43497-28]
DR   Ensembl; ENST00000512389; ENSP00000426261; ENSG00000006283. [O43497-6]
DR   Ensembl; ENST00000513689; ENSP00000426172; ENSG00000006283. [O43497-25]
DR   Ensembl; ENST00000513964; ENSP00000425451; ENSG00000006283. [O43497-26]
DR   Ensembl; ENST00000514079; ENSP00000423317; ENSG00000006283. [O43497-21]
DR   Ensembl; ENST00000514181; ENSP00000425698; ENSG00000006283. [O43497-15]
DR   Ensembl; ENST00000514717; ENSP00000422407; ENSG00000006283. [O43497-22]
DR   Ensembl; ENST00000515165; ENSP00000426098; ENSG00000006283. [O43497-11]
DR   Ensembl; ENST00000515411; ENSP00000423155; ENSG00000006283. [O43497-16]
DR   Ensembl; ENST00000515765; ENSP00000426232; ENSG00000006283. [O43497-7]
DR   GeneID; 8913; -.
DR   KEGG; hsa:8913; -.
DR   UCSC; uc002irj.3; human. [O43497-1]
DR   CTD; 8913; -.
DR   DisGeNET; 8913; -.
DR   GeneCards; CACNA1G; -.
DR   HGNC; HGNC:1394; CACNA1G.
DR   HPA; HPA004714; -.
DR   MalaCards; CACNA1G; -.
DR   MIM; 604065; gene.
DR   MIM; 616795; phenotype.
DR   neXtProt; NX_O43497; -.
DR   OpenTargets; ENSG00000006283; -.
DR   PharmGKB; PA381; -.
DR   eggNOG; KOG2302; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOGENOM; HOG000007742; -.
DR   HOVERGEN; HBG050764; -.
DR   InParanoid; O43497; -.
DR   KO; K04854; -.
DR   OMA; ALESNMQ; -.
DR   OrthoDB; EOG090300UA; -.
DR   PhylomeDB; O43497; -.
DR   TreeFam; TF313555; -.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   ChiTaRS; CACNA1G; human.
DR   GeneWiki; CACNA1G; -.
DR   GenomeRNAi; 8913; -.
DR   PRO; PR:O43497; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000006283; -.
DR   ExpressionAtlas; O43497; baseline and differential.
DR   Genevisible; O43497; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; ISS:BHF-UCL.
DR   GO; GO:0008332; F:low voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0086056; F:voltage-gated calcium channel activity involved in AV node cell action potential; ISS:BHF-UCL.
DR   GO; GO:0086059; F:voltage-gated calcium channel activity involved SA node cell action potential; ISS:BHF-UCL.
DR   GO; GO:0086016; P:AV node cell action potential; ISS:BHF-UCL.
DR   GO; GO:0086027; P:AV node cell to bundle of His cell signaling; ISS:BHF-UCL.
DR   GO; GO:0070509; P:calcium ion import; IDA:BHF-UCL.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; ISS:BHF-UCL.
DR   GO; GO:0007268; P:chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0086045; P:membrane depolarization during AV node cell action potential; ISS:BHF-UCL.
DR   GO; GO:0086046; P:membrane depolarization during SA node cell action potential; ISS:BHF-UCL.
DR   GO; GO:0045956; P:positive regulation of calcium ion-dependent exocytosis; IBA:GO_Central.
DR   GO; GO:0060371; P:regulation of atrial cardiac muscle cell membrane depolarization; IEA:Ensembl.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; ISS:BHF-UCL.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:BHF-UCL.
DR   GO; GO:0010045; P:response to nickel cation; IEA:Ensembl.
DR   GO; GO:0086015; P:SA node cell action potential; ISS:BHF-UCL.
DR   GO; GO:0086018; P:SA node cell to atrial cardiac muscle cell signalling; ISS:BHF-UCL.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR005445; VDCC_T_a1.
DR   InterPro; IPR030154; VDCC_T_a1G.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   PANTHER; PTHR10037:SF256; PTHR10037:SF256; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01629; TVDCCALPHA1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Calcium channel; Calcium transport;
KW   Cell membrane; Complete proteome; Cytoplasm; Disease mutation;
KW   Glycoprotein; Ion channel; Ion transport; Membrane; Neurodegeneration;
KW   Phosphoprotein; Reference proteome; Repeat; Spinocerebellar ataxia;
KW   Transmembrane; Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN         1   2377       Voltage-dependent T-type calcium channel
FT                                subunit alpha-1G.
FT                                /FTId=PRO_0000053952.
FT   TOPO_DOM      1     80       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     81    101       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    102    119       Extracellular. {ECO:0000255}.
FT   TRANSMEM    120    141       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    142    150       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    151    170       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    171    175       Extracellular. {ECO:0000255}.
FT   TRANSMEM    176    193       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    194    213       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    214    234       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    235    370       Extracellular. {ECO:0000255}.
FT   TRANSMEM    371    395       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    396    743       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    744    764       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    765    777       Extracellular. {ECO:0000255}.
FT   TRANSMEM    778    799       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    800    805       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    806    824       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    825    832       Extracellular. {ECO:0000255}.
FT   TRANSMEM    833    856       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    857    867       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    868    888       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    889    939       Extracellular. {ECO:0000255}.
FT   TRANSMEM    940    964       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    965   1272       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1273   1295       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1296   1313       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1314   1334       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1335   1344       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1345   1364       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1365   1378       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1379   1400       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1401   1410       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1411   1434       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1435   1511       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1512   1537       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1538   1610       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1611   1631       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1632   1645       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1646   1667       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1668   1674       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1675   1693       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1694   1707       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1708   1731       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1732   1745       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1746   1766       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1767   1826       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1827   1854       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1855   2377       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       68    398       I.
FT   REPEAT      729    967       II.
FT   REPEAT     1263   1540       III.
FT   REPEAT     1596   1854       IV.
FT   COMPBIAS    290    295       Poly-Gly.
FT   COMPBIAS    496    506       Poly-His.
FT   SITE        354    354       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        924    924       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1465   1465       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1770   1770       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES     467    467       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54898}.
FT   MOD_RES     715    715       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54898}.
FT   MOD_RES    1139   1139       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54898}.
FT   MOD_RES    1145   1145       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54898}.
FT   MOD_RES    1146   1146       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54898}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    246    246       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    306    306       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    310    310       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1448   1448       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1451   1451       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1698   1698       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     971    993       Missing (in isoform 1, isoform 2, isoform
FT                                3, isoform 4, isoform 8, isoform 9,
FT                                isoform 10, isoform 21, isoform 26,
FT                                isoform 27, isoform 28 and isoform 32).
FT                                {ECO:0000303|PubMed:10493502,
FT                                ECO:0000303|PubMed:10648811,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_000940.
FT   VAR_SEQ    1505   1538       Missing (in isoform 21, isoform 22,
FT                                isoform 23, isoform 24 and isoform 25).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047545.
FT   VAR_SEQ    1505   1531       Missing (in isoform 33 and isoform 35).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047546.
FT   VAR_SEQ    1505   1529       Missing (in isoform 34).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047547.
FT   VAR_SEQ    1569   1587       NLMLDDVIASGSSASAASE -> K (in isoform 2,
FT                                isoform 13, isoform 14, isoform 15,
FT                                isoform 22, isoform 26 and isoform 29).
FT                                {ECO:0000303|PubMed:10574461,
FT                                ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_000944.
FT   VAR_SEQ    1569   1586       NLMLDDVIASGSSASAAS -> SKEKQMA (in isoform
FT                                1, isoform 4, isoform 6, isoform 7,
FT                                isoform 8, isoform 18, isoform 19,
FT                                isoform 24, isoform 25, isoform 31,
FT                                isoform 32, isoform 34 and isoform 35).
FT                                {ECO:0000303|PubMed:10648811,
FT                                ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_000943.
FT   VAR_SEQ    1569   1569       N -> SKEKQMAD (in isoform 20).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047548.
FT   VAR_SEQ    1736   1769       VMQALPQVGNLGLLFMLLFFIFAALGVELFGDLE -> LWA
FT                                WSSLETWSVTRHTPVRAWAVMPPFGTLAWPS (in
FT                                isoform 27).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047549.
FT   VAR_SEQ    1737   1743       Missing (in isoform 14 and isoform 16).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047550.
FT   VAR_SEQ    1743   1776       VGNLGLLFMLLFFIFAALGVELFGDLECDETHPC -> LWA
FT                                WSSLETWSVTRHTPVRAWAVMPPFGTLAWPS (in
FT                                isoform 26, isoform 28, isoform 29,
FT                                isoform 30 and isoform 31).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047551.
FT   VAR_SEQ    1770   2377       Missing (in isoform 27).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047552.
FT   VAR_SEQ    1777   2377       Missing (in isoform 26, isoform 28,
FT                                isoform 29, isoform 30 and isoform 31).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_047553.
FT   VAR_SEQ    1928   2020       Missing (in isoform 1, isoform 2, isoform
FT                                4, isoform 6, isoform 9, isoform 11,
FT                                isoform 13, isoform 14, isoform 16,
FT                                isoform 17, isoform 18, isoform 20,
FT                                isoform 21, isoform 22, isoform 23,
FT                                isoform 25, isoform 33, isoform 34 and
FT                                isoform 35).
FT                                {ECO:0000303|PubMed:10574461,
FT                                ECO:0000303|PubMed:10648811,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_000946.
FT   VAR_SEQ    1928   1975       Missing (in isoform 10). {ECO:0000305}.
FT                                /FTId=VSP_000945.
FT   VAR_SEQ    1976   2020       Missing (in isoform 7, isoform 8, isoform
FT                                12, isoform 15 and isoform 24).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_000947.
FT   VAR_SEQ    2156   2234       Missing (in isoform 4, isoform 17 and
FT                                isoform 18).
FT                                {ECO:0000303|PubMed:16671074}.
FT                                /FTId=VSP_000948.
FT   VARIANT    1715   1715       R -> H (in SCA42; changed voltage-gated
FT                                calcium channel activity; membrane
FT                                potential dependency is shifted toward
FT                                more positive potentials).
FT                                {ECO:0000269|PubMed:26456284,
FT                                ECO:0000269|PubMed:26715324}.
FT                                /FTId=VAR_076292.
FT   CONFLICT   1345   1345       S -> I (in Ref. 10; AAD12731).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2377 AA;  262472 MW;  1C9F7C557D9D32DF CRC64;
     MDEEEDGAGA EESGQPRSFM RLNDLSGAGG RPGPGSAEKD PGSADSEAEG LPYPALAPVV
     FFYLSQDSRP RSWCLRTVCN PWFERISMLV ILLNCVTLGM FRPCEDIACD SQRCRILQAF
     DDFIFAFFAV EMVVKMVALG IFGKKCYLGD TWNRLDFFIV IAGMLEYSLD LQNVSFSAVR
     TVRVLRPLRA INRVPSMRIL VTLLLDTLPM LGNVLLLCFF VFFIFGIVGV QLWAGLLRNR
     CFLPENFSLP LSVDLERYYQ TENEDESPFI CSQPRENGMR SCRSVPTLRG DGGGGPPCGL
     DYEAYNSSSN TTCVNWNQYY TNCSAGEHNP FKGAINFDNI GYAWIAIFQV ITLEGWVDIM
     YFVMDAHSFY NFIYFILLII VGSFFMINLC LVVIATQFSE TKQRESQLMR EQRVRFLSNA
     STLASFSEPG SCYEELLKYL VYILRKAARR LAQVSRAAGV RVGLLSSPAP LGGQETQPSS
     SCSRSHRRLS VHHLVHHHHH HHHHYHLGNG TLRAPRASPE IQDRDANGSR RLMLPPPSTP
     ALSGAPPGGA ESVHSFYHAD CHLEPVRCQA PPPRSPSEAS GRTVGSGKVY PTVHTSPPPE
     TLKEKALVEV AASSGPPTLT SLNIPPGPYS SMHKLLETQS TGACQSSCKI SSPCLKADSG
     ACGPDSCPYC ARAGAGEVEL ADREMPDSDS EAVYEFTQDA QHSDLRDPHS RRQRSLGPDA
     EPSSVLAFWR LICDTFRKIV DSKYFGRGIM IAILVNTLSM GIEYHEQPEE LTNALEISNI
     VFTSLFALEM LLKLLVYGPF GYIKNPYNIF DGVIVVISVW EIVGQQGGGL SVLRTFRLMR
     VLKLVRFLPA LQRQLVVLMK TMDNVATFCM LLMLFIFIFS ILGMHLFGCK FASERDGDTL
     PDRKNFDSLL WAIVTVFQIL TQEDWNKVLY NGMASTSSWA ALYFIALMTF GNYVLFNLLV
     AILVEGFQAE EISKREDASG QLSCIQLPVD SQGGDANKSE SEPDFFSPSL DGDGDRKKCL
     ALVSLGEHPE LRKSLLPPLI IHTAATPMSL PKSTSTGLGE ALGPASRRTS SSGSAEPGAA
     HEMKSPPSAR SSPHSPWSAA SSWTSRRSSR NSLGRAPSLK RRSPSGERRS LLSGEGQESQ
     DEEESSEEER ASPAGSDHRH RGSLEREAKS SFDLPDTLQV PGLHRTASGR GSASEHQDCN
     GKSASGRLAR ALRPDDPPLD GDDADDEGNL SKGERVRAWI RARLPACCLE RDSWSAYIFP
     PQSRFRLLCH RIITHKMFDH VVLVIIFLNC ITIAMERPKI DPHSAERIFL TLSNYIFTAV
     FLAEMTVKVV ALGWCFGEQA YLRSSWNVLD GLLVLISVID ILVSMVSDSG TKILGMLRVL
     RLLRTLRPLR VISRAQGLKL VVETLMSSLK PIGNIVVICC AFFIIFGILG VQLFKGKFFV
     CQGEDTRNIT NKSDCAEASY RWVRHKYNFD NLGQALMSLF VLASKDGWVD IMYDGLDAVG
     VDQQPIMNHN PWMLLYFISF LLIVAFFVLN MFVGVVVENF HKCRQHQEEE EARRREEKRL
     RRLEKKRRNL MLDDVIASGS SASAASEAQC KPYYSDYSRF RLLVHHLCTS HYLDLFITGV
     IGLNVVTMAM EHYQQPQILD EALKICNYIF TVIFVLESVF KLVAFGFRRF FQDRWNQLDL
     AIVLLSIMGI TLEEIEVNAS LPINPTIIRI MRVLRIARVL KLLKMAVGMR ALLDTVMQAL
     PQVGNLGLLF MLLFFIFAAL GVELFGDLEC DETHPCEGLG RHATFRNFGM AFLTLFRVST
     GDNWNGIMKD TLRDCDQEST CYNTVISPIY FVSFVLTAQF VLVNVVIAVL MKHLEESNKE
     AKEEAELEAE LELEMKTLSP QPHSPLGSPF LWPGVEGPDS PDSPKPGALH PAAHARSASH
     FSLEHPTDRQ LFDTISLLIQ GSLEWELKLM DELAGPGGQP SAFPSAPSLG GSDPQIPLAE
     MEALSLTSEI VSEPSCSLAL TDDSLPDDMH TLLLSALESN MQPHPTELPG PDLLTVRKSG
     VSRTHSLPND SYMCRHGSTA EGPLGHRGWG LPKAQSGSVL SVHSQPADTS YILQLPKDAP
     HLLQPHSAPT WGTIPKLPPP GRSPLAQRPL RRQAAIRTDS LDVQGLGSRE DLLAEVSGPS
     PPLARAYSFW GQSSTQAQQH SRSHSKISKH MTPPAPCPGP EPNWGKGPPE TRSSLELDTE
     LSWISGDLLP PGGQEEPPSP RDLKKCYSVE AQSCQRRPTS WLDEQRRHSI AVSCLDSGSQ
     PHLGTDPSNL GGQPLGGPGS RPKKKLSPPS ITIDPPESQG PRTPPSPGIC LRRRAPSSDS
     KDPLASGPPD SMAASPSPKK DVLSLSGLSS DPADLDP
//
ID   CAC1H_HUMAN             Reviewed;        2353 AA.
AC   O95180; B5ME00; F8WFD1; O95802; Q8WWI6; Q96QI6; Q96RZ9; Q9NYY4;
AC   Q9NYY5;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   19-SEP-2002, sequence version 4.
DT   15-FEB-2017, entry version 162.
DE   RecName: Full=Voltage-dependent T-type calcium channel subunit alpha-1H;
DE   AltName: Full=Low-voltage-activated calcium channel alpha1 3.2 subunit;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav3.2;
GN   Name=CACNA1H;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-664, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=9670923; DOI=10.1161/01.RES.83.1.103;
RA   Cribbs L.L., Lee J.-H., Yang J., Satin J., Zhang Y., Daud A.N.,
RA   Barclay J., Wiliamson M.P., Fox M., Rees M., Perez-Reyes E.;
RT   "Cloning and characterization of alpha1H from human heart, a member of
RT   the T-type Ca2+ channel gene family.";
RL   Circ. Res. 83:103-109(1998).
RN   [2]
RP   SEQUENCE REVISION.
RA   Cribbs L.L., Lee J.-H., Yang J., Daud A.N., Perez-Reyes E.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT HIS-2077, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Thyroid carcinoma;
RX   PubMed=9930755; DOI=10.1046/j.1471-4159.1999.0720791.x;
RA   Williams M.E., Washburn M.S., Hans M., Urrutia A., Brust P.F.,
RA   Prodanovich P., Harpold M.M., Stauderman K.A.;
RT   "Structure and functional characterization of a novel human low-
RT   voltage activated calcium channel.";
RL   J. Neurochem. 72:791-799(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT ALA-664, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=11751928; DOI=10.1074/jbc.M105345200;
RA   Jagannathan S., Punt E.L., Gu Y., Arnoult C., Sakkas D., Barratt C.L.,
RA   Publicover S.J.;
RT   "Identification and localization of T-type voltage-operated calcium
RT   channel subunits in human male germ cells. Expression of multiple
RT   isoforms.";
RL   J. Biol. Chem. 277:8449-8456(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS VAL-313
RP   AND HIS-2060.
RX   PubMed=11157797; DOI=10.1093/hmg/10.4.339;
RA   Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K.,
RA   Tufarelli C., Kearney L., Buckle V.J., Doggett N.A., Flint J.,
RA   Higgs D.R.;
RT   "Sequence, structure and pathology of the fully annotated terminal 2
RT   Mb of the short arm of human chromosome 16.";
RL   Hum. Mol. Genet. 10:339-352(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-313.
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 424-661 AND 838-2373 (ISOFORM 1),
RP   AND VARIANTS LEU-640 AND HIS-2077.
RA   Mittman S., Agnew W.S.;
RT   "Organization and alternative splicing of CACNA1H.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   ZINC-BINDING SITES.
RX   PubMed=19940152; DOI=10.1074/jbc.M109.067660;
RA   Kang H.W., Vitko I., Lee S.S., Perez-Reyes E., Lee J.H.;
RT   "Structural determinants of the high affinity extracellular zinc
RT   binding site on Cav3.2 T-type calcium channels.";
RL   J. Biol. Chem. 285:3271-3281(2010).
RN   [9]
RP   VARIANTS ECA6 LEU-161; LYS-282; SER-456; SER-499; LEU-648; GLN-744;
RP   VAL-748; ASP-773; SER-784; MET-831; SER-848 AND ASN-1463, AND VARIANTS
RP   VAL-313; LEU-640; ALA-664; SER-684; CYS-788; HIS-2060; HIS-2077 AND
RP   SER-2173.
RX   PubMed=12891677; DOI=10.1002/ana.10607;
RA   Chen Y., Lu J., Pan H., Zhang Y., Wu H., Xu K., Liu X., Jiang Y.,
RA   Bao X., Yao Z., Ding K., Lo W.H., Qiang B., Chan P., Shen Y., Wu X.;
RT   "Association between genetic variation of CACNA1H and childhood
RT   absence epilepsy.";
RL   Ann. Neurol. 54:239-243(2003).
RN   [10]
RP   VARIANTS EIG6 LEU-618 AND ASP-755.
RX   PubMed=15048902; DOI=10.1002/ana.20028;
RA   Heron S.E., Phillips H.A., Mulley J.C., Mazarib A., Neufeld M.Y.,
RA   Berkovic S.F., Scheffer I.E.;
RT   "Genetic variation of CACNA1H in idiopathic generalized epilepsy.";
RL   Ann. Neurol. 55:595-596(2004).
RN   [11]
RP   VARIANT HALD4 VAL-1549, CHARACTERIZATION OF VARIANT HALD4 VAL-1549,
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=25907736; DOI=10.7554/eLife.06315;
RA   Scholl U.I., Stoelting G., Nelson-Williams C., Vichot A.A., Choi M.,
RA   Loring E., Prasad M.L., Goh G., Carling T., Juhlin C.C., Quack I.,
RA   Rump L.C., Thiel A., Lande M., Frazier B.G., Rasoulpour M.,
RA   Bowlin D.L., Sethna C.B., Trachtman H., Fahlke C., Lifton R.P.;
RT   "Recurrent gain of function mutation in calcium channel CACNA1H causes
RT   early-onset hypertension with primary aldosteronism.";
RL   Elife 4:E06315-E06315(2015).
RN   [12]
RP   VARIANTS HALD4 LEU-196; ILE-1549 AND LEU-2083, VARIANT GLU-1951,
RP   CHARACTERIZATION OF VARIANTS HALD4 LEU-196; ILE-1549 AND LEU-2083,
RP   CHARACTERIZATION OF VARIANT GLU-1951, FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=27729216; DOI=10.1016/j.ebiom.2016.10.002;
RA   Daniil G., Fernandes-Rosa F.L., Chemin J., Blesneac I., Beltrand J.,
RA   Polak M., Jeunemaitre X., Boulkroun S., Amar L., Strom T.M., Lory P.,
RA   Zennaro M.C.;
RT   "CACNA1H mutations are associated with different forms of primary
RT   aldosteronism.";
RL   EBioMedicine 13:225-236(2016).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. The isoform alpha-1H
CC       gives rise to T-type calcium currents. T-type calcium channels
CC       belong to the "low-voltage activated (LVA)" group and are strongly
CC       blocked by nickel and mibefradil. A particularity of this type of
CC       channels is an opening at quite negative potentials, and a
CC       voltage-dependent inactivation. T-type channels serve pacemaking
CC       functions in both central neurons and cardiac nodal cells and
CC       support calcium signaling in secretory cells and vascular smooth
CC       muscle. They may also be involved in the modulation of firing
CC       patterns of neurons which is important for information processing
CC       as well as in cell growth processes. In the adrenal zona
CC       glomerulosa, participates in the signaling pathway leading to
CC       aldosterone production in response to either AGT/angiotensin II,
CC       or hyperkalemia (PubMed:25907736, PubMed:27729216).
CC       {ECO:0000269|PubMed:25907736, ECO:0000269|PubMed:27729216}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=A1H-a;
CC         IsoId=O95180-1; Sequence=Displayed;
CC       Name=2; Synonyms=A1H-b;
CC         IsoId=O95180-2; Sequence=VSP_000949;
CC         Note=Ref.4 (CAD12646) sequence is in conflict in position:
CC         1587:K->E. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: In nonneuronal tissues, the highest expression
CC       levels are found in the kidney, liver, and heart. In the brain,
CC       most abundant in the amygdala, caudate nucleus, and putamen
CC       (PubMed:9670923, PubMed:9930755). In the heart, expressed in blood
CC       vessels. Isoform 1 and isoform 2 are expressed in testis,
CC       primarily in the germ cells, but not in other portions of the
CC       reproductive tract, such as ductus deferens. Isoform 2 is not
CC       detected in brain (PubMed:11751928). Expressed in the adrenal
CC       glomerulosa (at protein level) (PubMed:25907736, PubMed:27729216).
CC       {ECO:0000269|PubMed:11751928, ECO:0000269|PubMed:25907736,
CC       ECO:0000269|PubMed:27729216, ECO:0000269|PubMed:9670923,
CC       ECO:0000269|PubMed:9930755}.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- PTM: In response to raising of intracellular calcium, the T-type
CC       channels are activated by CaM-kinase II.
CC   -!- DISEASE: Epilepsy, idiopathic generalized 6 (EIG6) [MIM:611942]: A
CC       disorder characterized by recurring generalized seizures in the
CC       absence of detectable brain lesions and/or metabolic
CC       abnormalities. Generalized seizures arise diffusely and
CC       simultaneously from both hemispheres of the brain.
CC       {ECO:0000269|PubMed:15048902}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Epilepsy, childhood absence 6 (ECA6) [MIM:611942]: A
CC       subtype of idiopathic generalized epilepsy characterized by an
CC       onset at age 6-7 years, frequent absence seizures (several per
CC       day) and bilateral, synchronous, symmetric 3-Hz spike waves on
CC       EEG. Tonic-clonic seizures often develop in adolescence. Absence
CC       seizures may either remit or persist into adulthood.
CC       {ECO:0000269|PubMed:12891677}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Hyperaldosteronism, familial, 4 (HALD4) [MIM:617027]: A
CC       form of familial hyperaldosteronism, a disorder characterized by
CC       hypertension, elevated aldosterone levels despite low plasma renin
CC       activity, and abnormal adrenal steroid production. There is
CC       significant phenotypic heterogeneity, and some individuals never
CC       develop hypertension. {ECO:0000269|PubMed:25907736,
CC       ECO:0000269|PubMed:27729216}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1H subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK61268.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAC42094.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF051946; AAC67239.3; -; mRNA.
DR   EMBL; AF073931; AAD17668.1; -; mRNA.
DR   EMBL; AJ420779; CAD12646.1; -; mRNA.
DR   EMBL; AE006466; AAK61268.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL031703; CAC42094.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC120498; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF223562; AAF60162.1; -; Genomic_DNA.
DR   EMBL; AF223563; AAF60163.1; -; Genomic_DNA.
DR   CCDS; CCDS45375.1; -. [O95180-1]
DR   CCDS; CCDS45376.1; -. [O95180-2]
DR   RefSeq; NP_001005407.1; NM_001005407.1. [O95180-2]
DR   RefSeq; NP_066921.2; NM_021098.2. [O95180-1]
DR   UniGene; Hs.459642; -.
DR   ProteinModelPortal; O95180; -.
DR   BioGrid; 114426; 5.
DR   IntAct; O95180; 2.
DR   STRING; 9606.ENSP00000334198; -.
DR   BindingDB; O95180; -.
DR   ChEMBL; CHEMBL1859; -.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB01244; Bepridil.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB01023; Felodipine.
DR   DrugBank; DB04841; Flunarizine.
DR   DrugBank; DB00270; Isradipine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB01054; Nitrendipine.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 536; -.
DR   TCDB; 1.A.1.11.5; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; O95180; -.
DR   PhosphoSitePlus; O95180; -.
DR   BioMuta; CACNA1H; -.
DR   PaxDb; O95180; -.
DR   PeptideAtlas; O95180; -.
DR   PRIDE; O95180; -.
DR   Ensembl; ENST00000348261; ENSP00000334198; ENSG00000196557. [O95180-1]
DR   Ensembl; ENST00000358590; ENSP00000351401; ENSG00000196557. [O95180-2]
DR   Ensembl; ENST00000565831; ENSP00000455840; ENSG00000196557. [O95180-2]
DR   GeneID; 8912; -.
DR   KEGG; hsa:8912; -.
DR   UCSC; uc002cks.4; human. [O95180-1]
DR   CTD; 8912; -.
DR   DisGeNET; 8912; -.
DR   GeneCards; CACNA1H; -.
DR   H-InvDB; HIX0038538; -.
DR   HGNC; HGNC:1395; CACNA1H.
DR   HPA; HPA039125; -.
DR   MalaCards; CACNA1H; -.
DR   MIM; 607904; gene.
DR   MIM; 611942; phenotype.
DR   MIM; 617027; phenotype.
DR   neXtProt; NX_O95180; -.
DR   OpenTargets; ENSG00000196557; -.
DR   Orphanet; 64280; Childhood absence epilepsy.
DR   PharmGKB; PA380; -.
DR   eggNOG; ENOG410IP4J; Eukaryota.
DR   eggNOG; COG1226; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOVERGEN; HBG050764; -.
DR   InParanoid; O95180; -.
DR   KO; K04855; -.
DR   OMA; KMYSLAV; -.
DR   OrthoDB; EOG090300TD; -.
DR   PhylomeDB; O95180; -.
DR   TreeFam; TF313555; -.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   ChiTaRS; CACNA1H; human.
DR   GeneWiki; CACNA1H; -.
DR   GenomeRNAi; 8912; -.
DR   PRO; PR:O95180; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000196557; -.
DR   CleanEx; HS_CACNA1H; -.
DR   ExpressionAtlas; O95180; baseline and differential.
DR   Genevisible; O95180; HS.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; TAS:ProtInc.
DR   GO; GO:0008332; F:low voltage-gated calcium channel activity; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0032342; P:aldosterone biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0070509; P:calcium ion import; IDA:BHF-UCL.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IEP:UniProtKB.
DR   GO; GO:0035865; P:cellular response to potassium ion; IEP:UniProtKB.
DR   GO; GO:0034651; P:cortisol biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   GO; GO:0007517; P:muscle organ development; NAS:ProtInc.
DR   GO; GO:0007520; P:myoblast fusion; TAS:ProtInc.
DR   GO; GO:2000344; P:positive regulation of acrosome reaction; IMP:UniProtKB.
DR   GO; GO:0008016; P:regulation of heart contraction; TAS:ProtInc.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:BHF-UCL.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR005445; VDCC_T_a1.
DR   InterPro; IPR030160; VDCC_T_a1H.
DR   PANTHER; PTHR10037:SF227; PTHR10037:SF227; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR01629; TVDCCALPHA1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Calcium channel; Calcium transport;
KW   Complete proteome; Disease mutation; Epilepsy; Glycoprotein;
KW   Ion channel; Ion transport; Membrane; Metal-binding; Polymorphism;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix;
KW   Transport; Voltage-gated channel; Zinc.
FT   CHAIN         1   2353       Voltage-dependent T-type calcium channel
FT                                subunit alpha-1H.
FT                                /FTId=PRO_0000053954.
FT   TOPO_DOM      1    100       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    101    119       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    120    141       Extracellular. {ECO:0000255}.
FT   TRANSMEM    142    160       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    161    169       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    170    184       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    185    193       Extracellular. {ECO:0000255}.
FT   TRANSMEM    194    212       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    213    232       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    233    253       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    254    394       Extracellular. {ECO:0000255}.
FT   TRANSMEM    395    419       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    420    793       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    794    814       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    815    827       Extracellular. {ECO:0000255}.
FT   TRANSMEM    828    849       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    850    855       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    856    874       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    875    882       Extracellular. {ECO:0000255}.
FT   TRANSMEM    883    906       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    907    917       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    918    938       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    939    990       Extracellular. {ECO:0000255}.
FT   TRANSMEM    991   1015       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1016   1290       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1291   1313       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1314   1331       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1332   1352       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1353   1362       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1363   1382       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1383   1396       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1397   1418       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1419   1428       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1429   1452       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1453   1529       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1530   1555       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1556   1616       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1617   1637       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1638   1651       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1652   1673       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1674   1680       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1681   1699       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1700   1713       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1714   1737       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1738   1751       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1752   1772       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1773   1835       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1836   1863       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1864   2353       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       87    422       I.
FT   REPEAT      779   1018       II.
FT   REPEAT     1281   1558       III.
FT   REPEAT     1602   1863       IV.
FT   COMPBIAS    520    530       Poly-His.
FT   COMPBIAS   1107   1110       Poly-Ser.
FT   COMPBIAS   1583   1586       Poly-Arg.
FT   METAL       140    140       Zinc.
FT   METAL       189    189       Zinc.
FT   METAL       191    191       Zinc.
FT   SITE        378    378       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        974    974       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1504   1504       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1808   1808       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   CARBOHYD    192    192       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    271    271       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1466   1466       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ    1587   1593       STFPSPE -> K (in isoform 2).
FT                                {ECO:0000303|PubMed:11751928}.
FT                                /FTId=VSP_000949.
FT   VARIANT     161    161       F -> L (in ECA6; dbSNP:rs119454947).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045935.
FT   VARIANT     196    196       S -> L (in HALD4; changed calcium channel
FT                                activity; increased aldosterone
FT                                production in response to potassium ion
FT                                stimulation; increased expression of
FT                                genes involved in aldosterone
FT                                biosynthesis, with the strongest effect
FT                                observed on CYP11B2 expression in
FT                                response to potassium ion stimulation;
FT                                dbSNP:rs780596901).
FT                                {ECO:0000269|PubMed:27729216}.
FT                                /FTId=VAR_077064.
FT   VARIANT     282    282       E -> K (in ECA6; dbSNP:rs119454948).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045936.
FT   VARIANT     313    313       M -> V (in dbSNP:rs36117280).
FT                                {ECO:0000269|PubMed:11157797,
FT                                ECO:0000269|PubMed:12891677,
FT                                ECO:0000269|PubMed:15616553}.
FT                                /FTId=VAR_045937.
FT   VARIANT     456    456       C -> S (in ECA6).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045938.
FT   VARIANT     499    499       G -> S (in ECA6; dbSNP:rs560915333).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045939.
FT   VARIANT     618    618       P -> L (in EIG6; dbSNP:rs60734921).
FT                                {ECO:0000269|PubMed:15048902}.
FT                                /FTId=VAR_066986.
FT   VARIANT     640    640       P -> L (in dbSNP:rs61734410).
FT                                {ECO:0000269|PubMed:12891677,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_045940.
FT   VARIANT     648    648       P -> L (in ECA6).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045941.
FT   VARIANT     664    664       V -> A (in dbSNP:rs4984636).
FT                                {ECO:0000269|PubMed:11751928,
FT                                ECO:0000269|PubMed:12891677,
FT                                ECO:0000269|PubMed:9670923}.
FT                                /FTId=VAR_045942.
FT   VARIANT     684    684       P -> S (in dbSNP:rs762185083).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045943.
FT   VARIANT     744    744       R -> Q (in ECA6; dbSNP:rs373764821).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045944.
FT   VARIANT     748    748       A -> V (in ECA6; dbSNP:rs770371468).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045945.
FT   VARIANT     755    755       G -> D (in EIG6; dbSNP:rs142306293).
FT                                {ECO:0000269|PubMed:15048902}.
FT                                /FTId=VAR_066987.
FT   VARIANT     773    773       G -> D (in ECA6; dbSNP:rs267606697).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045946.
FT   VARIANT     784    784       G -> S (in ECA6; dbSNP:rs779526640).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045947.
FT   VARIANT     788    788       R -> C (in dbSNP:rs3751664).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045948.
FT   VARIANT     812    812       V -> M (in dbSNP:rs28365119).
FT                                /FTId=VAR_045949.
FT   VARIANT     831    831       V -> M (in ECA6; dbSNP:rs119454949).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045950.
FT   VARIANT     848    848       G -> S (in ECA6; dbSNP:rs374272094).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045951.
FT   VARIANT    1463   1463       D -> N (in ECA6; dbSNP:rs542245543).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045952.
FT   VARIANT    1549   1549       M -> I (in HALD4; changed calcium channel
FT                                activity; increased aldosterone
FT                                production in response to potassium ion
FT                                stimulation; increased expression of
FT                                genes involved in aldosterone
FT                                biosynthesis, with the strongest effect
FT                                observed on CYP11B2 expression in
FT                                response to potassium ion stimulation).
FT                                {ECO:0000269|PubMed:27729216}.
FT                                /FTId=VAR_077065.
FT   VARIANT    1549   1549       M -> V (in HALD4; changed calcium channel
FT                                activity; dbSNP:rs786205050).
FT                                {ECO:0000269|PubMed:25907736}.
FT                                /FTId=VAR_077066.
FT   VARIANT    1871   1871       R -> Q (in dbSNP:rs58124832).
FT                                /FTId=VAR_061104.
FT   VARIANT    1951   1951       V -> E (probable disease-associated
FT                                mutation responsible for primary
FT                                aldosteronism found in a patient with
FT                                aldosterone-producing adenoma; changed
FT                                Ca(2+) channel activity;
FT                                dbSNP:rs746967306).
FT                                {ECO:0000269|PubMed:27729216}.
FT                                /FTId=VAR_077067.
FT   VARIANT    1974   1974       E -> G (in dbSNP:rs3751886).
FT                                /FTId=VAR_033698.
FT   VARIANT    2060   2060       R -> H (in dbSNP:rs1054644).
FT                                {ECO:0000269|PubMed:11157797,
FT                                ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045953.
FT   VARIANT    2077   2077       R -> H (in dbSNP:rs1054645).
FT                                {ECO:0000269|PubMed:12891677,
FT                                ECO:0000269|PubMed:9930755,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_045954.
FT   VARIANT    2083   2083       P -> L (in HALD4; changed calcium channel
FT                                activity; dbSNP:rs759924732).
FT                                {ECO:0000269|PubMed:27729216}.
FT                                /FTId=VAR_077068.
FT   VARIANT    2173   2173       P -> S (in dbSNP:rs200675829).
FT                                {ECO:0000269|PubMed:12891677}.
FT                                /FTId=VAR_045955.
FT   CONFLICT      7      7       A -> S (in Ref. 5; AC120498).
FT                                {ECO:0000305}.
FT   CONFLICT     31     31       E -> K (in Ref. 5; AC120498).
FT                                {ECO:0000305}.
FT   CONFLICT     55     55       A -> S (in Ref. 5; AC120498).
FT                                {ECO:0000305}.
FT   CONFLICT     94     94       L -> V (in Ref. 5; AC120498).
FT                                {ECO:0000305}.
FT   CONFLICT    215    215       S -> T (in Ref. 6; CAC42094).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2353 AA;  259163 MW;  E13E270635173D98 CRC64;
     MTEGARAADE VRVPLGAPPP GPAALVGASP ESPGAPGREA ERGSELGVSP SESPAAERGA
     ELGADEEQRV PYPALAATVF FCLGQTTRPR SWCLRLVCNP WFEHVSMLVI MLNCVTLGMF
     RPCEDVECGS ERCNILEAFD AFIFAFFAVE MVIKMVALGL FGQKCYLGDT WNRLDFFIVV
     AGMMEYSLDG HNVSLSAIRT VRVLRPLRAI NRVPSMRILV TLLLDTLPML GNVLLLCFFV
     FFIFGIVGVQ LWAGLLRNRC FLDSAFVRNN NLTFLRPYYQ TEEGEENPFI CSSRRDNGMQ
     KCSHIPGRRE LRMPCTLGWE AYTQPQAEGV GAARNACINW NQYYNVCRSG DSNPHNGAIN
     FDNIGYAWIA IFQVITLEGW VDIMYYVMDA HSFYNFIYFI LLIIVGSFFM INLCLVVIAT
     QFSETKQRES QLMREQRARH LSNDSTLASF SEPGSCYEEL LKYVGHIFRK VKRRSLRLYA
     RWQSRWRKKV DPSAVQGQGP GHRQRRAGRH TASVHHLVYH HHHHHHHHYH FSHGSPRRPG
     PEPGACDTRL VRAGAPPSPP SPGRGPPDAE SVHSIYHADC HIEGPQERAR VAHAAATAAA
     SLRLATGLGT MNYPTILPSG VGSGKGSTSP GPKGKWAGGP PGTGGHGPLS LNSPDPYEKI
     PHVVGEHGLG QAPGHLSGLS VPCPLPSPPA GTLTCELKSC PYCTRALEDP EGELSGSESG
     DSDGRGVYEF TQDVRHGDRW DPTRPPRATD TPGPGPGSPQ RRAQQRAAPG EPGWMGRLWV
     TFSGKLRRIV DSKYFSRGIM MAILVNTLSM GVEYHEQPEE LTNALEISNI VFTSMFALEM
     LLKLLACGPL GYIRNPYNIF DGIIVVISVW EIVGQADGGL SVLRTFRLLR VLKLVRFLPA
     LRRQLVVLVK TMDNVATFCT LLMLFIFIFS ILGMHLFGCK FSLKTDTGDT VPDRKNFDSL
     LWAIVTVFQI LTQEDWNVVL YNGMASTSSW AALYFVALMT FGNYVLFNLL VAILVEGFQA
     EGDANRSDTD EDKTSVHFEE DFHKLRELQT TELKMCSLAV TPNGHLEGRG SLSPPLIMCT
     AATPMPTPKS SPFLDAAPSL PDSRRGSSSS GDPPLGDQKP PASLRSSPCA PWGPSGAWSS
     RRSSWSSLGR APSLKRRGQC GERESLLSGE GKGSTDDEAE DGRAAPGPRA TPLRRAESLD
     PRPLRPAALP PTKCRDRDGQ VVALPSDFFL RIDSHREDAA ELDDDSEDSC CLRLHKVLEP
     YKPQWCRSRE AWALYLFSPQ NRFRVSCQKV ITHKMFDHVV LVFIFLNCVT IALERPDIDP
     GSTERVFLSV SNYIFTAIFV AEMMVKVVAL GLLSGEHAYL QSSWNLLDGL LVLVSLVDIV
     VAMASAGGAK ILGVLRVLRL LRTLRPLRVI SRAPGLKLVV ETLISSLRPI GNIVLICCAF
     FIIFGILGVQ LFKGKFYYCE GPDTRNISTK AQCRAAHYRW VRRKYNFDNL GQALMSLFVL
     SSKDGWVNIM YDGLDAVGVD QQPVQNHNPW MLLYFISFLL IVSFFVLNMF VGVVVENFHK
     CRQHQEAEEA RRREEKRLRR LERRRRSTFP SPEAQRRPYY ADYSPTRRSI HSLCTSHYLD
     LFITFIICVN VITMSMEHYN QPKSLDEALK YCNYVFTIVF VFEAALKLVA FGFRRFFKDR
     WNQLDLAIVL LSLMGITLEE IEMSAALPIN PTIIRIMRVL RIARVLKLLK MATGMRALLD
     TVVQALPQVG NLGLLFMLLF FIYAALGVEL FGRLECSEDN PCEGLSRHAT FSNFGMAFLT
     LFRVSTGDNW NGIMKDTLRE CSREDKHCLS YLPALSPVYF VTFVLVAQFV LVNVVVAVLM
     KHLEESNKEA REDAELDAEI ELEMAQGPGS ARRVDADRPP LPQESPGARD APNLVARKVS
     VSRMLSLPND SYMFRPVVPA SAPHPRPLQE VEMETYGAGT PLGSVASVHS PPAESCASLQ
     IPLAVSSPAR SGEPLHALSP RGTARSPSLS RLLCRQEAVH TDSLEGKIDS PRDTLDPAEP
     GEKTPVRPVT QGGSLQSPPR SPRPASVRTR KHTFGQRCVS SRPAAPGGEE AEASDPADEE
     VSHITSSACP WQPTAEPHGP EASPVAGGER DLRRLYSVDA QGFLDKPGRA DEQWRPSAEL
     GSGEPGEAKA WGPEAEPALG ARRKKKMSPP CISVEPPAED EGSARPSAAE GGSTTLRRRT
     PSCEATPHRD SLEPTEGSGA GGDPAAKGER WGQASCRAEH LTVPSFAFEP LDLGVPSGDP
     FLDGSHSVTP ESRASSSGAI VPLEPPESEP PMPVGDPPEK RRGLYLTVPQ CPLEKPGSPS
     ATPAPGGGAD DPV
//
ID   CAC1I_HUMAN             Reviewed;        2223 AA.
AC   Q9P0X4; B0QY12; B0QY13; B0QY14; O95504; Q5JZ88; Q7Z6S9; Q8NFX6;
AC   Q9NZC8; Q9UH15; Q9UH30; Q9ULU9; Q9UNE6;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   15-FEB-2017, entry version 141.
DE   RecName: Full=Voltage-dependent T-type calcium channel subunit alpha-1I;
DE   AltName: Full=Voltage-gated calcium channel subunit alpha Cav3.3;
DE            Short=Ca(v)3.3;
GN   Name=CACNA1I; Synonyms=KIAA1120;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=10454147; DOI=10.1016/S0304-3940(99)00319-5;
RA   Mittman S., Guo J., Emerick M.C., Agnew W.S.;
RT   "Structure and alternative splicing of the gene encoding alpha1I, a
RT   human brain T calcium channel alpha1 subunit.";
RL   Neurosci. Lett. 269:121-124(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10749850; DOI=10.1074/jbc.C000090200;
RA   Monteil A., Chemin J., Leuranguer V., Altier C., Mennessier G.,
RA   Bourinet E., Lory P., Nargeot J.;
RT   "Specific properties of T-type calcium channels generated by the human
RT   alpha1I subunit.";
RL   J. Biol. Chem. 275:16530-16535(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT VAL-1040.
RC   TISSUE=Brain;
RX   PubMed=12080115; DOI=10.1016/S0006-3495(02)75164-3;
RA   Gomora J.C., Murbartian J., Arias J.M., Lee J.-H., Perez-Reyes E.;
RT   "Cloning and expression of the human T-type channel Ca(v)3.3: insights
RT   into prepulse facilitation.";
RL   Biophys. J. 83:229-241(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1200-2223 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis
RT   from size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [6]
RP   INTERACTION WITH CATSPER1 AND CATSPER2.
RX   PubMed=16740636; DOI=10.1074/jbc.M511288200;
RA   Zhang D., Chen J., Saraf A., Cassar S., Han P., Rogers J.C.,
RA   Brioni J.D., Sullivan J.P., Gopalakrishnan M.;
RT   "Association of Catsper1 or -2 with Ca(v)3.3 leads to suppression of
RT   T-type calcium channel activity.";
RL   J. Biol. Chem. 281:22332-22341(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
CC   -!- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the
CC       entry of calcium ions into excitable cells and are also involved
CC       in a variety of calcium-dependent processes, including muscle
CC       contraction, hormone or neurotransmitter release, gene expression,
CC       cell motility, cell division and cell death. This channel gives
CC       rise to T-type calcium currents. T-type calcium channels belong to
CC       the "low-voltage activated (LVA)" group and are strongly blocked
CC       by nickel and mibefradil. A particularity of this type of channels
CC       is an opening at quite negative potentials, and a voltage-
CC       dependent inactivation. T-type channels serve pacemaking functions
CC       in both central neurons and cardiac nodal cells and support
CC       calcium signaling in secretory cells and vascular smooth muscle.
CC       They may also be involved in the modulation of firing patterns of
CC       neurons which is important for information processing as well as
CC       in cell growth processes. Gates in voltage ranges similar to, but
CC       higher than alpha 1G or alpha 1H (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with CATSPER1 and CATSPER2, leading to suppress
CC       T-type calcium channel activity. {ECO:0000269|PubMed:16740636}.
CC   -!- INTERACTION:
CC       Q8NEC5:CATSPER1; NbExp=5; IntAct=EBI-1220829, EBI-744545;
CC       Q96P56:CATSPER2; NbExp=3; IntAct=EBI-1220829, EBI-2215024;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Delta36b;
CC         IsoId=Q9P0X4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9P0X4-2; Sequence=VSP_000951;
CC       Name=3; Synonyms=Alpha1I-a;
CC         IsoId=Q9P0X4-3; Sequence=VSP_000950, VSP_000951;
CC       Name=4;
CC         IsoId=Q9P0X4-4; Sequence=VSP_000950;
CC   -!- TISSUE SPECIFICITY: Brain specific.
CC   -!- DOMAIN: Each of the four internal repeats contains five
CC       hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one
CC       positively charged transmembrane segment (S4). S4 segments
CC       probably represent the voltage-sensor and are characterized by a
CC       series of positively charged amino acids at every third position.
CC   -!- PTM: In response to raising of intracellular calcium, the T-type
CC       channels are activated by CaM-kinase II. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. CACNA1I subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF129133; AAD45251.1; -; mRNA.
DR   EMBL; AF142567; AAF25722.1; -; mRNA.
DR   EMBL; AF211189; AAF44626.1; -; mRNA.
DR   EMBL; AF393329; AAM67414.1; -; mRNA.
DR   EMBL; AL008716; CAI17903.1; -; Genomic_DNA.
DR   EMBL; AL022312; CAI17903.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAI17903.1; JOINED; Genomic_DNA.
DR   EMBL; AL022312; CAI19180.1; -; Genomic_DNA.
DR   EMBL; AL008716; CAI19180.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAI19180.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAI19662.1; -; Genomic_DNA.
DR   EMBL; AL022312; CAI19662.1; JOINED; Genomic_DNA.
DR   EMBL; AL008716; CAI19662.1; JOINED; Genomic_DNA.
DR   EMBL; AL022312; CAQ08289.1; -; Genomic_DNA.
DR   EMBL; AL008716; CAQ08289.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ08289.1; JOINED; Genomic_DNA.
DR   EMBL; AL022312; CAQ08290.1; -; Genomic_DNA.
DR   EMBL; AL008716; CAQ08290.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ08290.1; JOINED; Genomic_DNA.
DR   EMBL; AL022312; CAQ08291.1; -; Genomic_DNA.
DR   EMBL; AL008716; CAQ08291.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ08291.1; JOINED; Genomic_DNA.
DR   EMBL; AL008716; CAQ09516.1; -; Genomic_DNA.
DR   EMBL; AL022312; CAQ09516.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ09516.1; JOINED; Genomic_DNA.
DR   EMBL; AL008716; CAQ09517.1; -; Genomic_DNA.
DR   EMBL; AL022312; CAQ09517.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ09517.1; JOINED; Genomic_DNA.
DR   EMBL; AL008716; CAQ09518.1; -; Genomic_DNA.
DR   EMBL; AL022312; CAQ09518.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ09518.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ09681.1; -; Genomic_DNA.
DR   EMBL; AL008716; CAQ09681.1; JOINED; Genomic_DNA.
DR   EMBL; AL022312; CAQ09681.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ09682.1; -; Genomic_DNA.
DR   EMBL; AL008716; CAQ09682.1; JOINED; Genomic_DNA.
DR   EMBL; AL022312; CAQ09682.1; JOINED; Genomic_DNA.
DR   EMBL; AL022319; CAQ09683.1; -; Genomic_DNA.
DR   EMBL; AL008716; CAQ09683.1; JOINED; Genomic_DNA.
DR   EMBL; AL022312; CAQ09683.1; JOINED; Genomic_DNA.
DR   EMBL; AB032946; BAA86434.1; -; mRNA.
DR   CCDS; CCDS46710.1; -. [Q9P0X4-1]
DR   CCDS; CCDS46711.1; -. [Q9P0X4-4]
DR   RefSeq; NP_001003406.1; NM_001003406.1. [Q9P0X4-4]
DR   RefSeq; NP_066919.2; NM_021096.3. [Q9P0X4-1]
DR   UniGene; Hs.125116; -.
DR   ProteinModelPortal; Q9P0X4; -.
DR   BioGrid; 114425; 1.
DR   IntAct; Q9P0X4; 3.
DR   STRING; 9606.ENSP00000385019; -.
DR   BindingDB; Q9P0X4; -.
DR   ChEMBL; CHEMBL5558; -.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB04841; Flunarizine.
DR   DrugBank; DB00617; Paramethadione.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00661; Verapamil.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 537; -.
DR   TCDB; 1.A.1.11.7; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; Q9P0X4; -.
DR   PhosphoSitePlus; Q9P0X4; -.
DR   BioMuta; CACNA1I; -.
DR   DMDM; 23396521; -.
DR   EPD; Q9P0X4; -.
DR   PaxDb; Q9P0X4; -.
DR   PeptideAtlas; Q9P0X4; -.
DR   PRIDE; Q9P0X4; -.
DR   Ensembl; ENST00000401624; ENSP00000383887; ENSG00000100346. [Q9P0X4-2]
DR   Ensembl; ENST00000402142; ENSP00000385019; ENSG00000100346. [Q9P0X4-1]
DR   Ensembl; ENST00000404898; ENSP00000384093; ENSG00000100346. [Q9P0X4-4]
DR   Ensembl; ENST00000407673; ENSP00000385680; ENSG00000100346. [Q9P0X4-3]
DR   GeneID; 8911; -.
DR   KEGG; hsa:8911; -.
DR   UCSC; uc003ayc.5; human. [Q9P0X4-1]
DR   CTD; 8911; -.
DR   GeneCards; CACNA1I; -.
DR   HGNC; HGNC:1396; CACNA1I.
DR   MIM; 608230; gene.
DR   neXtProt; NX_Q9P0X4; -.
DR   OpenTargets; ENSG00000100346; -.
DR   PharmGKB; PA26011; -.
DR   eggNOG; KOG2302; Eukaryota.
DR   eggNOG; COG1226; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOVERGEN; HBG050764; -.
DR   InParanoid; Q9P0X4; -.
DR   KO; K04856; -.
DR   OMA; KMPNIAK; -.
DR   OrthoDB; EOG090300TD; -.
DR   PhylomeDB; Q9P0X4; -.
DR   TreeFam; TF313555; -.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   ChiTaRS; CACNA1I; human.
DR   GeneWiki; CACNA1I; -.
DR   GenomeRNAi; 8911; -.
DR   PRO; PR:Q9P0X4; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000100346; -.
DR   Genevisible; Q9P0X4; HS.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IEA:InterPro.
DR   GO; GO:0008332; F:low voltage-gated calcium channel activity; IEA:InterPro.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; TAS:ProtInc.
DR   GO; GO:0070509; P:calcium ion import; IEA:InterPro.
DR   GO; GO:0030317; P:flagellated sperm motility; IEA:InterPro.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0019228; P:neuronal action potential; IEA:Ensembl.
DR   GO; GO:0045956; P:positive regulation of calcium ion-dependent exocytosis; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0030431; P:sleep; IEA:Ensembl.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR030162; CACNA1I.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR005445; VDCC_T_a1.
DR   InterPro; IPR002077; VDCCAlpha1.
DR   PANTHER; PTHR10037:SF258; PTHR10037:SF258; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   PRINTS; PR00167; CACHANNEL.
DR   PRINTS; PR01629; TVDCCALPHA1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Calcium channel; Calcium transport;
KW   Complete proteome; Glycoprotein; Ion channel; Ion transport; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN         1   2223       Voltage-dependent T-type calcium channel
FT                                subunit alpha-1I.
FT                                /FTId=PRO_0000053957.
FT   TOPO_DOM      1     78       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     79     99       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    100    120       Extracellular. {ECO:0000255}.
FT   TRANSMEM    121    141       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    142    148       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    149    168       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    169    173       Extracellular. {ECO:0000255}.
FT   TRANSMEM    174    191       Helical; Name=S4 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    192    211       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    212    232       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    233    377       Extracellular. {ECO:0000255}.
FT   TRANSMEM    378    398       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    399    640       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    641    661       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    662    676       Extracellular. {ECO:0000255}.
FT   TRANSMEM    677    697       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    698    702       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    703    721       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    722    729       Extracellular. {ECO:0000255}.
FT   TRANSMEM    730    753       Helical; Name=S4 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    754    764       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    765    785       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    786    841       Extracellular. {ECO:0000255}.
FT   TRANSMEM    842    862       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    863   1166       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1167   1187       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1188   1209       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1210   1230       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1231   1244       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1245   1265       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1266   1272       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1273   1294       Helical; Name=S4 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1295   1304       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1305   1325       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1326   1410       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1411   1431       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1432   1485       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1486   1506       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1507   1522       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1523   1543       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1544   1556       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1557   1577       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1578   1583       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1584   1607       Helical; Name=S4 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1608   1621       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1622   1642       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1643   1709       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1710   1730       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1731   2223       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       66    401       I.
FT   REPEAT      626    865       II.
FT   REPEAT     1157   1434       III.
FT   REPEAT     1472   1733       IV.
FT   COMPBIAS    608    613       Poly-Glu.
FT   COMPBIAS   1775   1783       Poly-Gly.
FT   COMPBIAS   2110   2120       Poly-Gly.
FT   COMPBIAS   2138   2145       Poly-Pro.
FT   SITE        357    357       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE        821    821       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1380   1380       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   SITE       1678   1678       Calcium ion selectivity and permeability.
FT                                {ECO:0000250}.
FT   MOD_RES    1058   1058       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z0Y8}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    244    244       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1342   1342       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1345   1345       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     488    523       HGKTKGQGDEGRHLGSRHCQTLHGPASPGNDHSGRE -> Q
FT                                (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:10749850,
FT                                ECO:0000303|PubMed:12080115}.
FT                                /FTId=VSP_000950.
FT   VAR_SEQ    2010   2223       ATGSDTSLDASPSSSAGSLQTTLEDSLTLSDSPRRALGPPA
FT                                PAPGPRAGLSPAARRRLSLRGRGLFSLRGLRAHQRSHSSGG
FT                                STSPGCTHHDSMDPSDEEGRGGAGGGGAGSEHSETLSSLSL
FT                                TSLFCPPPPPPAPGLTPARKFSSTSSLAAPGRPHAAALAHG
FT                                LARSPSWAADRSKDPPGRAPLPMGLGPLAPPPQPLPGELEP
FT                                GDAASKRKR -> VPTPPRP (in isoform 2 and
FT                                isoform 3). {ECO:0000303|PubMed:10454147,
FT                                ECO:0000303|PubMed:10749850}.
FT                                /FTId=VSP_000951.
FT   VARIANT    1040   1040       I -> V (in dbSNP:rs136853).
FT                                {ECO:0000269|PubMed:12080115}.
FT                                /FTId=VAR_013883.
FT   VARIANT    1513   1513       T -> M (in dbSNP:rs8141262).
FT                                /FTId=VAR_048745.
FT   VARIANT    1782   1782       G -> A (in dbSNP:rs2294369).
FT                                /FTId=VAR_013884.
FT   VARIANT    1782   1782       G -> R (in dbSNP:rs2294369).
FT                                /FTId=VAR_020050.
SQ   SEQUENCE   2223 AA;  245103 MW;  3CAE4D1C4289D08B CRC64;
     MAESASPPSS SAAAPAAEPG VTTEQPGPRS PPSSPPGLEE PLDGADPHVP HPDLAPIAFF
     CLRQTTSPRN WCIKMVCNPW FECVSMLVIL LNCVTLGMYQ PCDDMDCLSD RCKILQVFDD
     FIFIFFAMEM VLKMVALGIF GKKCYLGDTW NRLDFFIVMA GMVEYSLDLQ NINLSAIRTV
     RVLRPLKAIN RVPSMRILVN LLLDTLPMLG NVLLLCFFVF FIFGIIGVQL WAGLLRNRCF
     LEENFTIQGD VALPPYYQPE EDDEMPFICS LSGDNGIMGC HEIPPLKEQG RECCLSKDDV
     YDFGAGRQDL NASGLCVNWN RYYNVCRTGS ANPHKGAINF DNIGYAWIVI FQVITLEGWV
     EIMYYVMDAH SFYNFIYFIL LIIVGSFFMI NLCLVVIATQ FSETKQREHR LMLEQRQRYL
     SSSTVASYAE PGDCYEEIFQ YVCHILRKAK RRALGLYQAL QSRRQALGPE APAPAKPGPH
     AKEPRHYHGK TKGQGDEGRH LGSRHCQTLH GPASPGNDHS GRELCPQHSP LDATPHTLVQ
     PIPATLASDP ASCPCCQHED GRRPSGLGST DSGQEGSGSG SSAGGEDEAD GDGARSSEDG
     ASSELGKEEE EEEQADGAVW LCGDVWRETR AKLRGIVDSK YFNRGIMMAI LVNTVSMGIE
     HHEQPEELTN ILEICNVVFT SMFALEMILK LAAFGLFDYL RNPYNIFDSI IVIISIWEIV
     GQADGGLSVL RTFRLLRVLK LVRFMPALRR QLVVLMKTMD NVATFCMLLM LFIFIFSILG
     MHIFGCKFSL RTDTGDTVPD RKNFDSLLWA IVTVFQILTQ EDWNVVLYNG MASTSPWASL
     YFVALMTFGN YVLFNLLVAI LVEGFQAEGD ANRSYSDEDQ SSSNIEEFDK LQEGLDSSGD
     PKLCPIPMTP NGHLDPSLPL GGHLGPAGAA GPAPRLSLQP DPMLVALGSR KSSVMSLGRM
     SYDQRSLSSS RSSYYGPWGR SAAWASRRSS WNSLKHKPPS AEHESLLSAE RGGGARVCEV
     AADEGPPRAA PLHTPHAHHI HHGPHLAHRH RHHRRTLSLD NRDSVDLAEL VPAVGAHPRA
     AWRAAGPAPG HEDCNGRMPS IAKDVFTKMG DRGDRGEDEE EIDYTLCFRV RKMIDVYKPD
     WCEVREDWSV YLFSPENRFR VLCQTIIAHK LFDYVVLAFI FLNCITIALE RPQIEAGSTE
     RIFLTVSNYI FTAIFVGEMT LKVVSLGLYF GEQAYLRSSW NVLDGFLVFV SIIDIVVSLA
     SAGGAKILGV LRVLRLLRTL RPLRVISRAP GLKLVVETLI SSLKPIGNIV LICCAFFIIF
     GILGVQLFKG KFYHCLGVDT RNITNRSDCM AANYRWVHHK YNFDNLGQAL MSLFVLASKD
     GWVNIMYNGL DAVAVDQQPV TNHNPWMLLY FISFLLIVSF FVLNMFVGVV VENFHKCRQH
     QEAEEARRRE EKRLRRLEKK RRKAQRLPYY ATYCHTRLLI HSMCTSHYLD IFITFIICLN
     VVTMSLEHYN QPTSLETALK YCNYMFTTVF VLEAVLKLVA FGLRRFFKDR WNQLDLAIVL
     LSVMGITLEE IEINAALPIN PTIIRIMRVL RIARVLKLLK MATGMRALLD TVVQALPQVG
     NLGLLFMLLF FIYAALGVEL FGKLVCNDEN PCEGMSRHAT FENFGMAFLT LFQVSTGDNW
     NGIMKDTLRD CTHDERSCLS SLQFVSPLYF VSFVLTAQFV LINVVVAVLM KHLDDSNKEA
     QEDAEMDAEL ELEMAHGLGP GPRLPTGSPG APGRGPGGAG GGGDTEGGLC RRCYSPAQEN
     LWLDSVSLII KDSLEGELTI IDNLSGSIFH HYSSPAGCKK CHHDKQEVQL AETEAFSLNS
     DRSSSILLGD DLSLEDPTAC PPGRKDSKGE LDPPEPMRVG DLGECFFPLS STAVSPDPEN
     FLCEMEEIPF NPVRSWLKHD SSQAPPSPFS PDASSPLLPM PAEFFHPAVS ASQKGPEKGT
     GTGTLPKIAL QGSWASLRSP RVNCTLLRQA TGSDTSLDAS PSSSAGSLQT TLEDSLTLSD
     SPRRALGPPA PAPGPRAGLS PAARRRLSLR GRGLFSLRGL RAHQRSHSSG GSTSPGCTHH
     DSMDPSDEEG RGGAGGGGAG SEHSETLSSL SLTSLFCPPP PPPAPGLTPA RKFSSTSSLA
     APGRPHAAAL AHGLARSPSW AADRSKDPPG RAPLPMGLGP LAPPPQPLPG ELEPGDAASK
     RKR
//
